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Abstract
Introduction. The ability to track cells in living organisms with sensitivity, accuracy and
high spatial resolution would revolutionize the way we study disease. Reporter genes
are valuable tools as they encode detectible products, allowing for “reporting” of viable
cells that express them. Previously, a gene encoding Organic anion-transporting
polypeptide 1a1 (Oatp1a1) was established as a magnetic resonance imaging (MRI)
reporter based on its ability to take up the paramagnetic contrast agent gadolinium
ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA). Our objective was
to assess, characterize and further develop this system for whole-body tracking of cells
in vivo. Methods. Cancer cells were engineered to synthetically express Oatp1a1, or
Oatp1b3, a closely related human transporter protein. In our first study, T1-weighted
images of Oatp1a1-expressing primary tumours in preclinical animals were acquired
before and after administration of 0.1-mmol/kg Gd-EOB-DTPA at 3-Tesla. At endpoint,
heterogenous contrast enhancement patterns within the primary tumour architecture
were compared to whole-tumour fluorescent histology. In the next study, T1-weighted
images of Oatp1b3-expressing primary tumours, and their spontaneous metastases to
the lymph nodes and lungs, were acquired before and after administration of 1-mmol/kg
Gd-EOB-DTPA at 3-Tesla. In the final study, the feasibility of Oatp1b3 as a
photoacoustic reporter gene was assessed by acquiring full-spectrum near infrared
photoacoustic images of primary tumours in preclinical animals before and after
administration of 8-mg/kg indocyanine green. Results. We were able to demonstrate
the feasibility of imaging cancer cells with Oatp1a1 at 3-Tesla and 0.1 mmol/kg GdEOB-DTPA. Importantly, as primary tumours grew over time, heterogeneous contrast
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enhancement patterns that emerged near-endpoint strongly correlated to viable cell
distributions on whole-tumour histology. Oatp1b3 was also shown to operate as an MRI
reporter gene at 3-Tesla, based on the same principle as Oatp1a1. Impressively, single
lymph node metastases and the formation of micro-metastases in the lungs of
preclinical animals were detected with Oatp1b3-MRI. Finally, we also demonstrated the
ability of Oatp1b3 to operate as a photoacoustic reporter gene based on its ability to
take up indocyanine green. Conclusion. The Oatp1 reporter gene system is a versatile
imaging tool for spatiotemporal tracking of engineered cells in vivo with high sensitivity,
high resolution, and 3-dimensional spatial information.
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Summary for Lay Audience
The ability to effectively detect a specific cell type, such as cancer cells, in the context of
a larger, living biological organism would be useful for the study of medicine and, more
broadly, for the life sciences. Though methods do exist to track cells non-invasively, the
imaging is limited to superficial surfaces and/or sub-optimal resolution. Our work here
tackles cellular imaging by focusing on magnetic resonance imaging (MRI) as a
platform, allowing us to overcome several of these limitations. Unlike other imaging
methods, MRI scanners produce highly detailed anatomical images and do not lose
signal with increasing tissue depth. To image specific cells on MRI, we have developed
a nanotechnology in the form of a protein that embeds itself on the surface of the cells
we are interested in studying, and allows those cells to “pack” themselves with an MR
imaging dye. Meanwhile, other cells do not have this capability. We test the
effectiveness of this system for tracking cancer cells in preclinical animal models, and
remarkably, it has allowed us to visualize the changing architecture of a primary tumour
over time, as well as track the spread of cancer cells from the primary tumour to other
parts of the body with high sensitivity and high resolution. This molecular technology
can, in principle, be applied to any cell type, and paves the path for imaging various
biological processes to better understand their mechanisms and develop new
treatments for disease.
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To all the women who inspire me.
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“Through countless generations, from the very beginning, the social
subservience of women resulted naturally in the partial atrophy or at least
the hereditary suspension of mental qualities which we now know the
female sex to be endowed with no less than men… It is not in the shallow
physical imitation of men that women will assert first their equality and later
their superiority, but in the awakening of the intellect of women… The
female mind has demonstrated a capacity for all the mental acquirements
and achievements of men, and as generations ensue that capacity will be
expanded; the average woman will be as well educated as the average
man, and then better educated, for the dormant faculties of her brain will be
stimulated to an activity that will be all the more intense and powerful
because of centuries of repose. Woman will ignore precedent and startle
civilization with her progress.”

-

Nikola Tesla
When Woman Is Boss
January 30, 1926
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CHAPTER 1 Introduction
The overarching goal of this thesis is to develop the organic anion-transporting
polypeptide 1 reporter gene system for non-invasive, longitudinal tracking of viable
cancer cells in preclinical animal models. This introductory chapter provides an
overview on known cancer mechanisms, clinical imaging methods, and preclinical
approaches for studying cancer. Additionally, an overview of current methods in
molecular imaging and in-depth background knowledge on the relevant modalities for
this thesis, including bioluminescence imaging, magnetic resonance imaging, and
photoacoustic imaging, will be provided. Background knowledge on organic aniontransporting polypeptides is also discussed to provide a baseline for its development as
a multimodality reporter gene.

1

1.1 Motivation and Overview
Cancer is a heterogenous group of diseases involving abnormal cell growth with
potential to invade and spread to other parts of the body. Cancerous, or malignant,
tumours are distinct from benign tumours, by their ability to spread throughout the body.
Each year, over 14 million new cases of cancer are diagnosed, and approximately 10
million deaths result directly from cancer, comprising 15.7% of all annual deaths (1).
Non-invasive imaging plays a critical role in the detection, staging, and monitoring of
cancer in individual patients (2). The technologies used for this purpose encompass
multiple modalities such as ultrasound (US), computed tomography (CT), magnetic
resonance imaging (MRI), and positron emission tomography (PET). These
technologies have also been applied for assessing cancer progression at the preclinical
stage.
“Precision Medicine” (PM) increasingly shows greater promise than conventional
“one-size-fits-all” traditional medicine with respect to patient outcomes, spurring the
need for understanding the molecular features of cancer in individual patients, rather
than its macroscopic features (3). Molecular imaging (MI) is a growing biomedical
research discipline that enables the visualization, characterization, and quantification of
biological processes taking place at both the cellular and subcellular levels within intact
living subjects over time, including patients (4). As a small part of this larger effort, this
thesis develops a reporter gene technology to image the viability of engineered cancer
cells in preclinical animals at the primary tumour stage, as well as for noninvasive,
longitudinal tracking of metastatic cancer cell dissemination throughout the entire body.
Specifically, this thesis employs, characterizes and develops methods for using organic
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anion-transporting polypeptide 1 (Oatp1) as a reporter gene for tracking of engineered
cancer cells in vivo in preclinical animal models. We also discuss the potential utility of
Oatp1 reporter genes for future use in clinical cell tracking studies.
In Chapter 2, Oatp1a1 was investigated for longitudinal imaging of primary triplenegative breast cancer tumours on magnetic resonance imaging (MRI) with concomitant
enhancement of bioluminescence imaging (BLI) signals, and effectively demonstrated
non-homogenous distributions of breast cancer cells within tumour masses. In Chapter
3, Oatp1b3 was explored for tracking of metastasizing triple-negative breast cancer
cells in preclinical animals on MRI, with simultaneous tracking of metastases with BLI.
This collection of experiments demonstrated detection of the spread from primary
orthotopic tumours to single lymph nodes via Oatp1b3-enhanced MRI, subsequent
visualization of multi-lymph node spread, and finally detection of small metastatic lung
lesions within the same animal over time.
In Chapter 4, Oatp1b3 was additionally assessed for its ability to take up a
fluorescent and photoacoustic contrast agent called indocyanine green (ICG), allowing
for the establishment of Oatp1b3 as a photoacoustic reporter gene for rapid, costeffective imaging of engineered cells in localized tissues with concurrent high-contrast
and resolution. Finally, Chapter 5 summarizes the conclusions and significance of this
thesis, discusses its experimental limitations, and presents ideas for future work to build
on the results presented in this thesis.

3

1.2 Modeling Cancer
1.2.1 Cancer Trends
In North America, one in every two women, and one in every three men
will develop cancer in their lifetime (5). In general, when the cancer is caught
when still confined to its tissue of origin, the main goal is to eradicate the tumour
from the primary site and prevent distant metastasis via surgical resection,
radiation, and/or systemic therapy (6). Prognosis is often hopeful at these stages,
though notable exceptions exist (1, 7). At the primary site, the tumour has been
demonstrated to comprise not only of cancer cells as one might expect. In fact,
nonmalignant cells can account for approximately half of the tumour mass, in
both primary and metastatic lesions (8) (Figure 1.1). These other components
profoundly influence its progression and metastatic efficiency, and shape its
therapeutic responses and resistance to treatment (9).
Direct targeting of non-cancer cells within the tumour microenvironment
(TME) has contributed to positive therapeutic outcomes (10-12). These TME
components include vascular endothelial cells, tumour-associated adipocytes,
fibroblasts, lymphocytes, neutrophils, and macrophages, secreted factors and
extracellular matrix (ECM) proteins (13). Once the cancer metastasizes, curative
treatment becomes less likely. Unfortunately, many patients present with distant
metastatic spread at their initial diagnosis (14). At that juncture, the goal often
becomes prolonging the life of the patient and symptom palliation (6). And while
metastatic disease accounts for the vast majority of cancer-associated deaths,
this process remains the least understood aspect of cancer biology (15).
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Figure 1.1. The Tumour Microenvironment. The tumour microenvironment is a
complex ecosystem of heterogeneous tumour cells, stromal cells, and a variety of
immune cells residing in a network of dysregulated vasculature and collagen. Poor
perfusion and densely-packed glycolytic tumour cells create pockets of reduced oxygen
or hypoxia, low pH, poor nutrient availability, anti-inflammatory cytokines, chemokines,
and accumulated metabolic by-products, such as lactate. Tumour-infiltrating immune
cells of both the myeloid and lymphoid lineages are found within the TME. NK, natural
killer. This figure was drawn by Nivin N. Nyström.

5

1.2.2 Preclinical Animal Models in Oncology
Clinical research in oncology is largely limited to analytical or
observational methods, for obvious ethical reasons, with therapy-focused clinical
trials being the one exception to this rule. Preclinical animal models therefore
offer an indispensable intermediate to clinical trials and reductionist in vitro
research that fails to model the complexity of cancer progression at both early
and late stages of the disease, including TME development and metastatic
colonization (16). Preclinical animal models provide a platform to improve our
understanding of underlying biological mechanisms in oncology, as well as a
platform to test the initial efficacy of new treatment strategies, and have
contributed to major breakthroughs, such as the first demonstration of immune
checkpoint blockade (17).
In 2016, approximately two-thirds of published studies in oncology
employed preclinical animal models in their methods, and immunodeficient mice
constitute the vast majority of animals in these studies (16). Immunodeficient
mice are required for xenografting of human cancer cells in order to avoid cancer
rejection; although models using mice reconstituted with components of the
human immune system, so called “humanized” mouse models, are being
developed (18). Syngeneic immunocompetent models also exist using mousederived cell lines but these are less utilized for “proof-of-concept” imaging
studies. The most common immunodeficient mouse strain used in oncology is
the athymic nude mouse (57% of all studies), followed by the NOD scid gamma
(NSG) mouse (24% of all studies).
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Specifically, the athymic nude strain was generated from a spontaneous
mutation of Foxn1, a transcription activator particularly important in thymic
epithelium. This resulted in mice unable to develop their thymus gland, and in
turn, a systemic depletion of T cells, and a decreased rejection rate of tumour cell
engraftments relative to immunocompetent mice (19). Although their natural killer
(NK) cell counts are low at birth, this metric increases with age, and their innate
immunity remains intact. In contrast, NSG mice are far more immunodeficient
than athymic nudes. Specifically, the NSG mouse model exhibits depletion of
both T and B cells, a dysfunctional complement system, extremely low
development of NK activity, and impaired innate immunity. As a result, NSG mice
ultimately feature the highest tumour engraftment rates of all mouse strains and
are highly permissive for metastasis (20).

1.2.3 Cancer Cell Lines and Tumour Initiation
There are different methods by which tumour growth can be initiated
within a preclinical animal. These include environmentally-induced tumour
models (6% of studies), genetically-engineered mouse models (24% of studies),
and, most commonly, due to cost-effectiveness and time efficiency, cell
implantation models (89% of studies) (16). This thesis focuses on cell
implantation models of tumour initiation. Most studies using cell implantation
methods for tumour initiation employ established cancer cell lines harvested from
tumours in human patients or animals, that are subsequently propagated in vitro
as a monolayer or in vivo as xenografts. The establishment of cell lines as a
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scientific tool has an unfortunate history, clouded with racism and medical
misconduct. The first cancer cell line, “HeLa,” was harvested in 1951 from
Henrietta Lacks, an African-American cervical cancer patient from a poor
socioeconomic background. Sampling of both her healthy tissue and cancer was
performed, with the intention of culturing the specimens for laboratory research,
without her knowledge or consent during her multiple visits to John Hopkins
University (21). This was conducted despite the contemporary norm of obtaining
consent at the time, which was propelled by the Nuremberg Code of 1947, and
soon followed by the legal recognition and duty of “Informed Consent” in 1957
(see Salgo v. Leland Stanford, Jr. University Board of Trustees) (22).
It was another 30 years before the first widely-used breast cancer cell
lines, the MD Anderson (MDA) series of cells, became established, which this
thesis uses to model breast cancer in vivo (23). More recent breast cancer cell
lines include the “SUM” series of cells derived from primary tumours, pleural
effusions or various metastatic sites (24). Additionally, the murine-derived 4T1
cell line established by Miller et al in 1983, which is also used in this thesis, was
isolated from a triple negative breast cancer, and is a widely-used metastatic
breast cancer model (25, 26). Since innate and adaptive immunity have been
demonstrated to play important roles in tumour growth and metastasis, a murinederived breast cancer cell line, which can be grown in immunocompetent mice,
represents an important tool for studying immune responses in cancer
development (27, 28). Though there are known caveats to using any animal
model (29, 30), cell lines remain powerful experimental tools. In many instances,
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information generated from a study has translated to clinical benefit. For
example, the discovery that anti-estrogens regulated growth of tamoxifenstimulated MCF-7 cells led to development and trials of fulvestrant (Faslodex®,
AstraZeneca Pharmaceutical LP, Wilmington, DE, USA), that is now regularly
recommended for treatment of recurrent ER-positive metastatic breast cancer in
menopausal women (31-34).
To establish a primary tumour with the cell implantation method, cells
often are introduced ectopically, that is subcutaneously, or orthotopically, into the
tissue that matches the tumour histotype. For breast cancer cells in mice,
orthotopic implantation means a cell injection into one (or more) of four mammary
fat pads. Orthotopic implantations of tumour cells have been extensively
described to be superior with respect to modelling tumour microenvironmental
interactions, therapeutic response and metastatic patterns, relative to ectopic
implantations (35-40). After implantation, a host of cell types come together and
actively interact with the implanted tumour cells to establish the TME. Depending
on the immunocompetency of the mouse strain, these may include
macrophages, fibroblasts, NK cells, neutrophils, decreases in local pH, and
remodeling of the ECM (41).

1.2.4 Established Mechanisms of Metastasis
Metastasis accounts for about 90% of cancer related deaths (15). Though
drastic improvements to survival have been shown for cancer at early stages,
randomized clinical trials over a 30-year period have largely failed to show
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sustained increases in survival for patients with metastatic disease (42). To
target metastatic disease, a better understanding of the metastatic process is
warranted, and this represents a major area of investigation for various cancer
types. The dissemination of cancer cells from primary tumours and subsequent
seeding of new tumour colonies into distant tissue involves a multi-step process
known as the invasion-metastasis cascade (15) (Figure 1.2). Before the
metastatic process can begin, the primary TME, that encompasses the tumour
cells and the stroma in which they grow as well as the interactions between these
two compartments, is established at the primary site (43).
The first step of the invasion-metastasis cascade is (1) dissociation of a
single cancer cell from the primary tumour through epithelial-to-mesenchymal
transition (EMT) or a collective of cancer cells in which some “leader cells” have
undergone mesenchymal transition but carry epithelial-type cargo cancer cells
along with them. The dissociated tumour cells infiltrate into the surrounding
stroma and invade and migrate through the basement membrane supporting the
endothelium of local blood and/or lymphatic vessels as the second step of the
invasion-metastasis cascade called (2) invasion. It is worth noting that spread of
tumour cells to nearby lymph nodes is an early and common event in patients,
and the lymphatic vasculature is therefore considered as an important route of
metastatic spread. It has been proposed that entry of cancer cells into the
lymphatic vasculature might be facilitated by the higher permeability of lymphatic
vessels relative to blood vessels and/or by the absence of a complete basement
membrane barrier (44). Yet, the relative frequencies at which distal organ
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metastasis occurs directly via lymphatics, or directly through the bloodstream, or
indirectly from the lymphatic system to the bloodstream and then to the organ,
are not fully understood.
Next, (3) intravasation occurs, whereby the dissociated tumour cells
enter the hematogenous and/or lymphagenous vasculature after having
successfully crossed through the extracellular matrix (ECM). In blood circulation,
the tumour cells are referred to as circulating tumour cells (CTCs). In this phase,
the bloodstream represents a hostile environment for CTCs, exposing them to
rapid clearance by natural killer cells or fragmentation due to the physical
stresses encountered in transit through the circulation. The dissociated tumour
cells are distributed to remote organs by blood or lymphatic flow and actively
leave the vasculature via (4) extravasation, at which point they are referred to
as disseminated tumour cells (DTCs). Having traveled far from the primary
tumour, DTCs find themselves in a new microenvironment devoid of familiar
stromal cells, growth factors, and ECM constituents that previously sustained the
viability of their predecessors in the primary site (45). DTCs may reside within
their newfound organ in a non-proliferative state for many months or even years
in a phase known as (5) dormancy. Finally, the growth of an overt metastatic
colony represents the concluding and most deadly phase in the malignant
progression of a tumour.
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Figure 1.2. The Invasion-Metastasis Cascade. (1) Epithelial to mesenchymal
transition (EMT) results in dissociation of the breast cancer cell from the primary
tumour. (2) Invasion of the dissociated tumour cell through the extracellular matrix
(ECM) and basement membrane of the primary site. (3) Intravasation of the dissociated
tumour cell into the bloodstream, or alternatively, into the lymphatic system. At this
point, the dissociated tumour cell is deemed to be a circulating tumour cell, CTC. (4)
Extravasation of the CTC from the bloodstream into the target tissue such as the lungs,
at which point, the tumour cell is called a disseminated tumour cell (DTC). (5) The DTC
remains in a non-proliferative state at the metastatic site for some time, a phase called
dormancy, and may or may not enter a proliferative state at a later time. This figure was
drawn by Nivin N. Nyström.
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1.2.5 Modeling Metastatic Disease
Metastasis accounts for about 90% of cancer-related deaths (15). Yet,
approximately 75% of studies employing preclinical animal models focus only on
the primary tumour and do not include the study of metastasis (16). Even more,
investigators in these studies largely use rudimentary measurements such as
primary tumour growth curves and tumour mass as study readouts to estimate
therapeutic response (16). In fact, many preclinical studies are limited to simple
end point readouts such as tumour weight, tumour volume or survival. While
these are clinically important parameters, end point readouts neglect the
temporal kinetics of tumour growth and metastatic progression. It is therefore
unsurprising that survival rates for patients diagnosed with metastatic disease
have not improved for breast cancer (42), as well as several other types of
cancer (46, 47). The low success rate of clinical trials in oncology warrant a
change in the approach taken to identify and assess new therapies (48).
To model metastatic disease in preclinical animal models, cells can be
injected via the intravenous, intracardiac, or intrasplenic routes to generate
reliable metastases within lung, brain, or liver tissue, respectively (49). These are
referred to as experimental metastasis models because they recapitulate
metastatic colonization but circumvent the primary disease. The most
comprehensive way to study the entire metastatic cascade in preclinical animal
models is orthotopic tumour cell implantation to induce the development of a
primary tumour followed by spontaneous cancer cell metastasis to other parts of
the body (16). These spontaneous metastasis models recapitulate the entire
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invasion-metastasis cascade for more precise modeling of tumour progression.
However, spontaneous models are used much less often than experimental
metastasis models due to a longer experimental timeline, and unpredictable
outcomes (49). For instance, it is difficult to determine, exactly and absolutely,
where the metastasizing cells colonize and patterns may differ from mouse to
mouse. In summary, preclinical evaluation of metastasis is challenging, but
necessary to expand knowledge on the metastatic process and test therapies
targeting metastatic disease.
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1.3 Molecular Imaging
1.3.1 Imaging Cancer in Patients
Imaging technologies play a critical role in the diagnosis of cancer. While
primary diagnostic tools include ultrasound (US) and computed tomography (CT),
other modalities such as magnetic resonance imaging (MRI) and positron
emission tomography (PET) have seen increasing use and have overall
demonstrated better detection and staging of disease (50). For example, PET
imaging of prostate-specific membrane antigen (PSMA) for prostate cancer
staging shows increased specificity and sensitivity compared to standard imaging
protocols, enabling personalized treatment planning and improved outcomes
(51). And while US-guided prostate biopsy exhibits true positive detection rates
of 10–19%, this increases to 59% for multiparametric MRI-guided biopsies (52).
Imaging is also playing an increasingly important role in monitoring
treatment delivery and treatment response (53). For instance, imaging therapy
response in gastrointestinal stromal cancer patients with 2-deoxy-2-[18F]fluoroglucose (18F-FDG) PET allowed for determination of patient response
status only 8 days after the start of treatment, compared to 8 weeks for CT,
thereby offering the opportunity to provide salvage therapies for non-responders
before the cancer has a chance to progress (54). Though costs of providing
advanced imaging technologies for cancer diagnosis, staging and monitoring
have deterred widespread utility, their usage is cost-effective with respect to lifeyear gains, and have been shown to offset costs via rapid determination of
effective personalized treatments (55, 56).
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1.3.2 Molecular Imaging of Cancer
Clinical imaging for abnormalities at the macroscopic scale is sensitive but
unspecific (57). To address these limitations, the motivation for molecular
imaging (MI) is to translate highly informative in vitro and ex vivo bioassays to an
in vivo or in situ setting, an approach which has strong roots in nuclear medicine
but is rapidly emerging in other modalities (58). While in vitro and ex vivo
techniques provide valuable insight into innerworkings of cells and biochemistry
of disease, they are limited by an inability to provide spatiotemporal information
over entire intact organisms, making it difficult to appreciate the “full picture” of
disease states and/or biochemical processes.
Additionally, the need to remove a tissue sample from its natural
environment and process it renders results not accurate of true in vivo
physiological conditions. Further, destruction or irreversible processing of tissue
makes each sample useful for a small number of in vitro protocols, which may
limit the information that could possibly be extracted per sample. Finally, the
need to euthanize animals for ex vivo protocols makes longitudinal studies of the
same animal impossible, and creates issues with respect to both increased costs
and inter-subject variability (59).
To visualize, quantify, and monitor cell populations over time, one of three
approaches may be taken: 1) development of an imaging probe that targets
biomarkers on cells and/or pathways of interest, 2) pre-loading cells of interest
with a contrast agent and subsequently introducing them into the biological
system, and 3) engineering cells with a reporter gene in vitro or ex vivo and
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subsequently introducing them into the biological system, or engineering them
with a reporter gene in situ. Each of these methods has its strengths and
limitations, which will be discussed in detail in Sections 1.3.3, 1.3.4, and 1.3.5,
respectively.
Further, each of these methods can be employed on various imaging
modalities. Likewise, each of these modalities also presents with its own set of
strengths and disadvantages, and its effective application depends greatly on the
details of the disease and/or biochemical process of interest. The relevant
imaging modalities for this thesis, which include bioluminescence imaging,
magnetic resonance imaging, and photoacoustic imaging, will be thoroughly
reviewed in Sections 1.4, 1.5, and 1.6, respectively.

1.3.3 Targeted Molecular Probes
The development of targeted molecular probes is perhaps the most
obvious approach for MI. These include a broad range of categories, including
small molecules, peptides, aptamers, relatively high-molecular-weight antibodies,
engineered protein fragments, and nanoparticles. Each type of agent falls within
a different size range and thus possesses distinct pharmacokinetic and binding
properties (59). In general, the objective of a molecular probe is to effectively
target a specific biomarker in situ and generate significant signal above
background for detection and image generation. In general, there are two main
mechanisms by which a targeted probe may function: 1) probes that bind specific
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receptors, transporters, or ion channels, (60) and 2) probes that enable imaging
of metabolism, enzymatic activity, and/or transport (61).
The main advantage of targeted molecular probes is the ease of their
translation into human patients, relative to all other MI approaches, once safety
and effectiveness has been demonstrated. Their limitation, however, is the time
and expense required to create a new molecular probe for each biological marker
(62). Additionally, the targeting mechanism of the probe may activate or inhibit its
target, which may cause undesired effects on the biochemical process being
studied, especially if binding is irreversible, although this is less of a concern for
modalities requiring biologically-negligible probe concentrations like PET (63).
On the other hand, probes that target metabolism, enzymatic activity,
and/or transport such as hyperpolarized carbon-13 pyruvate for MRI and 18FFDG for PET can be used to image a generic process, e.g. all cancers exhibit
increased pyruvate to lactate metabolism due to the Warburg effect, but this does
not allow for identification of specific molecular biomarkers for each individual
cancer patient (64). Further, specificity may be limited because other non-related
pathologies e.g. non-oncogenic inflammation, can exhibit similar changes in
metabolism (65); however, new metabolic probes for hyperpolarized carbon-13
MRI are being developed for increased cellular specificity (66-68).

1.3.4 Ex Vivo Cellular Loading
Cells can also be tracked by direct labelling via in vitro or ex vivo
incubation with a contrast agent prior to their introduction or re-introduction into
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the biological system, respectively. Examples of ex vivo cell loading approaches
include indium-111 for imaging of white blood cells in patients with PET (69),
iron-oxide nanoparticles for MRI of cancer cells in preclinical animal models (70),
and gold nanoparticles for PAI (71) and/or CT (72). This approach allows for
sensitive and specific determination of the location of labelled cells for a limited
time after their introduction into the body (73).
While cellular loading is clinically relevant for immune cells in patients, it is
limited to preclinical animal models for tracking of diseased cells, e.g. it is
unethical to (re-)introduce labelled cancer cells into a patient. After their
introduction into the biological system, the number of contrast agent molecules
per cell declines over time due to its diffusion out of the cell and/or dilution due to
cell division (74). This is a significant limitation for tracking proliferative cancer
cells in preclinical animal models, such as during the initial establishment of a
primary tumour, prior to their spontaneous spread to other parts of the animal.
On the other hand, some groups have taken advantage of the “dilutionwith-division” effect in cellular loading and used this method to study the
dormancy phase of cancer cells in experimental metastasis models (75, 76).
Some cells types are not extensively proliferative, like stem cells, and these have
been monitored using iron oxide nanoparticles and MRI with success (77). A
second limitation of cellular loading is that the contrast agent molecules can also
be engulfed by other cells once the initially loaded cells have died, e.g.
macrophages can ingest particles via phagocytosis, thereby generating false
positive signals in absence of the cells of interest (74). These limitations for in
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vitro or ex vivo labelling of cells, largely restrict the timeframe in which cells of
interest can be accurately detected and identified using in vitro or ex vivo direct
labelling (78). Further, considerations must be taken with the effects of foreign
particles packed into cells on normal cellular function. Ideally, the contrast agent
used for labelling would remain inert, but this is not always the case. For
example, cancer cells labelled in vitro with iron oxide nanoparticles and
subsequently introduced into preclinical animal models exhibited reduced rates of
growth due to pro-inflammatory effects caused by the labelling agent (79).

1.3.5 Reporter Genes
Reporter genes are functional pieces of deoxyribonucleic acid (DNA) that
encode detectable proteins. Unlike traditional contrast agents, they can be fused
to a gene of interest at the DNA-level to track the protein product across time and
space at sub-cellular resolutions, or alternatively, the reporter can be placed
under equivalent regulatory control to the gene of interest to indirectly track its
spatiotemporal expression at the supra-cellular level. Green fluorescent protein,
pioneered by Drs. Osamu Shimomura, Martin Chalfie and Roger Y. Tsien,
became so widely used in biomedical research that it was subject of the 2008
Nobel Prize in Chemistry. The means by which scientists employ reporter genes
can become quite complex to provide detailed information on highly specialized
processes, e.g. determination of stem cell differentiation status (80), resonance
transfer methods for detection of protein-protein interactions (81, 82), genetic
circuitry to image cell-cell interactions (83), fluorescent barcoding of cells to track
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cellular ancestry (84), but ultimately, reporter genes are used as a protein-based
detection mechanism to track and monitor the fates of live cells in tissues.
Recently, reporter genes have become of particular interest for development and
clinical management of gene and adoptive cell therapies in patients, which
represents a revolutionary form of treatment for a number of diseases (85-88).
Reporter genes and other genetic material can be introduced into cells in
a number of ways (89). In this thesis, the primary method of delivering genetic
material to the cell is through the utilization of lentiviruses, a technique first
described by Dr. Didier Trono’s group at the Salk Institute in 1996 (90). Lentiviral
vector systems typically consist of three separate plasmids: the packaging,
envelope, and transfer plasmids. Briefly, the packaging plasmid includes a set of
genes, including gag and pol that encode the major structural polyprotein
required for assembly of the viral capsid, and the reverse transcriptase required
for the integration of the genetic material of the virus into the host genome (91).
The envelope plasmid includes the env gene, which ultimately encodes the viral
spike protein, important in dictating the tropism of the virus (92). Finally, the
transfer plasmid encodes the transgene of interest, flanked by viral long terminal
repeats (LTRs) that facilitate viral packaging and host genome integration (93).
Following co-transfection of these plasmids, packaging cells such as the 293T
cell line release transgene-containing lentiviral particles into the media, which
could then be collected for experimental use.
In MI, reporter genes overcome several limitations presented by targeted
probes and cellular loading approaches, and as a result, have increasingly been
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utilized in the literature at the preclinical stage (94). Once a reporter gene is
established to work in one cell type, it can generally be used as a universal tool
to track any gene of interest, unlike targeted probes that need to be newly
designed for each biomarker. If scientists opt to integrate the reporter gene into
the genome of a target cell, its DNA sequence then replicates with cell division;
thus, its expression and subsequent detection depends only on the genetic
regulation employed in the study, independent of cell division. Importantly, after
the engineered cell dies, the DNA encoding the reporter is destroyed and its
contrast mechanism cannot be transferred to bystander and/or phagocytic cells,
unlike contrast agents used for cellular loading.
However, reporter gene contrast mechanisms also do present with some
shortcomings. For example, reporter genes have decreased sensitivity relative to
ex vivo cellular loading approaches (59). Additionally, while reporter genes are
highly useful for tracking protein entities in vivo, tracking of non-protein small
molecules in the body with genetically-encoded reporters becomes complicated
and is better suited for targeted probe approaches (95). Nonetheless, since
green fluorescent protein was first established, reporters for various modalities
have been developed, including bioluminescence imaging (96-100),
photoacoustic imaging (101), positron emission tomography (102-104), magnetic
resonance imaging (105-110), and ultrasound (111). Traditionally, cells would be
engineered in vitro or ex vivo, similar to cellular loading, but new methods are
emerging for genetic engineering of target cells in situ (112-114).
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1.3.6 Multimodality Imaging
It is important to recognize that all molecular imaging modalities have
advantages as well as inherent limitations. Multimodality imaging allows
researchers to combine different imaging datasets to gain a more complete
understanding of the biology being studied. The most widespread application of
multimodality imaging is the integration of PET, which allows for sensitive
detection of probe activity, with computed tomography that provides detailed
anatomical images of internal structures, thereby allowing clinicians and
researchers to determine the three-dimensional (3D) locations of radiotracers
(115). Within the last decade, PET/MRI has been increasingly commissioned at
research centres, to combine functional information from PET, with structural and
additional functional information from MRI for ultimate high sensitivity, high
specificity, and high resolution molecular imaging (116).
Beyond PET, researchers are combining other modalities and molecular
imaging approaches at the preclinical stage to better understand disease
pathogenesis in terms of the interplay between different cell types, to identify
putative mechanisms of disease and/or to evaluate the efficacy of new candidate
treatments. For example, in studying the biology of cancer cell dormancy, a
phenomenon that is increasingly being recognized as a hallmark of metastatic
disease (117), Parkins et al. combined cellular loading of iron oxide nanoparticles
for MRI with BLI of luciferase expression to detect viable cancer cells arrested
into the brains of mice after systemic administration (118). Iron oxide
nanoparticles allowed for high resolution 3D imaging of single cells with detailed
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anatomical context, but provided no information on the viability of the cancer
cells; i.e. hypointense signals on MRI may be stemming from uncleared particles
even after cancer cell death or, alternatively, from microglia that have engulfed
the nanoparticles as well as other unrelated sources of reduced MRI signal.
Adding BLI to their protocol allowed for viability measurements of engineered
cancer cells within brains of mice, confirming the presence of live cancer cells.
Other studies have utilized various combinations of modalities, which ultimately
serve to clarify or further experimental findings (119, 120). In the development of
Oatp1 as a reporter gene in this thesis, complementary modalities are used in
combination primarily to confirm reporter gene activity in vivo, e.g.
bioluminescence as a reference for reporter gene activity on MRI, ultrasound with
photoacoustics for anatomical context. The sections below introduce the imaging
modalities relevant to this thesis and include detailed discussions on established
reporter genes for each modality.
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1.4 Bioluminescence Imaging
1.4.1 Reporter Gene Development
Bioluminescence is a specific form of chemiluminescence whereby light is
produced and emitted from biological organisms. This process occurs widely in
marine vertebrates and invertebrates, as well as in some fungi, microorganisms,
including some bioluminescent bacteria, and terrestrial arthropods such as
fireflies (121). The principal reaction in bioluminescence involves the oxidation of
a molecule called the “luciferin” via an enzyme, called the “luciferase.” The
luciferase may require other cofactors, such as calcium or magnesium ions,
and/or the energy-carrying molecule adenosine triphosphate (ATP), in order to
perform the oxidation (Equation 1.1).

Equation 1.1. Biological oxidation of D-luciferin by firefly luciferase.
D-luciferin + ATP + O2 + Mg2+ → Oxyluciferin + AMP + CO2 + PPi + h#

In firefly luciferase, the oxygen of the C4 carboxyl end group on luciferin
acts as a strong nucleophile and attacks the electrophilic phosphorous in the αposition within ATP in an SN2 displacement (122). Inorganic pyrophosphate (PPi)
is removed as the leaving group, resulting in an enzyme-bound intermediate,
luciferyl-adenylate (123). The acidity of the C4 carbon is increased in its new
bond to AMP, allowing for its deprotonation, and carbanion formation (124). At
this step, the carbanion, as a nucleophile, will then tend to attack molecular
oxygen, thus generating a high-energy intermediate, the luciferin dioxetanone
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(125, 126). Finally, dioxetanone spontaneously decarboxylates to form
oxyluciferin (127). The resulting molecule, oxyluciferin, is in a singlet excited
state, and its decay to the ground state releases a photon (128). Throughout the
reaction, the Mg2+ shields the negative charges and influences the conformation
of the phosphate groups (129).
In the laboratory, luciferase-based systems are used as reporter genes for
biomedical research purposes. Work on luciferase as a reporter gene system first
began in 1982 when Belas et al. isolated and expressed luciferase genes from
marine bacteria in E. coli (130). The most widely used luciferase reporter gene
today, firefly luciferase, was first cloned and expressed in E. coli by De Wet et al.
in 1985 (131), expressed in mammalian cells just two years later in 1987 by
Keller et al. (132), and used to image cells of interest in mammalian hosts in
1995 by Contag et al. (133).

1.4.2 In Vivo Image Generation
Current methods to generate bioluminescence imaging data with live
animals first involves generation of stable Firefly luciferase-expressing cells and
subsequent implantation of these cells into animals. The animal would then
typically receive intraperitoneal administration of D-luciferin, after which, the
substrate diffuses into surrounding organs and, thereafter, is carried away by
capillary blood or lymph within those tissues. Evidence suggests that D-luciferin
diffuses slowly and passively across cell membranes to enter the cytoplasm
where the luciferase protein would be present within engineered cells (134). A
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broad spectral distribution of light peaked at a wavelength of 560 nm is emitted
following relaxation of excited oxyluciferin to its ground state (135). Light
emission from constitutively expressed luciferase is proportional to tumour cell
burden, and photon emission increases as the cell population multiplies (136).
Kinetic PET studies with radiolabeled 14C-D-luciferin revealed generally
low brain uptake likely due to presence of the blood brain barrier, high intestinal
uptake due to the intraperitoneal route of injection, and predominant renal
excretion of the luciferase substrate (137-139). Depending on the model, the
signal from in vivo bioluminescence generally peaks 10 to 15 minutes postadministration of D-luciferin, after which signals plateau and eventually drop as
the substrate is renally excreted. The bioluminescent reaction between the
luciferase enzyme and its substrate produces low-intensity light that ordinarily
cannot be seen with the human eye or by conventional microscopy (121).
A specialized imaging detector is required, especially when imaging cells
within preclinical animal models, as light scattering and light attenuation from
surrounding tissues further obscure the spatial location of the signal source. The
most common system for imaging bioluminescence in vivo comprises of a lighttight imaging chamber into which the anesthetized subjects are placed onto a
heated stage. A bright-field photograph from the top of the black chamber is first
taken of the subject as a spatial reference, after which a sensitive chargedcoupled device (CCD) camera is used to detect and spatially localize the
bioluminescent photons. The CCD is super-cooled to approximately -90°C to
minimize thermal noise and increase exposure times, thereby increasing its
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ability to detect very low levels of light (140). The units of measurement for
bioluminescence signals can include counts measured in photons (p), total flux
(p/s), or average radiance (p/s/cm2/sr). Total flux is generally used to calculate
total tumour burden for an animal, whereas average radiance can be utilized to
measure individual bioluminescence signals from a specific region of interest
(141).

1.4.3 Applications for Cancer Research
There are several advantages of bioluminescence imaging that make it a
useful modality for cancer research. Before bioluminescence imaging was
established, the default method by which preclinical scientists could dynamically
track tumour progression was with simple readouts such as caliper
measurements, which are not feasible for measuring tumour growth or metastatic
burden in deep tissues. More extensive measurements could be made
posthumously, by either staining tissue for cancer cell markers or by imaging
histology with confocal microscopy for fluorescent reporter gene expression.
These histological methods, require extensive and time-consuming tissue
preparation and provide information only at endpoint. Further, this preparation
meant that only ex vivo tissues could be observed, giving a static picture of gene
expression and/or cellular location, with the exception of translucent, nonmammalian model organisms e.g. C. elegans, D. rerio (142).
For longitudinal imaging in mammalian models with these previous
methods, studies needed to overcome inherent inter-subject variability at each
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timepoint. Thus, large numbers of animals would need to represent different
timepoints for a methodical understanding of the biological phenomenon being
studied. However, bioluminescence imaging allows for whole-body imaging
without euthanasia, offering a tool to longitudinally track the protein and/or cell of
interest in an individual animal over time, which greatly reduces the number of
animals needed to understand a hypothesis or effect (143). In addition,
mammalian systems do not naturally produce bioluminescence signals, so
luciferase-expressing cells in preclinical animal models generate sensitive
imaging data due to an inherently high contrast-to-background ratio.
Bioluminescent imaging has therefore become a critical tool in preclinical
oncology research. In recent years, the luciferase reporter gene has been used
to track the expression of specific oncoproteins (144-147), model metastatic
progression (148-150), and assess the delivery, biodistribution, and/or efficacy of
new candidate therapies (151-153).

29

Figure 1.3. Bioluminescence Imaging of Preclinical Animal Models.
Bioluminescence imaging measurements in counts (photons) of 2×105 luciferaseexpressing MDA-MB-435 cells immediately (A,C) or 33 days (B,D) after injection into
the left (A,B) or right (C,D) ventricle. A 120-second acquisition was taken for Day 0
images (A,C); Day 33 images required only a 10-second duration (B,D). This figure was
acquired from Zinn et al. (154).
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1.4.4 Limitations of Bioluminescence Imaging
The ultimate goal of molecular imaging for cancer research is to detect
cancer-associated molecular events as they occur within a biological system.
Bioluminescence imaging provides a unique platform to track these events with
high sensitivity and robustness, but light attenuation and light scattering from
surrounding tissues limit the depth of detection and resolution of imaging, making
it difficult to determine the precise location of the source of signal (155). A small
number of superficial cells and a large number of deep-seated cells generate
similar signals, which is particularly problematic when researching metastatic
spread in preclinical animal models. A photograph or X-ray image overlayed on
bioluminescence data, as is de rigueur on current imaging systems, can only
qualitatively approximate the possible source location. Additionally, tissue
scattering of bright sources of light emitted from larger tumours adjacent to
weaker regions of light emission i.e. smaller metastases, may obscure the
presence of smaller tumours or metastases in bioluminescence imaging, which
may only become apparent during histological evaluation if the corresponding
tissue is sampled (156).
Furthermore, imaging of larger animal models, and even humans, would
be challenging as light attenuation from surrounding tissues would completely
obscure any signals deeper than a few centimeters within the body of the subject
(157). New image acquisition systems offering bioluminescence tomography
have recently been developed, to generate multi-projection datasets overlayed
onto CT images, but the long acquisition times and increased costs of these
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systems counter some of the original benefits of bioluminescence imaging – its
high throughput and cost-effectiveness (158). Complicating factors also exist with
respect to the biochemical effects of luciferase expression on the biological
system being studied; during imaging, ATP-dependent luciferases become a
significant metabolic burden, and have been demonstrated to decrease ATP
availability by a factor of two (159), which may have effects on the ability of the
tumour to grow and progress. Along the same lines, metastasis has been shown
to be seriously debilitated in murine breast cancer models when cells are
engineered with luciferase, all things being equal (160). Reporter gene design
requires relative inertness, and while its expression may not seriously alter the
parameters of the study, the undesired effects of synthetic luciferase activity on
the biological system should be acknowledged to some extent.
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1.5 Magnetic Resonance Imaging
1.5.1 Magnetic Resonance Imaging in Medicine
Magnetic resonance imaging (MRI) is a versatile technology used to noninvasively acquire an increasing variety of imaging data. In addition to anatomy,
images of physiological processes of the body can also be achieved (65). Proton
(¹H) MRI, which represents the vast majority of scans acquired, and the imaging
performed in this thesis, is largely used to identify disease on a macroscopic
scale, such as a solid tumour. MRI also has potential for detection of events at
the molecular scale, with high resolution 3-dimensional spatial information and
surrounding anatomical context. The following sections provide a brief overview
of the fundamental processes involved with generating a proton image. The
information below is obtained from a combination of sources: Magnetic
Resonance Imaging: Physical Principles and Sequence Design, Second Edition
(2014), MRI from Picture to Proton, Third Edition (2017), and MRIquestions.com
(2020), unless otherwise referenced.

1.5.2 Nuclear Magnetic Resonance
MRI was originally known as NMRI, “nuclear magnetic resonance
imaging,” but the adjective, "nuclear" was dropped to avoid negative
connotations wrongly associated with radiation exposure (161). Atomic nuclei
possess an intrinsic property known as spin angular momentum (I, kg·m2·s−1)
that interacts with electromagnetic fields. The particle is not actually spinning.
Rather, like mass, spin is a fundamental property and does not arise from more
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basic mechanisms. Spin angular momentum is quantized into integer or halfinteger units e.g. ¹H has I = ½. Only nuclei with non-zero spins (I ≠ 0) can interact
with electromagnetic fields and precess around the axis of an applied external
magnetic field. The magnetic moment, &⃑ (A⋅m2) quantifying the interaction of the
nuclei with this field is given by Equation 1.2.

Equation 1.2. The gyromagnetic ratio of an atomic species.
&⃑ = * ∙ ,⃑

The proportionality constant, * is known as the gyromagnetic ratio, which is
unique for every nuclear isotope (Table 1.1). The nuclear magnetic dipole
moment experiences a torque in the external magnetic field, -! which causes the
dipole moment to precess around the field direction at a specific frequency
known as the Larmor frequency, .! (Equation 1.2).

Equation 1.3. The Larmor Equation.
.! = * ∙ -!

When an animal or human is placed in the scanner, the distribution of cones of
precession of the ensemble of spins becomes skewed towards the field direction,
resulting in a net longitudinal equilibrium magnetization. This longitudinal
magnetization is manipulated by application of additional alternating magnetic
fields producing signal for magnetic resonance imaging.
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Nucleus
1

H
H
3
H
3
He
7
Li
13
C
14
N
15
N
17
O
19
F
23
Na
27
Al
29
Si
31
P
57
Fe
63
Cu
67
Zn
129
Xe
2

"
#$

(MHz⋅T−1)
42.58
6.536
45.42
−32.43
16.55
10.71
3.077
−4.316
−5.772
40.05
11.26
11.10
−8.465
17.24
1.382
11.31
2.669
−11.78

Table 1.1. Gyromagnetic Ratios of Various Atomic Species. Nuclei and their
corresponding gyromagnetic ratio, measured in MHz/T. Note that some species have
negative gyromagnetic ratios, which results in an opposite precession direction.
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We can see from Table 1.1 that among common nuclear isotopes, ¹H has
the highest gyromagnetic ratio, dictating that it has the highest precession
frequency and, as a result, is the most “MR visible” nucleus. The Larmor
equation also dictates that larger magnetic fields generate higher precessional
frequencies. In a 1.5T field, the resonance frequency of ¹H would be (42.58
MHz/T) ∙ (1.5T) = 63.87 MHz. At 3.0T, the resonance frequency would be twice
00⃑) is a useful term to
as large, or 127.74 MHz. For MRI, the net magnetization (/
describe the vector sum of individual spins, ,⃑ obtained from millions of nuclei
00⃑ can be displaced from its equilibrium state (/
00⃑! )
placed in an external field. /
along the direction defined by -! through the application of a radiofrequency (RF)
pulse, -% . This alternating magnetic field oscillates in a plane transverse to the
static field at the Larmor frequency of the nuclei of interest e.g. ¹H. The
00⃑! causing it to be tipped into the
application of -% produces a torque on /
transverse plane and precess at the Larmor frequency around the external field.
Following the RF excitation, the net magnetization returns to its equilibrium state
according to the longitudinal (T1) and transverse (T2) relaxation times (Figure
1.4). The T1 relaxation time (and its inverse rate, R1) characterizes the re-growth
00⃑2 along the direction of the B0 field. This occurs through the transfer of
of 1/
energy from the excited nuclei to the lattice and is called spin-lattice relaxation for
this reason. The T2 relaxation time (and its inverse rate, R2), referred to as spinspin relaxation, characterizes the exponential decay of the excited magnetization,
/&' within the transverse plane through transfer of energy between spins.
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Figure 1.4. Transverse Decay and Longitudinal Restoration. When the net
00⃑! ) is tipped by a 90° radiofrequency pulse away from the magnetic field
magnetization (/
direction (3̂ ), the longitudinal magnetization, /( is completely transferred to the
transverse (xy) plane, where the resulting transverse magnetization (/&' ) precesses at
the Larmor frequency (.! ), about the axis of the external magnetic field (z). /( regrows
as a simple exponential with time constant T1. On the /( graph, it corresponds to the
time required for /( to grow to approximately 63% (1 − 1/e) of its final value (/! ).
Similarly, the transverse relaxation time T2 represents the time required for /& or /' to
decay to approximately 37% (1/e) of their initial maximum values. This image was
adapted from MRIquestions.com, courtesy of Dr. Allen D. Elster.
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1.5.3 Generating Image Contrast
A linear magnetic field z-gradient is imposed along each Cartesian axis to
spatially encode signals from every voxel in the MR imaging matrix. These
gradients are many orders of magnitude smaller than the main field and are used
to modify the frequency and phase of proton spins as a function of spatial
position. That is, spatial encoding is achieved by assigning a unique phase and
frequency to each location of the imaging volume. A series of instructions known
00⃑! and
as a “pulse sequence” is used to synchronize the RF excitation of /
manipulate the gradient fields at specified time intervals.
After RF excitation, the transverse magnetization, /&' induces a voltage
in the RF coil, which is digitized and stored as the MR signal. MR signals arise
from multiple voxels recorded all at once, each containing different tissues with
different proton densities and relaxation times. The resulting total MR imaging
data is thus the sum of many sinusoidal frequencies near the Larmor frequency
with different phases, whose amplitudes rise or fall as a result of T2 effects and
magnetic field inhomogeneities. Fourier transform methods are applied to the MR
imaging data to sort out the frequency components and accumulated phases for
reconstruction of the physical image.

1.5.4 Contrast in Images
Imaging parameters such as time-to-repetition (TR), time-to-echo (TE) and
flip or excitation angle (5) can be specifically chosen to highlight different
physical properties of tissues within the imaging volume related to their relaxation
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properties, which makes them more conspicuous. For example, using
parameters to produce T1-weighted images, tissues with short T1 values such as
fat appear bright since they magnetize quickly while those with a long T1 like
water or air appear dark. Contrast in T2-weighted images depends on the rate of
dephasing (spin-spin relaxation) in a particular voxel following an RF excitation.
In T2-weighted images, tissues with a long T2, like cerebrospinal fluid, appear
bright, while tissues with a short T2, such as fat, appear dark (Table 1.2).
Paramagnetic agents such as gadolinium (Gd)- and manganese (Mn)based contrast agents (GBCAs, MBCAs, respectively) are not directly observed
on MR images, but rather, enhance the relaxation of surrounding protons,
effectively shortening the T1 value of the tissue in which it accumulates, resulting
in hyperintense volumes on T1-weighted images. The paramagnetic susceptibility
of these elements is proportional to the number of unpaired electrons they
possess e.g. seven for Gd. However, the ionic radius of free Gd+3 mimics that of
Ca+2, and this chemical mimicry is cause for toxicity. Free gadolinium becomes a
competitive inhibitor in processes that depend on Ca+2, including voltage-gated
calcium channels and the activity of many vital enzymes. All GBCAs therefore
require a ligand to chelate the free ion. This thesis specifically applies a clinically
approved contrast agent, gadolinium ethoxybenzyl diethylene triamine
pentaacetic acid (Gd-EOB-DTPA), known as Primovist, (Bayer, Inc.) as a probe
for the development of a magnetic resonance imaging reporter gene.
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Tissue
Water/CSF
Gray Matter
White Matter
Muscle
Liver
Fat

T1 Time (ms)
3700 - 4000
1331 - 1485
832 - 923
898 - 1249
745 - 809
382 - 391

T2 Time (ms)
2000
80 - 96
70 - 110
29 - 34
31 - 34
68 - 87

Table 1.2. Relaxation Times of Common Tissues at 3 Tesla. Spin-lattice relaxation
(T1) times, and spin-spin relaxation (T2) times, in milliseconds of various human tissues
at 3 Tesla (162).
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1.5.5 Reporter Genes for Magnetic Resonance Imaging
Reporter genes for MRI include a diverse group of protein-based
mechanisms through which contrast is enhanced. These can be separated into
different classes based on the type of contrast produced: 1) negative contrast on
1

H MRI (106, 163-166), 2) positive contrast on 1H MRI (110, 167), 3)

hyperpolarization-based reporters (168, 169), 4) diffusion-weighted reporters
(169, 170), and those based on 5) chemical exchange saturation transfer (CEST)
(105, 168). Perhaps the most widely investigated class of MR reporter genes are
those that generate negative contrast (hypointense signal), based on the
principle of iron sequestration. High concentrations of iron cause magnetic
susceptibility changes in tissues that, in turn, increase their effective spin-spin
relaxation i.e. decrease T2*.
Negative contrast reporter genes include the iron storage molecule ferritin
(163), the transferrin receptor (TfR) (164), the bacterial iron transporter magA
(165), and the tyrosinase enzyme that produces iron-chelating melanin (166).
Although negative contrast reporter genes have been demonstrated for various
cancer-related applications, e.g. detection of dendritic cell migration to lymph
nodes (171), presence of cancer cells in lymph nodes (172), regions of limited or
no contrast already exist throughout the body at various major sites, making it
difficult to definitively identify the location of engineered cells with accuracy and
precision without serious reliance on pre-contrast images acquired at the start of
the study.
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Positive contrast mechanisms overcome this limitation by instead
increasing the spin-lattice relation of tissues, or in other words decreasing T1,
thereby causing increased local image intensity. Additionally, most of these
positive contrast mechanisms depend on the administration of an agent for
contrast enhancement, allowing for comparison of pre- and post-contrast images
for increased conspicuity. Positive contrast reporter genes include the βgalactosidase enzyme capable of cleaving a caged synthetic Gd3+ probe (110), a
divalent metal transporter capable of taking up Mn2+ (167), and an organic aniontransporting polypeptide transporter capable of taking up chelated Gd (173). This
thesis focuses on the development of organic anion-transporting polypeptides as
multimodality reporter genes that facilitate cancer cell tracking with magnetic
resonance and photoacoustic imaging, with concomitant enhancement of
bioluminescence signals in luciferase-expressing cells.

1.5.6 Organic Anion-Transporting Polypeptides
Organic anion-transporting polypeptides (Oatp) represent a large family of
multispecific transporter proteins, differentially expressed on various mammalian
tissues, including the kidneys, the liver, the heart, the brain, and the testis (174).
Physiologically, they play a role in mediating the uptake of various compounds,
including bile acids and steroid conjugates (175). Their presence in the body,
however, have made them an important factor to consider in the design and
development of several xenobiotics e.g. statins, some antibiotics, and anticancer
drugs (176). Though the exact mechanism of Oatp-mediated transport remains
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controversial, it is well established that transport is ATP- and sodiumindependent. The driving force for its transport remains an active area of
research in both pharmacology and hepatology. With respect to imaging, human
Oatp1b1 and Oatp1b3 are exploited for detection of liver lesions with MRI using a
clinical contrast agent, gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic
acid (Gd-EOB-DTPA), whose trade name is Primovist (Bayer, Inc) (177). Healthy
liver cells expressing Oatp1b1 and Oatp1b3 are capable of taking up Gd-EOBDTPA and appear bright on MRI after its administration. Diseased regions of the
liver (e.g. hepatocellular carcinoma cells or fibrosis) do not express these
transporters and are unable to take up Gd-EOB-DTPA, and appear hypointense
relative to regions of healthy liver.
Motivated by this mechanism, work on Oatp reporter gene development
began by scientists at the University of Cambridge who established rat-derived
Oatp1a1 as an MR reporter gene, based on its ability to transport Gd-EOB-DTPA
into expressing cells (173). As the Gd concentration increases within engineered
cells following injection of the contrast agent, the Gd interacts with the water
protons in the intracellular environment, increasing the spin-lattice relaxation rate
of those protons, which in turn, increases the signal intensity from those voxels
on T1-weighted MR images. Longitudinal in vivo imaging has determined the
optimal time to image is approximately 5 hours after administration of the
contrast agent. At this time interval, most nonspecific (extracellular) contrast is
cleared from the body and only cells engineered to express Oatp1 retain the
agent, thereby increasing the image contrast for those cells with up to a 7.8-fold
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in vivo signal enhancement at 7 Tesla following an injection of 2-mmol/kg GdEOB-DTPA in mice. Contrast enhancement in the Oatp1a1-expressing
xenografts returned to baseline levels by 60 hours (Figure 1.5). Since this initial
publication, however, very little further research has been undertaken to develop
this technology for gene and/or cell tracking applications. The unique
combination of advantages presented by this reporter gene, which include its
employment of a clinical probe as well as its reversibility, dose-dependent
expression, positive contrast, and multimodal capabilities, warranted further
study into its development as a reporter gene for whole-body tracking of
engineered cells.
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Figure 1.5. Magnetic Resonance Imaging of Oatp1 Expression In Vivo. (A) T1weighted images before (0) and 5, 10, 25, 50, and 80 hours after intravenous injection
of Gd-EOB-DTPA, of a representative animal bearing 293T xenografts. Control
xenograft (left flank) expressed luciferase and the xenografts on the right flank
expressed luciferase and Oatp1. (B) Xenograft relaxation rates (R1) before (0) and
following intravenous injection of Gd-EOB-DTPA (0.664 mmoles/kg) were significantly
greater compared with controls [*P < 0.001, **P < 0.0001, n = 5 (n = 4 at 107 h)]. (C) R1
increased in control and Oatp1-expressing xenografts after repeated intravenous
injection with Gd-EOB-DTPA (0.664 mmoles/kg), following washout of the original dose
in A/B and injection and washout of Gd-DTPA. This figure was acquired from Patrick et
al. (173).
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1.6 Photoacoustic Imaging
1.6.1 Basic Principles
Light in the visible portion of the spectrum is highly scattered by tissues.
Methods that attempt to form images from light passing through tissue fall into
two categories: ballistic (minimally scattered) microscopy e.g. fluorescence
microscopy, and diffuse (multi-scattered) imaging e.g. bioluminescence imaging.
The former provides fine resolution but with a shallow imaging depth in tissue, up
to approximately 1 mm, as defined by the optical diffusion limit (178). When
incident photons reach this depth, most have undergone tens of scattering
events, which randomize the photon paths and inhibit effective optical focusing
and image formation. On the other hand, diffuse optical imaging can probe
centimeters into tissue but with limited spatial resolution, equivalent to about onethird the imaging depth (179). Randomized paths of the diffuse photons render
the image reconstruction difficult. It remains a challenge for conventional optical
imaging to attain fine spatial resolution at depths beyond the optical diffusion
limit.
Photoacoustic imaging (PAI), or optoacoustic imaging, is a hybrid imaging
modality based on acoustic detection of optically-excited sources, thereby
combining the advantages of optical contrast specificity with the spatial resolution
of ultrasound (180). In the photoacoustic effect, endogenous molecules such as
de-oxyhemoglobin and oxyhemoglobin, or exogenous contrast agents, are
excited by nanosecond-pulsed laser beams and rapidly convert a fraction of that
energy into heat during relaxation. This heat energy leads to a transient
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thermoelastic expansion, resulting in the emission of ultrasonic waves that can
be detected with ultrasound transducers to produce images. Photoacoustic
imaging side steps the optical diffusion limit by exploiting low acoustic scattering
in tissue, about three orders of magnitude less than optical scattering in tissue
per unit path length (181). By exciting different molecules at different optical
wavelengths, photoacoustic imaging reveals rich optical contrasts according to
chemical composition, and provides inherently background-free detection
because the photoacoustic amplitude is proportional to the optical absorption and
quantum yield of the target molecules (182). In relation to other optical modalities
(e.g., fluorescence imaging), photoacoustic imaging has the capability of
improved resolution and increased depth of imaging (Figure 1.6).
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Figure 1.6. Imaging Resolution vs Imaging Depth of Optical or Optic-based
Modalities. Comparison of the performance of photoacoustic imaging with that of
optical and ultrasonic modalities, with respect to their imaging depth and spatial
resolution. PAM, photoacoustic microscopy; PACT, photoacoustic computed
tomography; US, ultrasound imaging. Figure was acquired from Brunker et al. (101).
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1.6.2 Applications for Cancer Research
Photoacoustic imaging is a relatively nascent modality, first demonstrated
in the late 1990s (183-185) and recent refinements have led to broad
applications in biology and medicine. Major preclinical applications include
imaging of angiogenesis, microcirculation, tumour microenvironments, drug
response, biomarkers, and gene activities (186), while initial clinical applications
include melanoma cancer imaging, gastrointestinal tract endoscopy,
intravascular catheter imaging, neonatal brain imaging, breast and prostate
cancer detection, sentinel lymph node needle guidance, imaging of early
chemotherapy response, in vivo label-free histology, blood perfusion imaging,
blood oxygenation imaging, and tissue metabolism imaging (186-188).

1.6.3 Photoacoustic Reporter Genes
Though the field of photoacoustic imaging is relatively new, the small
number of endogenous contrast sources within biological tissues, and the ability
to acquire real-time co-registered anatomical images with ultrasound, has
spurred rapid development of several reporter genes for gene and/or cell tracking
on photoacoustic imaging. Photoacoustic reporter genes can be classified as
either direct or indirect, depending on whether the protein encoded is the source
of contrast, or whether the protein instead processes an injected agent that, in
turn, generates the contrast (101). Briefly, photoacoustic reporter genes with
direct mechanisms include fluorescent, nonfluorescent/chromoprotein, and
photoswitchable reporter genes. On the other hand, indirect mechanisms have
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so far consisted of enzymatic proteins, including tyrosinase, β-galactosidase, and
the VioA-E operon. Of these, tyrosinase and β-galactosidase have been more
widely employed. Human-derived tyrosinase is responsible for the rate limiting
step in the melanin synthesis pathway, that is, the oxidation of tyrosine to
dopaquinone (189). Specifically, melanin exhibits a broad extinction coefficient
spectrum, that spans the visible to near-infrared wavelength region and
possesses a relatively low quantum yield, allowing for its detection on
photoacoustic imaging (190, 191). The β-galactosidase reporter, encoded by the
bacterial-derived LacZ gene, is naturally responsible for lactose metabolism, but
is more widely known for its role in a chromogenic complementation assay,
whereby the colourless lactose analog 5-bromo-4-chloro-3-indolyl-β-Dgalactoside probe, known as X-gal, is cleaved, thereby yielding a stable dark
blue product (192). In 2007, β-galactosidase was demonstrated as the first
photoacoustic reporter gene for in vivo imaging, with significant contrast-to-noise
at 650 nm wavelengths (193). Indirect mechanisms of genetically-encoded
photoacoustic contrast present with several advantages over direct mechanisms,
but primarily offer signal amplification, allowing for increased sensitivity for gene
and/or cell tracking (194). Interestingly, both tyrosinase and β-galactosidase have
also been previously established as MR reporter genes, thereby allowing for
multi-modality molecular imaging for in vivo gene and/or cell tracking (195).
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1.7 Purpose of Thesis
1.7.1 Rationale
The reporter gene approach for in vivo molecular imaging has significant
potential for cell tracking applications in preclinical research and clinical
medicine. Specifically, the ability of the Oatp1 reporter gene to transport and
concentrate specific clinical contrast agents within engineered cells, could allow
for sensitive, high resolution imaging in 3D, with positive contrast with several
imaging modalities. The overall objective of the work presented in this thesis is to
develop and assess new methods of reporter gene imaging for tracking of
engineered cancer cells in preclinical mouse models.

1.7.2 Hypothesis
In its development and assessment of Oatp1 as a multimodality reporter gene
for in vivo molecular imaging, this thesis is testing three primary hypotheses:
1. Rat-derived Oatp1a1 will facilitate longitudinal imaging of viable cancer
cell distributions within primary tumours on MRI at 3 Tesla, based on its in
vivo ability to transport Gd-EOB-DTPA into cells.
2. Human-derived Oatp1b3 will allow for longitudinal, whole-body imaging of
spontaneous cancer cell metastasis on MRI at 3 Tesla, based on its ability
to take up Gd-EOB-DTPA in vivo.
3. Human-derived Oatp1b3 can be utilized as a photoacoustic imaging
reporter gene, for detection of viable cancer cells, based on its ability to
take up indocyanine green in vivo.
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1.7.3 Overview of Studies
In our initial research, we strove to build on the seminal work first reported
in PNAS, which established rat-derived Oatp1a1 as an MRI reporter gene using
the paramagnetic contrast agent, Gd-EOB-DTPA (173). We wanted to extend
this work by establishing the feasibility of using Oatp1a1 at clinical doses of GdEOB-DTPA and a clinical field strength of 3 Tesla. In Chapter 2, we
demonstrated for the first time that Oatp1a1 is able to provide high resolution, 3D
information on the distribution of viable cancer cells in primary tumours, at clinical
contrast agent dose and field strength. Importantly, we validated the local
contrast enhancement exhibited on MRI with quantitative histology. This chapter
has been peer-reviewed and accepted for publication as: Nyström NN, Hamilton
AM, Xia W, Liu S, Scholl TJ, Ronald JA. “Longitudinal Visualization of Viable
Cancer Cell Intratumoral Distribution in Mouse Models Using Oatp1a1-Enhanced
Magnetic Resonance Imaging.” Investigative Radiology. 2019 May; 54(5): 302311. DOI: 10.1097/RLI.000000000 0000542. In Chapter 3, we worked with
human-derived Oatp1b3, a closely-related transporter to the rat-derived Oatp1a1,
and worked to establish its potential future use in humans as a clinical-grade
reporter gene. This research validated that Oatp1b3, like Oatp1a1, can also
transport Gd-EOB-DTPA with a significant efficiency for MR imaging. Importantly,
we further demonstrated that Oatp1b3 facilitates sensitive imaging of
spontaneous metastasis in preclinical mouse models at the single lymph node,
multi-lymph node, and distant organ metastatic stages on MRI at 3 Tesla.
Chapter 3 is currently in preparation as a manuscript for submission to peer-
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review. In Chapter 4, our research was focused on expanding the Oatp1 imaging
reporter gene “toolkit” beyond MR imaging to include photoacoustic imaging. This
extension offers potential for cost-effective, 3D imaging at tissue depths of
several centimeters. Here, we first demonstrated in in vitro experiments that
Oatp1b3 will transport indocyanine green resulting in increased signal-to-noise
ratios for both fluorescence and photoacoustic imaging. Using in vivo
fluorescence imaging, we determined the optimal imaging timepoint after
administration of indocyanine green to be 24 hours post-intraperitoneal injection.
And finally, we established in a murine breast cancer model that in vivo
photoacoustic imaging can readily detect Oatp1b3-engineered cancer cells after
injection of indocyanine green. This chapter has been peer-reviewed and
accepted for publication as: NN Nyström, LCM Yip, JJL Carson, TJ Scholl, JA
Ronald. “Development of a Human Photoacoustic Imaging Reporter Gene Using
the Clinical Dye Indocyanine Green.” Radiology: Imaging Cancer 1 (2), e190035.
DOI: 10.1148/rycan.201919 0035.
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CHAPTER 2 Intratumoral Distribution of Viable Cancer Cells over Time
Rationale. Multimodality reporter gene imaging provides valuable, non-invasive
information on the fate of engineered cell populations. To complement magnetic
resonance imaging (MRI) measures of tumour volume and 2-dimensional reporterbased optical measures of cell viability, reporter-based MRI may offer 3-dimensional
information on the distribution of viable cancer cells in deep tissues. Methods. Here, we
engineered human and murine triple-negative breast cancer cells with lentivirus
encoding tdTomato and firefly luciferase for fluorescence imaging and bioluminescence
imaging (BLI). A subset of these cells was additionally engineered with lentivirus
encoding organic anion transporting polypeptide 1a1 (Oatp1a1) for MRI. Oatp1a1
operates by transporting gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
(Gd-EOB-DTPA) into cells, and it concomitantly improves BLI substrate uptake. After
orthotopic implantation of engineered cells expressing or not expressing Oatp1a1,
longitudinal fluorescence imaging, BLI, and 3-Tesla MRI were performed. Results.
Oatp1a1-expressing tumours displayed significantly increased BLI signals relative to
control tumours at all time points (p<0.05). On MRI, post-Gd-EOB-DTPA T1-weighted
images of Oatp1a1-expressing tumours exhibited significantly increased contrast-tonoise ratios compared with control tumours and pre-contrast images (p<0.05). At
endpoint, tumours expressing Oatp1a1 displayed intratumoral MR signal heterogeneity
not present at earlier time points. Pixel-based analysis of matched in vivo MR and ex
vivo fluorescence microscopy images revealed a strong, positive correlation between
MR intensity and tdTomato intensity for Oatp1a1-expressing tumours (p<0.05), but not
control tumours. Conclusions. These results characterize Oatp1a1 as a sensitive,
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quantitative, positive contrast MRI reporter gene for 3-dimensional assessment of viable
cancer cell intratumoral distribution and concomitant BLI enhancement. This
multimodality reporter gene system can provide new insights into the influence of viable
cancer cell intratumoral distribution on tumour progression and metastasis, as well as
improved assessments of anticancer therapies.
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2.1 Introduction
Fluorescent reporter genes have provided valuable insight towards the
understanding of molecular processes occurring in cancer, from the role of regulatory
RNA (1, 2), to new knowledge on cancer stem cells (3), and the intercellular interactions
involved in metastasis (4). Although fluorescence imaging (FLI) produces excellent
resolution, it is restricted to superficial tissue depth due to light scattering in deep tissues.
Bioluminescence imaging (BLI) allows for sensitive whole-body imaging of luciferaseengineered cells in preclinical animal models with increased detection depth compared
to FLI but presents data with low two-dimensional resolution and minimal anatomic
information. Similar to FLI, BLI still suffers from light scattering, often preventing
researchers from pinpointing precise locations of reporter gene expression in deep
tissues. Additionally, light attenuation by surrounding tissues may fully impede the
detection of weaker signals from deeply-located and/or smaller populations of engineered
cells (5). Multimodality imaging can ameliorate inherent limitations present in a single
imaging modality (6-8). For example, reporter genes for magnetic resonance imaging
(MRI) would provide the high resolution, 3-dimensional and quantitative information
needed to complement data provided by more affordable and time-efficient optical
modalities such as FLI and BLI. Hence, development of a multimodality FLI/BLI/MRI
reporter system could be used to provide a more complete picture of the cellular and
molecular changes occurring in vivo over time, including its use in studying longitudinal
cancer progression and treatment response in preclinical animal models.
In recent years, MRI reporter gene development has largely focused on negative
contrast technologies based on iron-accumulating proteins such as ferritin heavy chain
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(FTH) and the transferrin receptor (TfR) (9). However, negative contrast in tumour
microenvironments can be the result of other processes such as hemorrhage, thereby
generating uncertainty in the source of the loss of contrast on MRI (10). Moreover, regions
of low signal naturally exist in MR images throughout the body (e.g., lungs). Alternatively,
positive contrast MRI reporter genes are also being developed (11-13). Recently, a
member of the organic anion-transporting polypeptide (OATP) family of proteins, namely
Oatp1a1 (slco1a1, slc21a1, slc21a3, oatp1, OATP-1), has been established as a positive
contrast MRI reporter gene based on its ability to take up a clinically-approved, liverspecific paramagnetic contrast agent called gadolinium ethoxybenzyl diethylenetriamine
pentaacetic acid (Gd-EOB-DTPA; Primovist/Eovist, Bayer-Schering Pharma, Berlin,
Germany) (14). Gd-EOB-DTPA-enhanced MRI performed on high-field 7-Tesla and 9.4Tesla scanners showed contrast enhancement of Oatp1a1-expressing xenografts in mice
following administration of high Gd-EOB-DTPA doses (approximately 25-fold greater than
clinical doses) (14). An added advantage of this system is that Oatp1a1 co-expression
with firefly luciferase also increased BLI signal generation in engineered cells through
increased intracellular uptake of the luciferase substrate D-luciferin (15). Further
development and characterization of Oatp1a1 as an MRI reporter gene with concomitant
BLI enhancement would allow for its widespread use in longitudinal imaging studies of
preclinical cancer models, as well as clinical MRI applications such as tracking of geneor cell-based therapies.
Here, we established a multimodality reporter gene system composed of two
distinct lentiviruses: the first lentivirus was built to co-express the fluorescence reporter
tdTomato (tdT) with the BLI reporter human codon-optimized firefly luciferase (FLuc2);
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and the second encoded the fluorescence reporter zsGreen1 (zsG) co-expressed with
Oatp1a1. Human and murine triple negative breast cancer (TNBC) cells were engineered
with this system and imaged both in vitro and in vivo. Following cell implantation,
orthotopic TNBC tumours in mice were longitudinally imaged for three weeks with BLI
and MRI using a clinical 3-Tesla MRI scanner. Each week, pre-contrast MRI was
performed on mice, followed by administration of Gd-EOB-DTPA (0.1 mmol/kg) at a dose
deemed safe for use in humans (16) and post-contrast MRI. Significant MRI and BLI
enhancement of Oatp1a1-expressing tumours was observed relative to control tumours.
Moreover, as tumour growth progressed, Oatp1a1-based high-resolution, 3-dimensional
MRI revealed intratumoral heterogeneity in signal enhancement, with enhanced MR
regions containing viable fluorescent TNBC cells according to ex vivo microscopic
analysis, and non-enhanced MR regions composed of necrotic tissue, hemorrhage,
and/or non-fluorescent cells. Our studies highlight the utility of this tri-modality reporter
gene system for tracking the fate of viable cancer cells over time using complementary
imaging modalities. We posit that this imaging approach will have significant impact for
improved monitoring of viable cancer cell growth across a broad range of preclinical solid
tumour models.
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2.2 Materials and Methods
2.2.1 Lentiviral Construction and Production
Third

generation

packaging

and

envelope-expression

plasmids

pMDLg/pRRE, pRSV-Rev, and pMD2.G were obtained (gifts from Didier Trono;
Addgene plasmids #12251, #12253, and #12259, respectively), in addition to a
third-generation lentiviral transfer vector encoding tdT and firefly luciferase (FLuc)
separated by a P2A self-cleaving peptide sequence (pUltra-Chili-Luc; gift from
Malcolm Moore; Addgene plasmid #48688). All cloning was performed using InFusion HD Cloning (Takara Bio USA, Inc.). In the pUltra-Chili-Luc vector, we first
replaced FLuc with FLuc2 and then replaced the Ubiquitin C promoter with a
human elongation factor 1 alpha promoter (pEF1α) obtained from the pSelect-ZeoSEAP Vector (Cat. psetz-seap, InvivoGen). This latter transfer vector was called
pEF1α-tdT/FLuc2. The resultant transfer vector was further cloned, using the same
protocol described above, to replace tdTomato with the zsGreen1 fluorescence
reporter gene (zsG) sequence, obtained from the pLVX-ZsGreen1-N1 Vector (Cat.
632565, Takara Bio USA, Inc.), generating an intermediary pEF1α-zsG/FLuc2
transfer plasmid. The LV-PGK-SO plasmid co-expressing mStrawberry- and
Oatp1a1 (14) was kindly provided by Dr. Kevin Brindle (University of Cambridge).
The E2A-Oatp1a1 sequence was amplified and cloned, as described above,
replacing the P2A-FLuc2 sequence within pEF1α-zsG/FLuc2 to obtain a pEF1αzsG/Oatp1a1 lentiviral transfer plasmid. To produce pEF1α-tdT/FLuc2 and pEF1αzsG/Oatp1a1 lentiviruses, the packaging, envelope and one of the transfer
plasmids were co-transfected into human embryonic kidney (HEK 293T) cells
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using

Lipofectamine

3000

(ThermoFisher

Scientific)

according

to

the

manufacturer’s lentiviral production protocol. Lentivirus-containing supernatants
were harvested 24h and 48h post transfection, filtered through a 0.45-μm filter,
and stored at -80°C prior to use.

2.2.2 Cell Culture and Stable Cell Generation
Human embryonic kidney cells (HEK 293T), human TNBC cells (MDA-MB231), and murine TNBC cells (4T1) were obtained from a commercial supplier
(American Type Culture Collection; ATCC) and cultured in Dulbecco's Modified
Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum at 37°C and
5% CO2. All cells were routinely verified as free of mycoplasma contamination
using the MycoAlert mycoplasma detection kit (Lonza Group). For stable cell
generation, MDA-MB-231 and 4T1 cells were first transduced with pEF1αtdT/FLuc2 lentivirus overnight in the presence of 4- to 8- μg/mL polybrene.
Transduced cells were washed, collected, and tdT-positive cells were sorted using
a FACSAria III fluorescence-activated cell sorter (BD Biosciences), thereby
generating luciferase-expressing cells. These luciferase-expressing cells were
expanded, and a subset of this population was additionally transduced with pEF1αzsG/Oatp1a1 lentivirus and zsG-positive cells were sorted. The resulting
population will be referred to as luciferase/Oatp1a1-expressing cells. During
sorting for zsG, cells were also sorted for tdTomato fluorescence intensity that was
equivalent to the original luciferase-expressing cells to maintain equivalent
luciferase expression. Fluorescence intensity of expanded cell populations was
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evaluated via flow cytometry using a FACSCanto flow cytometer (BD Biosciences).
Fluorescence was analyzed using FlowJo software (FlowJo LLC) to validate
luciferase- and luciferase/Oatp1a1-expressing cells had matched tdT fluorescence
signal (i.e., matched FLuc2 expression), and sorted and validated cells were
utilized for all experiments.

2.2.3 Immunofluorescence Staining
Luciferase- and luciferase/Oatp1a1-expressing cells were grown on glass
coverslips, rinsed with PBS, and fixed with 4% paraformaldehyde (PFA) for 10
minutes. Cells were then permeabilized via 0.02% Tween 20 (Sigma-Aldrich) for
20 minutes, incubated overnight at 4°C with rabbit anti-OATP1A1 primary antibody
(20 µg/ml, LS-C113034, LifeSpan BioSciences Inc.), followed by incubation with
goat anti-rabbit AlexaFluor 647-conjugated secondary antibodies for two hours at
room temperature (1:500 dilution, ab150079, Abcam). Coverslips were
counterstained with DAPI, mounted, and imaged using a LSM Meta 510
microscope (Zeiss).

2.2.4 Proliferation Assays
Non-transduced, luciferase-, and luciferase/Oatp1a1-expressing cells
(5×104) were seeded in 96-well plates and cell proliferation was evaluated using a
tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide,
MTT) assay. Optical absorbance measurements at 590 nm were made on a
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spectrophotometer at 0h, 24h and 48h post initial seeding. Measures at 24h and
48h were normalized to seeding values obtained at 0h to evaluate cell proliferation.

2.2.5 In Vitro Luciferase Assays
Total intracellular luciferase activity was measured on cell lysates using the
Dual-Luciferase Reporter Assay System (E1910, Promega). Light production in
relative light units (RLU) was measured on a GloMax 20/20 Luminometer
(Promega) after mixing of 10 μL of lysate and 5 μL of LARII substrate. Protein
concentrations were calculated using a Pierce BCA Protein Assay Kit for
normalization of light production (ThermoFisher Scientific). For BLI of intact cells,
1×105 cells/well were seeded in 6-well plates and grown for 3 days, after which
0.15 mg/ml D-luciferin was added to each well, and plates were imaged on an IVIS
Lumina XRMS In Vivo Imaging System (PerkinElmer). Following BLI, cells from
each well were harvested and protein concentrations were measured using a
Pierce BCA Protein Assay Kit. Average radiance values in photons/s/cm2/sr were
measured from each well using the software LivingImage (PerkinElmer) and
normalized to protein levels as a surrogate measure of cell number.

2.2.6 In Vitro Magnetic Resonance Imaging
Non-transduced, luciferase-, and luciferase/Oatp1a1-expressing cells
(2×106) were seeded in T-175 flasks and grown for 3 days. Cells were incubated
with media containing 1.6-mM Gd-EOB-DTPA or with media containing an
equivalent volume of PBS for 90 minutes at 37°C and 5% CO2. Cells were then
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washed 3 times with PBS, trypsinized and pelleted in 0.2-mL tubes, and placed
into a 2% agarose phantom mold that was incubated in a 37°C chamber for two
hours to mimic body temperature. MRI was performed on a 3-T GE clinical MR
scanner (General Electric Healthcare Discovery MR750 3.0 T, Milwaukee WI,
U.S.A.) and a 3.5-cm diameter birdcage RF coil (Morris Instruments, Ottawa, ON,
Canada). A fast spin echo inversion recovery (FSE-IR) pulse sequence was used
with the following parameters: field of view (FOV) = 256´256, repetition time (TR)
= 5000 ms, echo time (TE) = 19.1 ms, echo train length (ETL) = 4, number of
excitations (NEX) = 1, receiver bandwidth (rBW) = 12.50 MHz, inversion times (TI)
= 50, 100, 125, 150, 175, 200, 250, 350, 500, 750, 1000, 1500, 2000, 2500, 3000,
in-plane resolution = 0.27 mm2, slice thickness = 2.0 mm, scan time = 5 min and
25 s per inversion time. Spin-lattice relaxation rates (R1) were determined by nonlinear least-squares fitting (MATLAB, MathWorks, Natick, Massachusetts, United
States) of signal intensities across the series of variable inversion time images on
a pixel by pixel basis. The most common inversion recovery equation presented in
the literature is as follows:
! = # ∙ (1 − 2)

!

#$
#!

+ )

!

#%
#! )

Here, ! represents the acquired signal, and # is the proportionality
constant, which depends on the specific coil used, the main magnetic field, the
proton density, and the temperature, amongst other factors (17). However, two
practical obstacles exist that render this equation impractical for real-world
applications: first, a perfect 180° pulse is never truly achieved, and second, the
signal is not acquired immediately after the RF pulse (18). In practice, these real91

world limitations produce a different behavior at -. = 0 and -. = ∞ than
predicted theoretical outputs dictated by the equation above. To address these
limitations, and assuming -1 ≫ -. , the equation above was adjusted to the
following:
! = 3&& − (3&& − 3' ) ∙ )

"#$%
#!

Here, if -. = 0, then ! = −3' where 3' is simply the first value of the
inversion recovery curve, independent of the final, steady state magnetization 3&& .
Additionally, if -. = ∞, then ! = 3&& . Finally, we use the absolute value of this last
equation because the DICOM images acquired provided magnitude (non-phase)
information:
! = 43&& − (3&& − 3' ) ∙ )

"#$%
#!

4

The zero-crossing point, the -. at which point ! = 0, is extrapolated from
the data and the 1( of each pixel can be determined via the following
relationship:
1( = ln 27-.

)*++

2.2.7 Orthotopic Tumour Model
Animals were cared for in accordance with the standards of the Canadian
Council on Animal Care, and experiments were undertaken with an approved
protocol of the University of Western Ontario’s Council on Animal Care (AUP 2016026). One million luciferase- (n=4) or luciferase/Oatp1a1-expressing (n=5) MDA92

MB-231 cells, or 0.3×106 luciferase- (n=5) or luciferase/Oatp1a1-expressing (n=5)
4T1 cells were implanted orthotopically into the right fourth mammary fat pad of
immunocompromised (Nu/Foxn1-nu) female mice (Charles River). Fluorescence
imaging for tdTomato, BLI for luciferase with or without co-expression of Oatp1a1,
and Gd-EOB-DTPA enhanced MRI for Oatp1a1 was performed on mice according
to the imaging timelines specified below. Non-specific Gd-DTPA-enhanced MRI
was also performed on mice bearing luciferase-expressing tumours (n=2) or
luciferase/Oatp1a1-expressing tumours (n=2) at endpoint.

2.2.8 In Vivo Fluorescence and Bioluminescence Imaging
FLI and BLI were performed on an IVIS Lumina XRMS In Vivo Imaging
System (PerkinElmer). For MDA-MB-231 mice, FLI and BLI was performed on
days 0, 4, 8, 12, and 16 after cell implantation. For 4T1 mice, FLI and BLI was
performed on days 0, 4 and 8 after cell implantation. Mice were anesthetized with
1-2% isoflurane using a nose cone attached to an activated carbon charcoal filter
for passive scavenging. FLI for tdTomato was performed using 554-nm excitation
and 581-nm emission filters. Images were acquired with a 0.15-s exposure time.
Mice were then administered 150 μL of 30-mg/mL D-luciferin intraperitoneally and
BLI images with 0.15-s exposure times were captured every 30 s for 30 minutes.
Regions of interest (ROIs) were manually drawn around tumour borders using
LivingImage software (PerkinElmer) to measure fluorescence radiance efficiency
(µW/cm2). The ROI of the tdTomato fluorescence image for each mouse on each
day was then overlayed onto the corresponding BLI image, that was acquired
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subsequently, to measure bioluminescent average radiance (p/s/cm2/sr). The ratio
of BLI average radiance to fluorescence radiance efficiency, which we called
normalized radiance in accordance with previous literature (19), was then
calculated for each tumour on each day.

2.2.9 In Vivo Magnetic Resonance Imaging
Scans were performed on a 3-T GE clinical MR scanner (General Electric
Healthcare Discovery MR750 3.0 T, Milwaukee WI, U.S.A.) using a custom-built
gradient insert and a bespoke 5-cm-diameter solenoidal radiofrequency coil. For
MDA-MB-231 mice, MRI was performed on days 7, 9, 14, 16, 21, and 23 after cell
implantation. 4T1 mice were imaged on days 7 and 9. Mice were anesthetized
with 1-2% isoflurane using a nose cone attached to an activated carbon charcoal
filter for passive scavenging. T1-weighted images were acquired using a Spoiled
Gradient Recalled Acquisition in Steady State (SPGR) pulse sequence using the
following parameters: FOV = 50mm, TR = 15.8 ms, TE = 10.5 ms, rBW = 31.25
MHz, ETL = 4, Frequency and Phase 500×500, Flip Angle: 60°, NEX = 1, v 100µm isotropic voxels, scan time = approximately 22-24 minutes per mouse
(dependent on mouse size). Pre-contrast images were acquired approximately 48
hours prior to post-Gd-EOB-DTPA imaging, on days 7, 14, and 21. For post-GdEOB-DTPA imaging on days 9, 16, and 23, mice were administered 0.1 mmol/kg
Gd-EOB-DTPA via the tail vein and imaged on MRI 5 hours post-injection. (See
timeline in Supplementary Figure 1.) Additionally, mice bearing luciferase- (n=2)
and luciferase/Oatp1a1-expressing (n=2) MDA-MB-231 tumours at endpoint were
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administered 0.1 mmol/kg gadolinium-diethylenetriamine pentaacetic acid (GdDTPA; Magnevist, Bayer-Schering Pharma, Berlin, Germany) and imaged 10
minutes post-injection using the scanning parameters described above. Following
imaging, whole-tumours were manually segmented in three-dimensions using ITKSNAP software and contrast-to-noise ratios relative to hind-leg muscle in all
images were calculated (20).

2.2.10 Histology
Following in vivo experiments, mice were sacrificed via isoflurane overdose,
perfused with 4% PFA through the left heart ventricle and tumours were excised
from mammary fat pads. Tumours were then frozen in OCT medium (Sakura
Finetek) and 10-µm frozen sections were collected. Whole-tumour microscopy
images of tdTomato fluorescence were taken using an EVOS FL Auto 2 Imaging
System (Invitrogen) prior to hematoxylin/eosin (H&E) staining of the same and/or
adjacent histology sections and subsequent imaging with the same microscope.
For pixel-by-pixel analysis of MRI intensity to tdTomato fluorescence intensity,
fluorescence microscopy images of whole-tumours were converted to the
Neuroimaging Informatics Technology Initiative (NIfTI) data format (21). A blinded
participant matched fluorescence microscopy images to a corresponding Gd-EOBDTPA-enhanced MRI image plane for a luciferase- and luciferase/Oatp1a1 mouse,
and utilized a 15-fiducial system per image set on 3D Slicer (Version 4.31, Surgical
Planning Laboratory, Brigham & Women's Hospital Boston MA, U.S.A.) to perform
a non-rigid image registration using with a custom software plugin (22). Following
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registration, fluorescence microscopy and Gd-EOB-DTPA-enhanced MR images
of each tumour were imported into MATLAB, overlayed, and MR intensity and
fluorescence intensity were each binned into 256 values. Pixels with zero-values
for MR intensity and/or tdTomato fluorescence intensity were excluded from the
analysis. Once MR intensity and fluorescence intensity were obtained for each
pixel, the mean fluorescence intensity for each MR intensity bin was then
calculated. MR intensity bins with fewer than 100 pixels were excluded from the
analysis to eliminate bins with insufficient sampling numbers for meaningful
calculations.

2.2.11 Statistics
Unpaired two-tailed t tests were performed using Graphpad Prism software
(Version 7.00 for Mac OS X, GraphPad Software Inc., La Jolla California USA,
www.graphpad.com) for cell characterization and luciferase studies. Two-way
Analysis of Variance (ANOVA) and Tukey’s post-hoc multiple comparisons were
performed for MRI results. For pixel-by-pixel MRI-to-fluorescence image analysis,
Pearson correlation tests were performed. For all tests, a nominal p-value less
than 0.05 was considered statistically significant.
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2.3 Results
2.3.1 Lentiviral expression of reporter genes in human and murine TNBC cells
Lentiviral transfer plasmids encoding pEF1a-tdT/FLuc2 and pEF1azsG/Oatp1a1 were successfully engineered and utilized to produce lentiviral
vectors (Figure 2.1A). Human (MDA-MB-231) and murine (4T1) TNBC cell lines
were transduced with pEF1a-tdT/FLuc2 lentivirus and subsequently sorted for
tdTomato fluorescence with >95% purity to obtain luciferase-expressing cells.
Following sorting and expansion, a subset of luciferase-expressing cells was
transduced a second time with pEF1a-zsG/Oatp1a1 lentivirus and sorted again for
zsGreen1 fluorescence with >95% purity whilst also matching the tdTomato
intensity to that of the original luciferase-expressing cells (Figure 2.1B). OATP1A1
immunostaining confirmed absence of Oatp1a1 expression in luciferaseexpressing cells, whereas positive OATP1A1 staining was present in cells double
transduced with the pEF1a-zsG/Oatp1a1 lentivirus (Figure 2.1C), hereafter
referred to as luciferase/Oatp1a1-expressing cells. Proliferation assays showed no
difference in growth rates between non-transduced cells, luciferase-expressing
cells, and luciferase/Oatp1a1-expressing cells for both human and murine TNBC
cell lines.
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Figure 2.1. Lentiviral Engineering of Triple-Negative Breast Cancer Cells with a
Multimodality Reporter Gene System. A, Reporter gene constructs for co-expression
of tdT and human codon-optimized firefly luciferase (luciferase), and zsG and organic
anion-transporting polypeptide 1a1 (Oatp1a1). B, Histograms of 4T1 cells engineered
with the reporter gene constructs and fluorescence-activated cell sorted for tdT and zsG
fluorescence. C, Anti-Oatp1a1 immunofluorescence staining of MDA-MB-231 cells
engineered with tdT/luciferase lentivirus alone (Luciferase Control) or additionally
engineered with zsG/Oatp1a1 lentivirus (Luciferase OATP1A1). Scale bar = 20 μm.
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2.3.2 Increased BLI signal and Gd-EOB-DTPA-enhanced MRI contrast of TNBC cells
co-expressing luciferase/Oatp1a1
To first compare luciferase activity across engineered cells excluding any
contribution from OATP1A1, cell lysates were prepared and luciferase activity
assays exhibited no significant difference in intracellular luciferase activity between
luciferase- and luciferase/Oatp1a1-expressing cells (n=3 per group). By contrast,
for cells with intact membranes, where OATP1A1 functions, MDA-MB-231 cells
co-expressing luciferase and Oatp1a1 exhibited a significant 5.5-fold increase in
BLI signal (4.072 ± 0.145 ×1011 p/s/cm2/sr/μg) relative to cells expressing
luciferase alone (7.432 ± 0.515 ×1010 p/s/cm2/sr/μg) (n=3, p<0.05; Figure 2.2AB). Similarly, 4T1 cells co-expressing luciferase and Oatp1a1 exhibited a
significant 2.6-fold increase in BLI signal (4.091 ± 0.383 ×107 p/s/cm2/sr/μg)
relative to cells expressing luciferase alone (1.603 ± 0.068 ×107 p/s/cm2/sr/μg)
(n=3, p<0.05).
Next, non-transduced, luciferase-, and luciferase/Oatp1a1-expressing cells
were incubated with or without Gd-EOB-DTPA (1.6 mM) for 90 minutes, washed
thoroughly, and pelleted before being placed into an agarose cell phantom (Figure
2.2C-D). Inversion recovery MRI of the phantom was performed at 3T and 37°C,
and spin-lattice relaxation rate (R1) maps were generated. In the absence of GdEOB-DTPA, neither MDA-MB-231 (Figure 2.2C-D), nor 4T1 cells, displayed
differences in R1 rates between non-transduced and transduced genotypes.
Further, control non-transduced and luciferase-expressing cells treated with GdEOB-DTPA did not exhibit differences in R1 rates relative to untreated controls or
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to each other. Exclusively, cells engineered to express Oatp1a1 exhibited
significantly increased R1 rate following Gd-EOB-DTPA incubation compared to all
other conditions. MDA-MB-231 cells co-expressing Oatp1a1 demonstrated a
significant 3.7-fold increase in R1 rate following treatment with Gd-EOB-DTPA
(2.898 ± 0.484 s-1) relative to luciferase-expressing MDA-MB-231 cells (0.848 ±
0.011 s-1) (n=3, p<0.01; Figure 2.2C-D). 4T1 cells co-expressing Oatp1a1
demonstrated a 16.1-fold increase in R1 rate following incubation with Gd-EOBDTPA (14.325 ± 6.01 s-1) relative to luciferase-expressing 4T1 cells (0.859 ± 0.023
s-1) (n=3, p<0.01).

100

A

Average Radiance

B

BLI Radiance
3.4e8

***

Luciferase
Control
Luciferase
OATP1A1

4×1011
3×1011
2×1011
1×1011
0

2.5e7
p/s/cm2/sr
Tr

Spin-Lattice
Relaxation Map

C

n=3
*p<0.05

5.5-fold
5×1011

Average
AverageRadiance
Radiance
(p/s/cm
/sr/µg)
(p/s/cm2/sr/ug)

Non
Transduced

D

n
Naïve
N o ed
c
u
sd
an

e
Luciferase
as l

r
fe ro
ci ont
u
L C

OATP1A1
se

ra 1
fe A
ci TP1
u
L A
O

Spin-Lattice Relaxation Rates

s-1
1
6

Naïve

3.0

n=3
*p<0.05

Non
Naïve
Transduced

2
2.0

5

3

Gd-EOB-DTPA

Control

**

Luciferase
OATP1A1
OATP1A1
1.0

4

Untreated

Luciferase
Luciferase

0

1

2

3

4

R1 Relaxation Rate (s-1)

Figure 2.2. In Vitro Functional Characterization of Triple-Negative Breast Cancer
Cells Engineered with Reporter Genes. (A) Representative well plate of non
transduced,

luciferase-

(Luciferase

Control),

and

luciferase/Oatp1a1-expressing

(Luciferase OATP1A1) MDA-MB-231 cells imaged following administration of 1 μL of 150
mg/mL D-Luciferin. (B) Normalized average radiance (p/s/cm2/sr/μg) of MDA-MB-231
cells following administration of 1 μL of 150 mg/mL D-Luciferin (n=3, *p<0.05). (C) Spinlattice relaxation map of representative phantom containing cell pellets of MDA-MB-231
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cells either treated or untreated with 1.6 mM Gd-EOB-DTPA as follows: 1 treated nontransduced, 2 untreated non-transduced, 3 treated Luciferase Control, 4 untreated
Luciferase Control, 5 treated Luciferase OATP1A1, 6 untreated Luciferase OATP1A1.
(D) Spin-lattice relaxation rates (s-1) of engineered and non-engineered MDA-MB-231
cells either treated or untreated with 1.6 mM Gd-EOB-DTPA (n=3, *p<0.05). Error bars
indicate standard deviation.
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2.3.3 Oatp1a1 expression increases in vivo BLI and MRI signal of orthotopic TNBC
tumours over time
Immunocompromised female mice were implanted with luciferase- or
luciferase/Oatp1a1-expressing cells into the fourth mammary fat pad to generate
orthotopic tumours for longitudinal FLI, BLI, and MRI. tdTomato FLI was performed
to obtain relative measures of the total number of viable cells within each tumour
in order to normalize BLI signals across time. As a result, average radiance
measures (p/s/cm2/sr) from BLI images were normalized to fluorescence efficiency
measures (μW/cm2) in FLI images to obtain measures of normalized radiance.
Luciferase/Oatp1a1-expressing MDA-MB-231 tumours that had near-equivalent
FLI signals displayed higher BLI signals than luciferase-expressing tumours
without Oatp1a1 (Figure 2.3A). At each time point, MDA-MB-231 tumours
expressing both luciferase and Oatp1a1 (n=5) exhibited significantly increased
normalized radiance, relative to tumours expressing luciferase alone (n=4; p<0.05)
(Figure 2.3B-C). Similarly, 4T1 tumours expressing both luciferase and Oatp1a1
(n=5) also exhibited significantly increased normalized radiance relative to
luciferase-expressing tumours not expressing Oatp1a1, averaging a 2.9-fold
increase in normalized radiance (n=5; p<0.05). Collectively, pooled imaging data
across all time points for MDA-MB-231 tumours were significantly higher for
tumours co-expressing Oatp1a1 compared to tumours without, averaging a 4.0fold increase in normalized radiance.
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Figure 2.3. In Vivo Bioluminescence Enhancement via Oatp1a1. (A) Representative
fluorescence (top panel) and bioluminescence (bottom panel) images of mice bearing
MDA-MB-231 luciferase-expressing tumours (left; Luciferase Control) or MDA-MB-231
luciferase/Oatp1a1-expressing tumours (right; Luciferase OATP1A1). (B) tdTomato
fluorescence efficiency (μW/cm2) of MDA-MB-231 tumours over time. (C) Normalized
radiance (no units) of MDA-MB-231 tumours over time (*p<0.05). Error bars indicate
standard deviation.
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Next, we performed Gd-EOB-DTPA-enhanced MRI of these mice on a 3
Tesla MRI scanner. Pre-contrast images of MDA-MB-231 tumours (Figure 2.4A
and 2.4C) and 4T1 tumours exhibited no difference in CNR between luciferase
and luciferase/Oatp1a1 tumours across all time points. Conversely, following
administration of Gd-EOB-DTPA, luciferase/Oatp1a1 tumours showed significantly
elevated CNR across all time points compared to all other conditions (p<0.05;
Figure 2.4B, 2.4D, 2.4E). Mice bearing 4T1 tumours imaged at days 7 and 9 after
cell implantation showed a significant 2.6-fold increase in CNR after Gd-EOBDTPA administration in mice bearing luciferase/Oatp1a1 tumours relative to
luciferase-expressing tumours (n=5; p<0.05). Collectively, pooled data across all
time points showed a significant 2.2-fold average increase in CNR for
luciferase/Oatp1a1 MDA-MB-231 tumours (n=5) post-contrast images relative to
luciferase tumours (n=4; p<0.05). Contrast enhancement consistently returned to
baseline levels within 5 days following administration of Gd-EOB-DTPA (Figure
2.4E).
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Figure 2.4. In Vivo MR Signal Enhancement via Oatp1a1. Representative T1-weighted
3-dimensional reconstruction of mouse bearing luciferase-expressing MDA-MB-231
tumour (Luciferase Control) at Day 7 (A) before and (B) 5-hours following administration
of 0.1-mmol/kg Gd-EOB-DTPA at Day 9. Representative T1-weighted 3-dimensional
reconstruction of mouse bearing luciferase/Oatp1a1-expressing MDA-MB-231 tumour
(Luciferase OATP1A1) at Day 7 (C) before and (D) 5-hours following administration of
0.1-mmol/kg Gd-EOB-DTPA at Day 9. (E) Mean contrast-to-noise ratios (CNR) of MDAMB-231 tumours over time (*p<0.05, ****p<0.0001). Error bars indicate standard
deviation.
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2.3.4 Bright regions in Gd-EOB-DTPA-enhanced MR images of Oatp1a1-expressing
tumours correspond to areas of viable cancer cells in matched histological sections
Upon sacrifice, tumours were harvested and whole-tumour sections were
imaged for tdTomato fluorescence, followed by H&E staining (Figure 2.5).
Luciferase tumours did not display contrast enhancement and/or any patterns of
heterogeneity in post-Gd-EOB-DTPA images (Figure 2.5A). By comparison, as in
Figure 2.4, luciferase/Oatp1a1 tumours imaged following Gd-EOB-DTPA (0.1
mmol/kg) administration were brighter than in pre-contrast images, and in some
tumours (n=2), both enhancing and non-enhancing regions were notable (Figure
2.5E). Qualitatively, enhancing regions on Gd-EOB-DTPA-enhanced MRI of
luciferase/Oatp1a1 tumours corresponded to regions of increased tdTomato
fluorescence intensity on matched and co-registered confocal microscopy images
(Figure 2.5H), whereas non-enhancing regions corresponded to areas that either
lacked tdTomato fluorescence or displaying overtly bright fluorescence, which
were subsequently shown to be either acellular, necrotic regions (no fluorescence)
or hemorrhagic regions (autofluorescence) on H&E stained sections, respectively
(Figure 2.5G). For mice in Figure 2.5, MR images approximately 10 minutes postadministration of Gd-DTPA (0.1 mmol/kg) were acquired to compare contrastenhancement distribution patterns to that with Oatp1a1-based Gd-EOB-DTPA
enhancement (Figure 2.5B and 2.5F). In Gd-DTPA-enhanced images, control
tumours did display heterogeneous contrast enhancement (Figure 2.5B, yellow
contour), with enhancing regions identified to be largely lacking tdTomato
fluorescence and acellular according to histology (Figure 2.5C-D). Importantly,
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maximum contrast enhancement within Oatp1a1-expressing tumours is acquired
5-hours following administration of Gd-EOB-DTPA (12), once non-specific contrast
enhancement has already cleared, as demonstrated by the absence of
enhancement on MRI in the central region of the tumour evidently occupied by a
hemorrhagic core (Figure 2.5G).
For quantitative pixel-by-pixel analysis, post-Gd-EOB-DTPA MR images
and whole-tumour tdTomato fluorescence microscopy images of a luciferase- and
luciferase/Oatp1a1-expressing

tumour

were

successfully

co-registered

(Figure2.6). Using the exclusion criteria described in the methods, 0.86% of pixels
were eliminated from the analysis of the control luciferase tumour (99.14% pixels
analyzed), and 0.72% of pixels from the luciferase/Oatp1a1-expressing tumour
image analysis were eliminated (99.28% pixels analyzed). Fluorescence intensity
of the luciferase/Oatp1a1-expressing tumour exhibited a non-zero background
signal (Sbackground = 28.8) as well as a point of saturation in the fluorescence signal
(Ssaturation= 53.3); linear regression analysis was thus performed within these limits.
The luciferase/Oatp1a1-expressing tumour exhibited a significant strong, positive
correlation between MR intensity on in vivo Gd-EOB-DTPA-enhanced images and
tdTomato fluorescence intensity on ex vivo histology, with a goodness-of-fit (R2)
coefficient of 0.9821 (n=18,368 pixels, p<0.0001) (Figure 2.6A-C). The control
luciferase-expressing tumour did not exhibit any significant correlation between
MR intensity and fluorescence intensity, with a goodness-of-fit (R2) coefficient of
0.1992 (n=17,270 pixels, p=0.17) (Figure 2.6D-F).
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Figure 2.5. In Vivo Magnetic Resonance Imaging of TNBC Tumours with
Corresponding Histology. Luciferase-expressing MDA-MB-231 tumour (Luciferase
Control) (A) on Day 23, 5-hours following administration of 0.1-mmol/kg Gd-EOB-DTPA;
(B) on Day 25, approximately 10 minutes following administration of 0.1-mmol/kg GdDTPA; along with corresponding (C) H&E staining and (D) tdTomato fluorescence
microscopy. Note that this is the same tumour presented in Figure 4A-B. MDA-MB-231
tumour co-expressing luciferase and Oatp1a1 (Luciferase OATP1A1) (E) on Day 23, 5hours following administration of 0.1-mmol/kg Gd-EOB-DTPA; (F) on Day 25,
approximately 10 minutes following administration of 0.1-mmol/kg Gd-DTPA; along with
corresponding (G) H&E staining and (H) tdTomato fluorescence microscopy. Note that
this same tumour is presented in Figure 4C-D at an earlier timepoint. Yellow contours and
arrows indicate comparative features of interest. NT, non-transduced cells. NC, necrotic
core hemorrhaging, which is autofluorescent in the tdTomato image.
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Figure 2.6. Pixelwise Analysis of In Vivo MR Intensity to Ex Vivo Fluorescence
Intensity of TNBC Tumours Engineered with Reporter Genes. (A) T1-weighted image
of MDA-MB-231 tumour co-expressing luciferase and Oatp1a1 (Luciferase OATP1A1) 5hours following administration of 0.1-mmol/kg Gd-EOB-DTPA acquired on Day 23. (B)
Corresponding tdTomato fluorescence microscopy of same tumour, and (C) MR intensity
vs fluorescence intensity correlation plot (R2=0.9821, p<0.0001, n=18,368 pixels). (D) T1weighted image of luciferase-expressing MDA-MB-231 tumour (Luciferase Control) 5hours following administration of 0.1-mmol/kg Gd-EOB-DTPA acquired on Day 23. (E)
Corresponding tdTomato fluorescence microscopy of same tumour, and (F) MR intensity
vs fluorescence intensity correlation plot (R2=0.03967, p=0.1701, n=17,270 pixels)
(*p<0.05).
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2.4 Discussion
In this study, we present a robust approach for sensitive in vivo
multimodality tracking of viable engineered cancer cells based on Oatp1a1mediated BLI and MRI contrast agent uptake. This integrated system enables timeefficient, low cost BLI for 2D monitoring of cancer cell viability, as well as 3D
intratumoural cell viability measures with Gd-EOB-DTPA-enhanced MRI that is not
provided by traditional MRI techniques (Figures 2.4 and 2.5). Gd-EOB-DTPAenhancing regions of T1-weighted images of Oatp1a1-expressing tumours
matched remarkably well with areas of viable cancer cells in matched histological
images (Figure 2.5), which was further validated via pixel-by-pixel correlational
analysis (Figure 2.6). The resulting strong, positive correlation between in vivo
MRI intensity and ex vivo fluorescence intensity reveals a quantitative ability of
Oatp1a1-dependent MRI to convey surrogate information on viable cancer cell
distributions and densities within tumours. These tools therefore provide the ability
to obtain important tumour characteristics for a better understanding of tumour
architecture over time (23-25) and would be valuable for evaluating the efficacy of
candidate therapies in the future.
Arguments can be made on the benefits of reporter genes operating on
other modalities, particularly positron emission tomography (PET), such as the
mutant herpes simplex virus type 1 thymidine kinase (HSV1-sr39tk), which offers
relatively high SNR with respect to the trace amounts of contrast agent
administered into the biological system (26-28). However, the spatial resolution of
PET signals from reporter genes (~1 mm) are relatively poor compared to MRI

111

(~100 μm in-plane) (29). The strength and utility of MRI lies in its ability to generate
highly resolved anatomical information in 3-dimensions. Reporter genes operating
on MRI can contribute a unique advantage to this modality by providing information
on precise locations of viable, specific engineered cell populations. However, many
established MRI reporter genes, such as those that operate through ironsequestration, generate undesirable negative contrast that can spread beyond
precise locations of where the iron resides (i.e., a blooming artifact), obscuring
underlying anatomy. Negative contrast in tumour microenvironments can be
produced through other processes such as hemorrhage, thereby causing
uncertainty in the source of the signal (10). Additionally, negative contrast already
exists at major sites of oncogenesis and metastasis such as the lungs, hindering
the ability to image ectopic negative contrast within important regions of the body
(30). Iron-sequestering reporter genes have also been reported to alter phenotype
and differentiation patterns in therapeutic cells, likely due to their physiologically
central role in iron homeostasis and protection from oxidative stress (31). Positive
contrast reporter genes for MRI have also been described in the literature. The
most established class comprises of lysine-rich proteins capable of chemical
exchange saturation transfer (CEST), affording the unique ability to toggle between
detection and silencing of CEST signals through selective radiofrequency (RF)
pulses (12). The Oatp1a1 system operates via an entirely different contrast
mechanism relative to CEST, which opens potential to track two different cell
populations, or different genetic information within a single cell population, by using
both CEST and Oatp1a1 positive-contrast reporters within the same study.

112

Gd-EOB-DTPA and Oatp1a1 as a positive contrast probe-reporter system
offers a unique combination of advantages, which include physiological
compatibility, specificity in contrast enhancement, reversibility, as well as
mammalian-origin. With respect to physiological compatibility, Oatp1a1 is
biologically derived from a liver transporter protein that takes up bile acids (BAs)
and specific exogenous drugs for further metabolism and/or clearance by the liver;
in itself, the protein has not been reported to exhibit enzymatic or physiologicallycentral activity, though studies describing effects of altered Oatp1a1 expression
are very limited in number (32, 33). In our study, we did not find any quantitative
differences in cell proliferation, or qualitative observations in morphology that
distinguished Oatp1a1-expressing cells from their parental lines, supporting the
notion that physiological effects are negligible as a result of its synthetic
expression, though more studies are needed and are being pursued. Thus,
biological imaging studies can be performed using Oatp1a1 with little concern over
any confounding effects. It is important to caution, however, that candidate
therapies should be tested in vitro for specific uptake by Oatp1a1 prior to
performing a full preclinical animal study. Unanticipated uptake of a drug by
Oatp1a1 may result in its concentration within the tumour and, thus, a pronounced
therapeutic effect may be observed that would not have occurred in the absence
of Oatp1a1 expression. For example, methotrexate has been shown to be taken
up specifically by a human transporter, Oatp1b3, that overlaps in function with rat
Oatp1a1, while other anti-tumour drugs such as tyrosine kinase inhibitors exhibit
no uptake through this transporter (34).
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The Gd-EOB-DTPA and Oatp1a1 system additionally provides the benefits
of specificity in contrast enhancement and reversibility. Traditional contrastenhanced MRI methods for measuring tumour response to therapy in preclinical
animal models are largely based on blood-pooling contrast agents such as GdDTPA. Though these agents offer powerful means to detect cancerous lesions,
they fall short in conveying information pertaining to the distribution of viable
cancer cells within the enhancing mass. For example, reduction in tumour size as
measured by Gd-DTPA-enhanced MRI may be caused by eradication of noncancerous volumes by the candidate therapy, thereby generating false positive
treatment outcomes in preclinical animal studies. This is plausible when
considering that it is difficult to differentiate between important, antagonistic
parameters on Gd-DTPA-enhanced MRI, such as tumour recurrence and
treatment necrosis (35), or vasogenic edema and infiltrative tumour (36). With
Oatp1a1, images are acquired prior to and 5 hours post administration of Gd-EOBDTPA, long after any non-specific contrast enhancement is cleared, allowing for a
comparison of the two images for detection of engineered cancer cells with high
specificity. Further, the contrast enhancement returns to baseline approximately
40 hours post-administration of Gd-EOB-DTPA, as the contrast agent washes out
(14), demonstrating its reversibility, unlike other genetically-encoded reporters
such as ferritin heavy chain for example, which exhibits signal persistence for more
than seven days following inactivation of an established inducible promoter driving
its expression (37). It is important to note, however, that these timepoints for
maximal tumour CNR and washout kinetics of Gd-EOB-DTPA by Oatp1a1-
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expressing cells are based on previous publications (12) and have not been
verified in our study. The point of maximum contrast agent retention and contrast
agent washout may differ between different engineered cell types and will also
likely depend on the site of implantation. We do show that tumour CNR
enhancement of Oatp1a1-expressing mammary fat pad tumours does return to
pre-contrast baseline levels five days after Gd-EOB-DTPA administration (Figure
4E). Further, Oatp1a1-expressing tumours were imaged immediately following GdDTPA administration (n=2) two days following Gd-EOB-DTPA imaging (Figure
2.5F), where CNR in non-dynamic contrast enhancing regions was observed to be
similar to baseline (i.e. pre-contrast) values. Though only anecdotal, this finding
supports previous reports that Gd-EOB-DTPA contrast enhancement within
Oatp1a1-expressing cells returns to baseline approximately two days postadministration (14).
In comparison to previous studies using high-field scanners and relatively
high Gd-EOB-DTPA doses (14), we demonstrate the feasibility of the system using
a 3-Tesla scanner and Gd-EOB-DTPA doses (0.1 mmol/kg) that, while
approximately 4-fold the traditional dose (0.025 mmol/kg) used in the clinic, was
deemed safe for patients who do not have renal impairments (16, 38). Doses up
to 0.5 mmol/kg have also been used in patients (39). Recent work has been
performed on a human transporter that overlaps in function with rat-derived
Oatp1a1, namely Oatp1b3, where xenografts engineered to express Oatp1b3
showed contrast enhancement following administration of Gd-EOB-DTPA using a
7-Tesla scanner (40). This human variant may mitigate immunogenicity concerns
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over introducing a non-human protein into human cells for clinical translation or
when performing imaging of patient-derived tumour xenografts in humanized mice
(41). Future work should also evaluate the utility of rat (i.e., Oatp1a1) and mouse
(i.e., Oatp1 (42)) transporter proteins for performing longitudinal MRI of cancer cell
viability in immunocompetent rat and mouse models, respectively. Such advances
could help alleviate the use of immunogenic reporters such as GFP and luciferases
for monitoring tumour progression in syngeneic immunocompetent experimental
models or transgenic models.
This technology could also be applied to monitor oncotherapies in real-time,
including the viability and location of engineered therapeutic cells targeting
cancerous tissue (43-45), and for tracking the activation of gene-based therapies
directed toward cancers (46-50). In conclusion, the promising sensitivity,
specificity, positive contrast, reversibility, high resolution, and 3D spatial
information generated by this multimodality reporter gene system warrant the
application of Oatp1a1 to uncover new dynamic insights about how tumours
develop

and

respond

to

therapies

through

simultaneous

fluorescence,

bioluminescence, and magnetic resonance imaging.
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CHAPTER 3 Whole-Body, Sensitive Visualization of Spontaneous Metastasis in
Mice using the Oatp1b3 MRI Reporter System
Rationale. Metastasis is the leading cause of cancer-related deaths. However, 75% of
preclinical cancer studies do not examine metastasis, focusing only on primary tumour
growth, in part due to a lack of technologies for accurate quantification of metastatic
spread over time. To better understand the metastatic process and advance our ability
to test therapies targeting metastatic disease, tools for accurate spatiotemporal
quantification of metastasis are needed. Our objective was to assess Oatp1b3 for
whole-body in vivo tracking of cancer cells in a spontaneous metastasis model.
Methods. Breast cancer cells were engineered with lentivirus to express luciferase for
bioluminescence imaging (BLI). A subset of these cells was additionally engineered to
co-express Oatp1b3 for MRI. Luciferase control (Luc-CTL) or luciferase/Oatp1b3 (Luc1B3) cells were implanted into the 4th mammary fat pad of female mice. BLI and T1weighted 3T-MRI was performed before and after 1-mmol/kg Gd-EOB-DTPA injection.
Results. Macro-metastases (>1mm3) located at axillary lymph nodes exhibited
significantly increased MR signal intensity in Luc-1B3 mice on post-contrast images
relative to pre-contrast images, and to Luc-CTL mice both pre- and post-contrast (n=3,
p<0.0001). Importantly, numerous micro-metastases (<1mm3) were detected throughout
lungs of Luc-1B3 mice on post-contrast MRI, which were not detected in corresponding
pre-contrast MRI, with BLI, nor on post-contrast images of Luc-CTL mice. Analyzing
mean signal intensity and volume of individual foci (N=60 across 3 mice) demonstrated
that lesions around 0.01 mm3, correlating to ~104 cells, could be detected. A Luc-1B3
cohort (n=7) was imaged over time, and metastasis was first detected at the ipsilateral

125

axillary lymph node, with significantly increased MR signal intensity relative to
surrounding muscle tissue (p<0.0001). Follow-up MRI at 20-days post-implantation
revealed tumor growth at the initial ipsilateral axillary lymph node lesion, as well as
subsequent metastases at other loci, including the contralateral axillary and ipsilateral
brachial lymph nodes. These subsequent metastases were not at all detectable with
BLI. Conclusions. BLI provides whole-body information on locations of engineered
cells, but smaller populations can go undetected. Oatp1b3-MRI mitigates these
limitations for effective tracking of metastatic spread. We show that this reporter can
dynamically track the metastatic process at its earliest stages, including small single
lymph node lesions. At late stages, we demonstrate its superiority over BLI to track
cancer spread to multiple lymph nodes and other organs such as the lungs. Oatp1b3
fulfills a long-standing gap in our ability to accurately study metastatic disease over
time, and offers a path towards deep-tissue tracking of any Oatp1b3-engineered cell
type with combined high resolution, sensitivity, 3D spatial information, and surrounding
anatomical context.
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3.1 Introduction
Metastatic disease is responsible for over 90% of cancer-related
mortalities (1). Preclinical animal models provide an essential platform for the
study of metastasis, intermediate to reductionist in vitro research and clinical
investigations. Yet, approximately 75% of preclinical animal studies do not
investigate metastasis to any extent, and instead focus only on primary tumour
models. This is often due to a lack of technologies for sensitive longitudinal
quantification of metastatic spread (2). Bioluminescence imaging (BLI) is
frequently used for assessing metastatic burden because of its high throughput
and sensitivity; however, assessing total burden with BLI, particularly in
spontaneous metastasis models, remains challenging due to light scatter and
attenuation by surrounding tissues (3). Small superficial lesions cannot be readily
differentiated from larger lesions in deep tissues, and light from large superficial
tumors complicates detection of deeper lesions. To address these limitations,
preclinical oncology studies focused on examining metastatic disease have
supplemented BLI observations with parallel methods, such as multi-modality
imaging (4-6) and/or ex vivo analysis of whole-body or whole-organ systems (7,
8). For example, BLI has been paired with tissue clearing protocols, light-sheet
microscopy and computational methods for sensitive imaging of metastatic cells
at endpoint (9). In contrast, sensitive, high resolution, 3-dimensional dynamic
tracking of metastatic spread in alive animals remains an elusive goal (10).
To better understand the metastatic process and advance our ability to
test therapies targeting metastatic disease, tools for accurate spatiotemporal
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quantification of metastasis are needed. As a modality, magnetic resonance
imaging (MRI) uniquely provides versatile, high resolution, 3-dimentional spatial
information, with surrounding anatomical context. Further, MRI is the standard of
care for detection and monitoring of cancer and many other diseases. Contrastenhanced MRI can be used to visualize tumours due to leaky vasculature,
however small tumours often go undetected with these methods. The use of
reporter genes to enhance the conspicuity of engineered cancer cells may
improve our ability to track these cells dynamically. Several MRI reporter genes
have been developed including those providing either positive (11, 12) or
negative (13-16) contrast on proton-MRI, diffusion-weighted MRI (17), chemicalexchange saturation transfer MRI (18), or hyperpolarized MRI (19, 20). Despite
these efforts, MRI reporter genes have often been overlooked in cancer cell
tracking applications due to a perception that they provide limited imaging
sensitivity, i.e. labelled metastatic lesions would have to be quite large before
enough signal is generated for detection (21). Recent development of Organic
Anion-Transporting Polypeptide 1 (Oatp1) has demonstrated the possibility for
sensitive, positive contrast MRI of engineered cells (22-24). Specifically, Oatp1
encodes expression of a transporter on the surface of cells that is capable of
taking up the paramagnetic contrast agent gadolinium ethoxybenzyl diethylene
triamine pentaacetic acid (Gd-EOB-DTPA), thereby generating positive contrast
on T1-weighted images. Although previous studies have focused on primary
tumour models, optimization of experimental parameters including contrast agent
concentration, field strength and choice of pulse sequence could facilitate
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sensitive whole-body in vivo detection of metastasizing cells. The objective of this
study therefore was to evaluate the use of whole-body MRI to track Oatp1b3expressing cancer cells in a spontaneous murine breast cancer metastasis
model. The ability to track spontaneously metastasizing cancer cells in preclinical
animal models in real-time, with sensitivity, high resolution, and 3-dimentional
spatial information could offer new insights into complex metastatic mechanisms,
and provide a new approach towards assessing the efficacy of candidate
therapies for treatment of metastatic disease.
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3.2 Materials and Methods
3.2.1. Lentiviral Construction and Production
Lentiviral transfer plasmids co-encoding tdTomato fluorescent protein with
firefly luciferase 2 (25), and zsGreen fluorescent protein with Oatp1b3 (26) were
previously cloned. The cDNA for Organic anion transporting polypeptide 1b1
(Oatp1b1) was acquired from the hOATP1B1/SLCO1B1 VersaClone cDNA
Vector (Cat. RDC1113, R&D Systems, Minneapolis, Minnesota, United States). A
lentiviral transfer plasmid co-encoding zsGreen with Oatp1b1 was cloned using
the In-Fusion HD Cloning kit (Takara Bio USA Inc, Madison, Wisconsin, United
States). Third-generation packaging and envelope-expression plasmids
(pMDLg/pRRE, pRSV-Rev, and pMD2.G, Addgene plasmids: #12251, #12253,
and #12259, respectively; gifts from Didier Trono) were co-transfected with each
of the three transfer plasmids (tdTomato/Luciferase, zsGreen/Oatp1b1,
zsGreen/Oatp1b3) into human embryonic kidney (HEK 293T) cells using
Lipofectamine 3000 according to the manufacturer’s lentiviral production protocol
(Thermo Fisher Scientific Inc., Waltham, Massachusetts, United States).
Lentivirus-containing supernatants were harvested 24h and 48h post
transfection, filtered through a 0.45-μm filter, and used immediately for
transductions.

3.2.2. Cell Culture and Stable Cell Generation
Human embryonic kidney (HEK 293T) and human triple negative breast
cancer cells (MDA-MB-231) were obtained from a commercial supplier (American
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Type Culture Collection, Manassas, Virginia, United States) and cultured in
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal
bovine serum at 37°C and 5% CO2. All cells were routinely verified as free of
mycoplasma contamination using the MycoAlert mycoplasma detection kit
(Lonza Group, Basel, Switzerland). MDA-MB-231 cells were first transduced with
lentivirus co-encoding tdTomato and Firefly Luciferase, and fluorescenceactivated cell sorting was performed to sort for tdTomato-positive cells using a
FACSAria III cell sorter (BD Biosciences, Mississauga, Ontario, Canada). The
sorted cells were expanded and transduced again with lentivirus co-encoding
zsGreen with either Oatp1b1 or Oatp1b3 and fluorescence-activated cell sorting
was performed to select for tdTomato and zsGreen double-positive cells using
equivalent intensity-gating for each colour. Sorted cells, hereon referred to as
either Luc-CTL, Luc-1B1 or Luc-1B3 cells, were utilized for all experiments.

3.2.3. In Vitro Bioluminescence Imaging
Luciferase- and Oatp1b3-expressing cells were seeded into 24-well plates
with the following numbers of cells per well: 1x106, 5x105, 3x105, 1x105, and
5x104. Immediately after seeding, 0.15 mg/ml D-luciferin was added to each well,
and plates were imaged on an IVIS Lumina XRMS In Vivo Imaging System
(PerkinElmer, Waltham, Massachusetts, United States). Average radiance values
in photons/s/cm2/sr were measured from each well using LivingImage software
(PerkinElmer, Waltham, Massachusetts, United States).
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3.2.4. Western Blot
A million Luc-CTL, Luc-1B1 or Luc-1B3 cells were washed three times in
PBS and incubated with 200-µL 4°C RIPA buffer and protease inhibitors for 30
minutes. Lysates were collected and sonicated with five 5.0-s 40 kHz bursts
before being centrifuged at 13,000G for 20 minutes at 4°C. Supernatants were
collected, quantified and 40 µg of protein from each sample was loaded into an
acrylamide gel composed of a 4.0% stacking layer buffered at pH 6.8 and a 15%
separation layer buffered at pH 8.8. Gel electrophoresis was performed for 20
minutes at 90V and 1 hour at 110V. Protein was transferred to a nitrocellulose
membrane for 7.5 minutes via the iBlot™ 2 Gel Transfer Device (IB21001,
Thermo Fisher Scientific, Waltham, Massachusetts, United States) and blocked
with 0.05% Tween-20, 3% BSA solution for 30 minutes. Rabbit anti-Oatp1b3
antibody (1:1000 dilution, ab139120, Abcam, Cambridge, United Kingdom) was
added and incubated overnight at 4°C. The blot was washed 3x with 0.05%
Tween-20 solution for 10 minutes and Goat anti-Rabbit 790-nm antibody
(1:10,000 dilution, A11369, Thermo Fisher Scientific, Waltham, Massachusetts,
United States) was added for 45 minutes at room temperature. The blot was
washed again 3x with 0.05% Tween-20 solution for 10 minutes and imaged on
the Odyssey CLx Imaging System (LI-COR Biosciences, Lincoln, Nebraska,
United States).
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3.2.5. In Vitro Magnetic Resonance Imaging
Luciferase- and Oatp1b3-expressing cells (1×106) were seeded in
individual15-cm dishes and grown for 3 days. Cells were incubated with media
containing 1.6-mM Gd-EOB-DTPA or 1.6-mM Gd-DTPA (control) for 60 minutes
at 37°C and 5% CO2. In a separate experiment, cells were also incubated with
media containing 16-mM Gd-EOB-DTPA or 16-mM Gd-DTPA (control) for 60
minutes at 37°C and 5% CO2. Cells were subsequently washed 3 times with PBS,
trypsinized and pelleted in 0.2-mL tubes. MRI was performed on a 3-T GE clinical
MR scanner (General Electric Healthcare Discovery MR750 3.0 T, Milwaukee,
Wisconsin, United States) using a 3.5-cm-diameter birdcage RF coil (Morris
Instruments, Ottawa, Ontario, Canada). Imaging data were acquired at 19.5°C with
a fast spin echo inversion recovery (FSE-IR) pulse sequence using the following
parameters: Matrix size = 256´256, repetition time (TR) = 5000 ms, echo time (TE)
= 19.1 ms, echo train length (ETL) = 4, number of excitations (NEX) = 1, receiver
bandwidth (rBW) = 12.50 kHz, inversion times (TI) = 20, 35, 50, 100, 125, 150,
175, 200, 250, 350, 500, 750, 1000, 1500, 2000, 2500, 3000, in-plane resolution =
0.2x0.2 mm2, slice thickness = 2.0 mm, acquisition time = 5 min and 25 s (per
inversion time). Spin-lattice relaxation rates (R1) were determined by non-linear
least-squares fitting (MATLAB, MathWorks, Natick, Massachusetts, United States)
of signal intensities across the series of variable inversion time images on a pixel
by pixel basis. The most common inversion recovery equation presented in the
literature is as follows:
! = # ∙ (1 − 2)

!

#$
#!

+ )

!

#%
#! )
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Here, ! represents the acquired signal, and # is the proportionality constant,
which depends on the specific coil used, the main magnetic field, the proton
density, and the temperature, amongst other factors (27). However, two practical
obstacles exist that render this equation impractical for real-world applications:
first, a perfect 180° pulse is never truly achieved, and second, the signal is not
acquired immediately after the RF pulse (28). In practice, these real-world
limitations produce a different behavior at -. = 0 and -. = ∞ than predicted
theoretical outputs dictated by the equation above. To address these limitations,
and assuming -1 ≫ -., the equation above was adjusted to the following:
! = 3&& − (3&& − 3' ) ∙ )

"#$%
#!

Here, if -. = 0, then ! = −3' where 3' is simply the first value of the
inversion recovery curve, independent of the final, steady state magnetization 3&& .
Additionally, if -. = ∞, then ! = 3&& . Finally, we use the absolute value of this last
equation because the DICOM images acquired provided magnitude (non-phase)
information:
! = 43&& − (3&& − 3' ) ∙ )

"#$%
#!

4

The zero-crossing point, the -. at which point ! = 0, is extrapolated from
the data and the 1( of each pixel can be determined via the following
relationship:
1( = ln 27-.

)*++
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3.2.6. Spontaneous Metastasis Model
Animals were cared for in accordance with the standards of the Canadian
Council on Animal Care, and experiments were undertaken with an approved
protocol of the University of Western Ontario’s Council on Animal Care (AUP
2016-026). Luc-CTL or Luc-1B3 cells (3×105) were implanted into the left 4th
mammary fat pad of female nod scid gamma mice (Jackson Laboratory, Bar
Harbor, Maine, United States). BLI was performed after 150-mg/kg D-luciferin
injection. T1-weighted 3T-MRI was performed before and 5h post 1-mmol/kg GdEOB-DTPA injection. Detectability of widespread metastases was evaluated by
imaging Luc-CTL and Luc-1B3 mice (n=3 each) 30 days after cell implantation.
Subsequently, a second Luc-1B3 cohort (n=7) was imaged over time until
endpoint (up to Day 24) to assess ability to monitor metastasis dynamically.

3.2.7. In Vivo Bioluminescence Imaging
Bioluminescence imaging was performed on an IVIS Lumina XRMS In
Vivo Imaging System (PerkinElmer). Mice were anesthetized with 1-2%
isoflurane using a nose cone attached to an activated carbon charcoal filter for
passive scavenging, and administered 150 μL of 30-mg/mL D-luciferin
intraperitoneally. Whole-body bioluminescent images were acquired with
repeated 1.0-s exposure times every minute for approximately 15 minutes. Once
the maximum signal plateaued, the lower half of the mouse i.e. location of
primary tumour, was shielded with opaque black cloth and the front limbs of the
mice were taped down to fully expose the surface area of the thoracic region.
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The field-of-view was adjusted to fit the upper body of the mouse and an image
was captured with a 5-minute exposure time to detect spontaneous metastases.
Regions-of-interest (ROIs) were manually drawn around primary tumour borders
using LivingImage software (PerkinElmer, Waltham, Massachusetts, United
States) to measure bioluminescent average radiance (p/s/cm2/sr). For analysis of
spontaneous metastases, ROIs were automatically generated with LivingImage
software (PerkinElmer, Waltham, Massachusetts, United States).

3.2.8. In Vivo Magnetic Resonance Imaging
Scans were performed on a 3-T GE clinical MR scanner (General Electric
Healthcare Discovery MR750 3.0 T, Milwaukee, Wisconsin, United States) using
a custom-built gradient insert and a bespoke 5-cm-diameter solenoidal
radiofrequency coil. Mice were anesthetized with 1-2% isoflurane using a nose
cone attached to an activated carbon charcoal filter for passive scavenging. T1weighted images were acquired using a 2D Spoiled Gradient Recalled
Acquisition in Steady State (SPGR) pulse sequence using the following
parameters: FOV = 40mm, TR = 15.8 ms, TE = 10.5 ms, rBW = 31.25 kHz, ETL
= 4, Matrix size 400×400, Flip Angle: 60°, NEX = 3, v = 0.1-µm3 isotropic voxels,
scan time = approximately 20 minutes per mouse, dependent on mouse size.
Volumes-of-interest (VOIs) were manually delineated around metastatic lesions
in post-contrast images using both ITK-SNAP (29) and Horos Project software
(horosproject.org, Nimble Co LLC d/b/a Purview, Annapolis, Maryland, United
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States). VOIs were manually segmented to acquire measures of signal intensity
on both pre-contrast and post-contrast images.

3.2.9. Statistics
Analysis of Variance (ANOVA) and Tukey’s post-hoc multiple comparisons
were performed for all MRI results. For all tests, a nominal p-value less than 0.05
was considered statistically significant.

137

3.3 Results
3.3.1 Lentiviral-mediated integration of reporter genes in cancer cells
Lentiviral transfer plasmids encoding pEF1a-tdTomato/Luciferase, pEF1azsGreen/Oatp1b1, and pEF1a-zsGreen/Oatp1b3, each separated by self-cleaving
2A peptide sequences, were successfully cloned and utilized to produce lentiviral
vectors (Figure 3.1B, 3.1C). A human triple-negative breast cancer cell line (MDAMB-231) was transduced with pEF1a-tdTomato/Luciferase lentivirus and
subsequently sorted for tdTomato fluorescence with >95% purity to obtain
luciferase-expressing control cells, hereafter referred to as Luc-CTL cells.
Following sorting and expansion, a subset of Luc-CTL cells was transduced a
second time with either zsGreen/Oatp1b1 or pEF1a-zsGreen/Oatp1b3 lentivirus
and sorted again for zsGreen fluorescence with >95% purity whilst also matching
the tdTomato intensity to that of the sorted Luc-CTL cells. These resulting cell lines
are hereafter referred to as Luc-1B1 and Luc-1B3 cells, respectively. In vitro
bioluminescence imaging demonstrated a significant linear correlation with cell
number for both Luc-CTL (R2=0.9916) and Luc-1B3 (R2=0.9893) with slopes that
were not considerably different between cell lines (Figure 3.1D, 3.1E). Immunoblotting for OATP1B3 protein confirmed absence of Oatp1b3 expression in both
Luc-CTL and Luc-1B1 cells, whereas bands correlating with the molecular weight
of glycosylated (100 kDa) and unmodified (77 kDa) OATP1B3 protein (30) were
observed in the lane containing lysates from Luc-1B3 cells (Figure 3.1F). Nonspecific bands across all cell types were observed at about 65 kDa and 72 kDa.
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Figure 3.1. Imaging Principle and In Vitro Reporter Gene Expression. A, Illustration
of the Oatp1b3 reporter gene mechanism. Cells engineered to express Oatp1b3 encode
a transporter capable of taking up Gd-EOB-DTPA, a paramagnetic agent that interacts
with proton spins to increase the spin-lattice relaxation rate of the intracellular
environment, which in turn, allows those cells to exhibit increased signal intensity on T1weighted magnetic resonance images. B, Reporter gene cassette constitutively
encoding tdTomato and firefly luciferase. C, Reporter gene cassette constitutively
expressing zsGreen and Oatp1b3. D, Bioluminescence radiance (p/s/cm2/sr) of various
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numbers of MDA-MB-231 cells per well expressing luciferase (Luc-CTL) or coexpressing luciferase and Oatp1b3 (Luc-1B3). E, Quantification of average radiance
(p/s/cm2/sr) of wells containing various numbers of Luc-CTL or Luc-1B3 cells. F,
Western blot of cells expressing luciferase (Luc-CTL), co-expressing luciferase and
Oatp1b1 (Luc-1B1, a closely related transporter), or co-expressing luciferase and
Oatp1b3 (Luc-1B3).

140

3.3.2 Increased spin-lattice relaxation rates of cells expressing Oatp1b3
Luc-CTL cells treated with low and high doses of Gd-DTPA did not exhibit
significant differences in R1 rates (0.5827 ± 0.04658, 0.7464 ± 0.009090 s-1,
respectively) to Luc-CTL cells treated with low and high doses of Gd-EOB-DTPA
(0.6166 ± 0.05755, 0.7568 ± 0.03942 s-1, respectively), nor to Luc-1B3 cells treated
with low and high doses of Gd-DTPA (0.5821 ± 0.04658, 0.7494 ± 0.1061 s-1)
(Figure 3.2). Only Luc-1B3 cells incubated with low and high Gd-EOB-DTPA
doses exhibited significantly increased R1 rates compared to all other conditions
(1.320 ± 0.2229, 3.797 ± 0.1353 s-1) (n=3, p<0.05).
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Figure 3.2. Spin-lattice Relaxation Rates of Oatp1b3-engineered cells at 3 Tesla. A,
Map of spin-lattice relaxation rates (Hz) for MDA-MB-231 cells expressing luciferase (LucCTL) or co-expressing luciferase and Oatp1b3 (Luc-1B3) treated with 1.6 mM of either
Gd-DTPA (control probe) or Gd-EOB-DTPA. B, Map of spin-lattice relaxation rates (Hz)
for MDA-MB-231 cells expressing luciferase (Luc-CTL) or co-expressing luciferase and
Oatp1b3 (Luc-1B3) treated with 16 mM of either Gd-DTPA (control probe) or Gd-EOBDTPA. C) Quantification of spin-lattice relaxation (R1) rates (Hz) at 3 Tesla of cells treated
with either Gd-DTPA or Gd-EOB-DTPA (n=3, ***p<0.001, ****p<0.0001).
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3.3.3 Increased contrast enhancement of macro-metastatic lesions, and detection of
micro-metastatic lesions with Oatp1b3
Macro-metastases (>1mm3) located at axillary lymph node regions
exhibited significantly increased MR signal intensity in Luc-1B3 mice on postcontrast images (4631 ± 968.6 arbitrary units, a.u.) relative to pre-contrast
images (766.7 ± 234.7 a.u.), and to Luc-CTL mice both pre- (840.1 ± 122.2 a.u.)
and post-contrast (1058 ± 198.0 a.u.) (n=3 mice per group, p<0.0001) (Figure
3.3A, 3.3B). Importantly, numerous micro-metastases (<1mm3) were detected
throughout lungs of Luc-1B3 mice on post-contrast MRI, which were not detected
in corresponding pre-contrast MRI, with BLI, nor on post-contrast images of LucCTL mice. It was particularly surprising that micro-metastases could be detected
in the lungs, because motion artifacts from breathing and susceptibility artifacts
from the air-tissue interface were anticipated to present a serious challenge to
imaging lung micro-metastases on MRI. Analyzing mean signal intensity and
volume of individual foci (N=60 across 3 mice) demonstrated that several lesions
as small as ~0.01 mm3 could be detected on Day 30 post-implantation of the
primary tumour (Figure 3.3C). The smallest volume that demonstrated mean
intensity (3332 a.u.) considerably above the mean intensity of lungs in control
animals (236.08 ± 172.9 a.u.), was measured at 0.0043 mm3, but a more
reproducible minimal volume of detection was highlighted by a cluster of lesions
(N=7) around 0.01 mm3.
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Figure 3.3. Bioluminescence Imaging and Magnetic Resonance Imaging at 3 Tesla
of Spontaneous Metastases. A, Bioluminescence imaging (BLI, p/s/cm2/sr) and
magnetic resonance imaging (MRI) of mice burdened with MDA-MB-231 cells
engineered to express luciferase (Luc-CTL) or co-express luciferase and Oatp1b3 (Luc1B3). Magnetic resonance imaging was acquired pre- and 5 hours post-administration
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of 1-mm/kg Gd-EOB-DTPA. Maximum intensity projections are also shown. B, Mean
signal intensity (a.u.) of macro-metastases composed of MDA-MB-231 cells engineered
to express luciferase (Luc-CTL) or co-express luciferase and Oatp1b3 (Luc-1B3) before
and 5 hours after administration of 1-mmol/kg Gd-EOB-DTPA (n=3, p<0.05). C, Mean
signal intensity (a.u.) and volume (mm3) of individual micro-metastatic lesions (<1mm3)
5 hours after administration of 1-mm/kg Gd-EOB-DTPA, colored according to mouse
identity (n=3, ****p<0.0001).
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3.3.4 Oatp1b3 allows for longitudinal tracking of engineered cells spontaneously
metastasizing through the lymph nodes and to the lungs
In the Luc-1B3 cohort imaged across three weeks, metastases were first
detected via BLI and MRI at the ipsilateral axillary lymph node on average 11 ±
1.3 days after cell implantation into the left-bearing 4th mammary fat pad, with
significantly increased MR signal intensity (2903 ± 616.6 a.u.) relative to
surrounding muscle tissue (1123 ± 110.4 a.u.) (n=7, p<0.0001) (Figure 3.4A).
Five out of 7 mice displayed significant lymph node MRI enhancement within 24
hours following first detection of BLI signal in that region. The remaining two mice
showed MR signal enhancement up to two days before BLI signal detection.
Follow-up MRI at subsequent days revealed continued tumor growth at the initial
ipsilateral axillary lymph node lesion (Figure 3.4B), as well as subsequent
metastases at other loci, including the contralateral axillary lymph node (Figure
3.4C) and ipsilateral brachial lymph node (Figure 3.4D). Finally, lung micrometastases began to appear on MRI approximately 26 days post-implantation of
the primary tumor cells (Figure 3.4E). Mice were sacrificed at this point due to
ulceration of the primary tumour (out of field-of-view in the images). Note that
although the initial metastatic lesion in the ipsilateral axillary lymph node was
detectible on BLI, subsequent metastatic lesions that formed afterward could be
detected via Oatp1b3-MRI but could not be resolved on BLI. This was due to
excessive light scatter from the much larger first lesions. Eventually, once the
second-stage lesions grew to substantial cell numbers, the lesion could be
detected on BLI (Figure 3.4E). However, at this point, several third-stage
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metastases forming in the lungs of the animals, detectible on Oatp1b3-MRI, were
far too small relative to the bilateral lymph node lesions surrounding them for
detection on BLI (Figure 3.4E).
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Figure 3.4. Longitudinal Tracking of Spontaneously Metastasizing Cancer Cells
via Bioluminescence Imaging and Magnetic Resonance Imaging at 3 Tesla.
Representative bioluminescence images (BLI, p/s/cm2/sr) and magnetic resonance
images (MRI) at 3T of female nod scid gamma mice (n=7) after implantation of MDAMB-231 cells into the left-bearing 4th mammary fat pad on Day 10 (A), Day 15 (B), Day
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20 (C), Day 23 (D), and Day 26 (E). MIP, maximal intensity projection. Scale bar, 5 mm.
E, Quantification of mean signal intensity (a.u.) of initial ipsilateral axillary lymph node
lesions (Days 10-13) and mean signal intensity (a.u.) of surrounding muscle tissue on
MRI (n=7, ****p<0.0001).
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3.4 Discussion
Preclinical animal models provide an invaluable platform to improve our
understanding of the mechanisms of metastasis and test candidate antimetastatic therapies under controlled conditions. However, sensitive and
quantitative preclinical assessment of metastatic disease with a high degree of
accuracy is a significant challenge. Compared with traditional contrast agents,
reporter genes offer critical information on cell viability, and do not require the
presence of biomarkers to be specific to the cells of interest, as in triple-negative
breast cancer. Fluorescence reporter genes generate unparalleled sensitivity and
resolution but are largely limited to superficial surfaces and ex vivo histological
examination. Although the resolution of fluorescent imaging is excellent,
assessment of metastases based on histology is labor-intensive and the quality
of the output data depends highly on the extent of tissue sampling, e.g.
measurements across numerous slices composing entire organs versus
measurements from just a few slices, as well as the reproducibility of the staining
approach. To overcome the intensiveness of the process and sampling bias, the
last decade has seen a surge of tissue clearing methods that render large
biological samples transparent and allow unprecedented three-dimensional views
of large volumes of tissue with and advanced optical microscopy (31). However,
a major drawback of this approach, as with histology, is that only a single
timepoint can be acquired of an individual animal, which in turn, would require
large numbers of animals to generate effective conclusions for a study (32). This
is a particularly serious issue when working with spontaneous metastasis models
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that exhibit considerable variability between animals, with respect to both the
time and location of metastatic progression (33).
The ability to follow metastatic spread and its response to therapy in a
single animal is an important experimental capability. Bioluminescence aims to
accomplish this by providing sensitive whole-body information on locations of
luciferase-expressing cancer cells, but we demonstrate that smaller cell
populations can easily go undetected. Specifically, we show that initiated lymph
node lesions and micro-metastases in separate organs are obscured by larger
lesions throughout the metastatic process (Figure 3.3, Figure 3.4). Assuming
that contrast enhanced voxels constituted entirely of Luc-1B3 cells, i.e. assuming
no partial volume effects, and that 1 million cells correlate to a volume of 1-mm3,
micro-metastases containing approximately 104 cells could be detected with
Oatp1b3 post-administration of 1 mmol/kg of Gd-EOB-DTPA at 3 Tesla.
However, the range of mean signal intensities exhibited amongst individual
micro-metastases (Figure 3.3C) suggests that partial volume effects are in play,
and that the detection limit of the Oatp1b3 reporter gene system may fall below
this 10,000-cell threshold. Immediate next steps are focused on validating this
measurement and accounting for partial volume effects.
Bioluminescence measurements are often biased to detection of larger,
more established lesions, that may not necessarily progress and respond to
treatment in the same way as much smaller, recently-seeded metastases located
in entirely different organ micro-environments. It may be that successful
treatments for micro-metastases have been wrongly deemed ineffective simply
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because much larger lesions dominated the measurements (34, 35). Oatp1b3
mitigates these limitations of BLI for effective tracking of metastatic spread. We
show that this reporter can dynamically track the metastatic process at its earliest
stages, including small single lymph node lesions, even prior to BLI detection in
some cases. At late stages, we demonstrate its superiority over BLI to track
cancer spread to multiple lymph nodes and other organs such as the lungs. At
this resolution, as demonstrated by others with endpoint analysis, we
demonstrate that the metastatic process in this model starts when cells from the
primary tumor travel to the ipsilateral axillary lymph node, subsequently spreads
to the ipsilateral brachial lymph node or the contralateral axillary lymph node, and
then the cancer cells appear to migrate down into the lungs. Although the sites of
metastasis are in close agreement with previously published literature (36), and
exhibit a pattern of metastasis similar to that observed in human breast cancer
patients (37-39), imaging the dynamic migration of cancer cells in single animals
from one location to the next has not previously been demonstrated. Oatp1b3
fulfills a long-standing gap in our ability to accurately study metastatic disease
over time and offers a path towards deep-tissue tracking of any Oatp1b3engineered cell type with combined high resolution, sensitivity, 3D spatial
information, and surrounding anatomical context.
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CHAPTER 4 Detection of Viable Cancer Lesions on Photoacoustic Imaging
Rationale. We wanted to develop a photoacoustic imaging (PAI) reporter gene that has
high translational potential. Previous research has shown that human Organic AnionTransporting Polypeptide 1b3 (Oatp1b3) promotes the uptake of the near-infrared
fluorescent dye indocyanine green (ICG). Our objective in this study was to establish
Oatp1b3 and ICG as a reporter gene–probe pair for in vivo PAI. Methods. Human breast
cancer cells were engineered to express Oatp1b3. Control cells (not expressing Oatp1b3)
or Oatp1b3-expressing cells were incubated with or without ICG, placed in a breastmimicking phantom, and imaged with PAI. Control (n = 6) or Oatp1b3-expressing (n = 5)
cells were then implanted orthotopically into female mice. Full-spectrum PAI was performed
before and 24 hours after ICG administration. One-way analysis of variance was
performed, followed by Tukey post-hoc multiple comparisons, to assess statistical
significance. Results. Oatp1b3-expressing cells incubated with ICG exhibited a 2.7-fold
increase in contrast-to-noise ratio relative to all other controls in vitro (p<0.05). In mice, PAI
signals after ICG administration were increased 2.3-fold in Oatp1b3 tumours relative to
those in controls (p<0.05). Conclusions. Oatp1b3 operates as an in vivo PAI reporter gene
based on its ability to promote the cellular uptake of ICG. Benefits include the human
derivation of Oatp1b3, combined with the use of wavelengths in the near-infrared region,
high extinction coefficient, low quantum yield, and clinical approval of ICG. We posit that
this system will be useful for localized monitoring of emerging gene- and cell-based
therapies in clinical applications.
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4.1 Introduction
Imaging reporter genes encode for proteins that can be used to visualize
cellular and molecular processes in living systems (1). Unlike traditional contrast
agents, reporter genes provide unique information on cellular viability as only living
cells would express the reporter; and further, reporter expression can be linked to a
gene of interest for dynamic tracking of its spatial and temporal expression patterns.
Reporter genes for various imaging modalities have been developed, contributing
extensively to monitoring the fates of various engineered cell types such as cancer,
immune and stem cells in preclinical models (2-4). Moreover, clinical studies have
applied reporter genes for monitoring of gene- (5) and cell-based (6) therapies in
cancer patients via positron emission tomography (PET). While PET produces
whole-body images with high sensitivity, it has limitations such as cost, availability,
and ionizing radiation concerns for longitudinal studies. Reporter genes for
affordable, portable, and safer imaging modalities are sought for continued localized
monitoring of gene and cell therapies in humans.
Photoacoustic imaging (PAI), or optoacoustic imaging, detects acoustic
waves from optically-excited sources and is considerably more affordable than PET.
Based on the photoacoustic effect, endogenous molecules such as deoxy- and
oxyhemoglobin are able to absorb light and convert a fraction of that energy into
heat. This heat energy leads to a transient thermoelastic expansion, resulting in
emission of ultrasonic waves that can be detected by transducers to produce
images. PAI thus combines the benefits of optical contrast with the resolution and
depth-detection of ultrasound. Clinical PAI systems currently provide significant
contrast at depths of several centimeters with resolutions of a few hundred microns
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(7, 8), and PAI is increasingly being applied to a growing number of biomedical
applications, from sentinel lymph node imaging to vertebrae imaging for spinal
surgery guidance (9-11). Reporter genes for PAI would allow for contrast
enhancement of cell populations that would not otherwise produce PAI signals, thus
potentially extending the utility of PAI for in vivo monitoring of gene- or cell-based
therapies. PAI reporter genes that operate in the near-infrared (NIR) window are
particularly desirable due to minimal endogenous photoacoustic molecules
absorbing at these wavelengths (12).
Though several PAI reporter genes have been developed and have shown
significant value in preclinical studies, their clinical utility is potentially limited due to
their non-human origin and/or undesirable toxicity (12). We sought to develop a PAI
reporter gene system that overcomes these issues to increase the potential for
clinical translation. As such, a member of the organic anion-transporting polypeptide
(Oatp) family of proteins, namely OATP1B3, is endogenously expressed in the
human liver and is responsible for hepatocyte uptake of the NIR fluorescent dye
indocyanine green (ICG) during liver function tests. Previous work has also shown
that OATP1B3 can take up ICG into cells that express it and can be used as a
fluorescence reporter gene system (13, 14). Here we extended these previous
studies to establish the combined use of OATP1B3 and ICG as a novel PAI human
reporter gene.
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4.2 Materials and Methods
4.2.1 Cell Culture
Human embryonic kidney cells (HEK 293T), human triple negative breast
cancer cells (MDA-MB-231), and murine triple negative breast cancer cells (4T1)
were obtained from a commercial supplier (American Type Culture Collection;
ATCC, Manassas, Virginia, United States) and cultured in Dulbecco’s Modified
Eagle Media (DMEM, Wisent Inc., Saint-Jean-Baptiste, Quebec, Canada)
supplemented with 10% fetal bovine serum at 37°C and 5% CO2. Cells were
routinely tested negative for mycoplasma using the MycoAlert mycoplasma
detection kit (Lonza Group, Basel, Switzerland).

4.2.2 Lentiviral Production and Generation of Stable Cells
Genetic engineering of the reporter gene system involved third-generation
packaging and envelope-expression plasmids (pMDLg/pRRE, pRSV-Rev, and
pMD2.G, Addgene plasmids: #12251, #12253, and #12259, respectively; gifts from
Didier Trono). A lentiviral transfer vector encoding the tdTomato (tdT) reporter gene
for fluorescence, under regulation of the human elongation factor 1 alpha promoter
(pEF1α) was obtained (15) along with a second lentiviral transfer plasmid encoding
the zsGreen1 (zsG) reporter gene for fluorescence and the Organic anion
transporting polypeptide 1a1 (Oatp1a1) reporter gene separated via a P2A selfcleaving peptide, also under regulation of pEF1α (15). The sequence for Organic
anion

transporting

polypeptide

1b3

(Oatp1b3)

was

acquired

from

the

hOATP1B3/SLCO1B3 VersaClone cDNA Vector (Cat. RDC0870, R&D Systems,
Minneapolis, Minnesota, United States). All cloning was performed using In-Fusion
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HD Cloning (Takara Bio USA Inc, Madison, Wisconsin, United States). The Oatp1a1
sequence in the second lentiviral transfer plasmid was replaced by the Oatp1b3
sequence to obtain a resultant zsG/Oatp1b3 lentiviral transfer plasmid. The zsG
fluorescent protein was utilized for fluorescence-activated cell sorting of Oatp1b3expressing cells, as it absorbs virtually no near-infrared light within the 680 to 970
nm wavelength range and thus, will not confound signals generated during analysis
of Oatp1b3 as a reporter gene for NIR-PAI (16).
To produce tdT and zsG/Oatp1b3 lentiviruses (LV-tdT and LV-zsG/Oatp1b3),
packaging, envelope and the relevant transfer plasmid were co-transfected into
human embryonic kidney (HEK 293T) cells using Lipofectamine 3000 according to
the manufacturer’s lentiviral production protocol (Thermo Fisher Scientific Inc.,
Waltham, Massachusetts, United States). Lentivirus-containing supernatants were
harvested 24h and 48h post transfection, filtered through a 0.45-μm filter, and stored
at -80°C prior to use. Human (MDA-MB-231) and murine (4T1) triple negative breast
cancer cells were transduced with lentivirus encoding tdTomato fluorescent protein
overnight in the presence of 4- to 8-μg/mL polybrene. Transduced cells were
washed, collected, and sorted using a FACSAria III fluorescence-activated cell
sorter (BD Biosciences, Mississauga, Ontario, Canada) for positive tdTomato
fluorescence, generating tdTomato Control cells. A subset of these was then
transduced with a second lentivirus co-encoding zsGreen fluorescent protein and
OATP1B3 and sorted for equivalent tdTomato fluorescence intensity relative to the
original tdTomato Control cells, as well as for positive zsGreen fluorescence. The
resulting population was named tdTomato OATP1B3 cells.
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4.2.3 Immunofluorescence Staining
Cells were grown on glass coverslips, fixed with 4% paraformaldehyde (PFA)
for 10 minutes, permeabilized via 0.02% Tween 20 for 20 minutes, and incubated
overnight at 4°C with rabbit anti-SLCO1B3 (OATP1B3) primary antibody (2-µg/mL
working concentration, HPA004943, Sigma-Aldrich Canada, Oakville, Ontario,
Canada). Goat anti-rabbit AlexaFluor 647-conjugated secondary antibody was then
applied (1:500 dilution; 4-µg/ml working concentration, ab150079, Lot E114795,
Abcam, Cambridge, Massachusetts, United States). Cells on coverslips were
counterstained with DAPI and imaged using an LSM Meta 510 microscope (Carl
Zeiss AG, Oberkochen, Germany).

4.2.4 Proliferation Assays
Non-transduced, tdTomato Control, and tdTomato OATP1B3 cells (5×104)
were seeded and cell proliferation was evaluated using a tetrazolium salt (3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT) assay. Cells were
incubated in phenol red-free DMEM (Cat. 319-051-CL, Wisent Inc., Saint-JeanBaptiste, Quebec, Canada) supplemented with 10% FBS that did or did not contain
35-µg/ml ICG. Prior to optical measurements, wells were washed three times with
PBS containing dimethyl sulfoxide (DMSO; 10% v/v). Absorbance measurements at
590 nm were acquired with a spectrophotometer at 0, 24 and 48 hours after seeding.
Proliferative measurements at 24 and 48 hours were normalized to absorption
values obtained at seeding (0 hours).
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4.2.5 In Vitro Fluorescence Imaging
Human (MDA-MB-231) and murine (4T1) tdTomato Control and tdTomato
OATP1B3 cells were incubated for 90 minutes at 37°C and 5% CO2 in media
containing either 35-µg/ml ICG or an equivalent volume of DMSO solvent. Cells
were then washed three times with DMSO-containing PBS (10% v/v), trypsinized,
counted and 1x106 cells were pelleted and subsequently transferred into the wells
of a custom-built 1% agarose, 0.5% intralipid phantom, designed to be asymmetrical
in its distribution of wells. Additionally, a well containing 35-µg/ml ICG, and a well
containing media without ICG were included as positive and negative controls,
respectively. An IVIS Lumina XRMS In Vivo Imaging System (PerkinElmer,
Waltham, Massachusetts, United States) was used to measure ICG fluorescence
intensity using a 0.5-s exposure time, 780-nm excitation filter, and 845-nm emission
filter.

4.2.6 In Vitro Photoacoustic Imaging
PAI of the cell phantoms was then performed using a custom-built
photoacoustic tomography system. The PAI system consisted of a transducer array
with 28 custom-built cylindrical unfocused transducers (2.7-MHz central frequency,
~127% bandwidth, 4.5-mm diameter) mounted on two concentric circular rungs. All
transducers were angled inwards to a point 25 mm below the array, providing a fieldof-view ~20 mm in diameter. 780-nm NIR illumination was provided by a tunable
(680 – 950 nm) 10-Hz-pulsed laser (Phocus InLine, Opotek Inc., California, United
States) injected into a four-legged fused-end fiber bundle (Lumen Dynamics Group
Inc., Mississauga, Ontario, Canada). The output ends of the fiber bundle were
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positioned at the centre of the circular transducer rings, pointing inwards towards
the same focal point as the transducers. The transducer array with attached fiber
bundles was mounted to an Epson SCARA robot (Epson C4, Suwa, Nagano
Prefecture, Japan) for scanning. All transducers were connected to a custom 28channel, 50-MHz data acquisition system. The phantom was sealed with water in a
modified Ziploc bag and submerged in a water tank along with the transducer array.
The imaging array was raster scanned in three dimensions with 4-mm steps in the
XY-plane, and 5-mm steps in the Z-direction to image the entire phantom. At each
scan point, signal averaging was performed over 16 laser pulses to increase the
signal-to-noise ratio. Following imaging, image reconstruction using universal backprojection was performed (17). A maximum intensity projection (MIP) image of the
3D stack was then acquired using ImageJ (18). Average signal intensity was
measured from each well and the contrast-to-noise ratio (CNR) was calculated
relative to an equal-sized ROI positioned at the centre of the MIP image.

4.2.7 In Vivo Fluorescence Imaging
All animal experiments were performed in compliance with an approved
protocol of the University of Western Ontario’s Council on Animal Care (Animal Use
Protocol 2016-026) and in accordance with the standards of the Canadian Council
on Animal Care. tdTomato Control (n=6) or tdTomato OATP1B3 (n=5) MDA-MB231 cells (3×105) were implanted orthotopically into the right-bearing fourth
mammary fat pad of immunocompromised (NU-Foxn1nu) 6-8-week-old female mice
(Charles River Laboratories, Wilmington, Massachusetts, United States). FLI was
performed on an IVIS Lumina XRMS In Vivo Imaging System (PerkinElmer,
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Waltham, Massachusetts, United States), starting 48h post cellular implantation.
Mice were anesthetized with 1-2% isofluorane using a nose cone attached to an
activated carbon charcoal filter for passive scavenging. FLI for tdTomato was
performed using 520-nm excitation and 570-nm emission filters and images were
acquired with a 5-minute exposure time. FLI for ICG was performed using 780-nm
excitation and 845-nm emission filters and images were acquired with a 5-min
exposure time.

4.2.8 In Vivo Photoacoustic Imaging
Mice were anesthetized as described above, and US and PAI were
performed using the Vevo LAZR-X System (Fujifilm VisualSonics Inc., Toronto,
Ontario, Canada). An LZ550 transducer was used to acquire US and PAI images
with axial resolutions of 40 μm. Acoustic signals at each wavelength were measured
ten times for signal averaging. The total acquisition time per wavelength was 2.0 s,
and a total time of approximately 1.93 minutes was required to image each slice
across all wavelengths. US images of tumours were first acquired, followed by NIR
spectrum (680-970 nm) PAI in 5-nm increments. For each tumour, a central slice,
along with adjacent slices 800 µm on either side were acquired. Regions-of-interest
(ROIs) around the perimeter of each tumour in US images were outlined and
subsequently overlayed onto corresponding photoacoustic images. Tumour ROIs
were processed through the software to generate a full-spectrum photoacoustic plot
for each tumour both before and 24 hours following administration of ICG. Vevo Lab
Image Software (Fujifilm VisualSonics Inc., Toronto, Ontario, Canada) was used to
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spectrally unmix ICG signals from tumour data to generate ICG localization images
within tumours, as previously described (19).

4.2.9 Ex Vivo FLI and Histology
Following in vivo imaging, mice were immediately sacrificed via isofluorane
overdose, perfused with 4% paraformaldehyde through the left heart ventricle and
tumours were excised from mammary fat pads. Tumours were subsequently frozen
in Tissue-Tik Optimum Cutting Temperature (OCT) medium (Sakura Finetek,
Maumee, Ohio, United States) and both 150-µm and 10-µm frozen sections were
collected via the Leica CM350 Cryostat (Leica Microsystems, Wetzlar, Germany).
The 150-µm sections were plated on glass slides and FLI images were collected
using the IVIS Lumina XRMS In Vivo Imaging System (PerkinElmer, Waltham,
Massachusetts, United States) for tdTomato expression (5-s exposure, 520-nm
excitation filter, 570-nm emission filter), zsGreen expression (10-s exposure, 480nm excitation filter, 520-nm emission filter), and ICG uptake/retention (10-s
exposure, 780-nm excitation filter, 845-nm emission filter). Microscopy images for
tdTomato and zsGreen fluorescence were taken of the 10-µm sections using an
EVOS FL Auto 2 Imaging System (Invitrogen, Thermo Fisher Scientific Inc.,
Waltham, Massachusetts, United States).

4.2.10 Statistics
One-way Analysis of Variance (ANOVA) was performed followed by Tukey’s
post-hoc multiple comparisons using Graphpad Prism software (Version 7.00 for
Mac OS X, GraphPad Software Inc., La Jolla, California, United States,
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www.graphpad.com). For time-course experiments, repeated measures ANOVA
was performed, followed by Tukey’s post-hoc multiple comparisons. For all tests, a
nominal p-value less than 0.05 was considered statistically significant.
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4.3 Results
4.3.1 Generation of breast cancer cells expressing reporter genes
Human (MDA-MB-231) and murine (4T1) cells were transduced first with
lentivirus encoding the fluorescence reporter tdTomato and were subsequently
sorted for tdTomato fluorescence with >95% purity to generate tdTomato Control
cells. A subset of these was then transduced with a second lentivirus co-encoding
the fluorescence reporter zsGreen1 (zsG) and Oatp1b3 (Figure 4.1A). This second
cell population was sorted for both tdTomato intensity equivalent to the tdTomato
Control cell population, as well as zsGreen intensity with >95% purity to generate
tdTomato OATP1B3 cells (Figure 4.1B). Immunofluorescence staining validated
absence of Oatp1b3 expression in tdTomato Control cells, whereas positive staining
was present in the tdTomato OATP1B3 cells (Figure 4.1C). Proliferation assays
showed no significant difference in growth rates between non-transduced cells,
tdTomato Control cells, and tdTomato OATP1B3 cells, or between cell populations
incubated in 35-µg/ml ICG for 60 minutes (Figure 4.1D).
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Figure 4.1. Cell Engineering and Characterization. A) Reporter gene constructs used to
engineer cells, which include the fluorescence reporter tdTomato (top; tdTomato Control),
or tdTomato in addition to the fluorescence reporter zsGreen (zsG) with Organic aniontransporting polypeptide 1b3 (Oatp1b3) separated by the self-cleaving peptide (P2A)
(bottom; tdTomato OATP1B3), each under control of the human elongation factor 1
promoter (pEF1a). B) Fluorescence-activated cell sorting plots following lentivirus
transduction of MDA-MB-231 cells with tdTomato Control transfer plasmids or tdTomato
OATP1B3 transfer plasmids. C) Microscopy of engineered MDA-MB-231 cells for nuclear
staining (DAPI; blue), tdTomato fluorescence (red), zsGreen fluorescence (green), and
immunofluorescence staining for OATP1B3 expression (purple). Scale bar, 20 µm. D)
Relative growth rates (arbitrary units, a.u.) of Non Transduced, tdTomato Control, and
tdTomato OATP1B3 cells grown in the presence or absence of 35 µg/ml indocyanine green
(ICG). Error bars represent one standard deviation.
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4.3.2 In vitro ICG-enhanced FLI and PAI of breast cancer cells expressing Oatp1b3
Next, we evaluated FLI and PAI contrast of both human and murine cells
expressing Oatp1b3 incubated with or without ICG. Both MDA-MB-231 and 4T1
tdTomato OATP1B3 cells incubated with 35-µg/ml ICG, and subsequently washed,
exhibited significantly increased fluorescence radiance (p/s/cm2/sr) at ICG
wavelengths relative to ICG-incubated tdTomato Control cells (4.0-fold, p<0.05;
Figure 4.2A). Fluorescence radiance from ICG-incubated tdTomato OATP1B3 cells
was also significantly increased relative to an equivalent volume of 35-µg/ml ICG
alone as the positive control (2.6-fold; p<0.05). No significant difference in
fluorescence radiance at ICG wavelengths was observed between tdTomato
Control and tdTomato OATP1B3 cells not incubated with ICG, ruling out any
contribution of zsGreen to signals at NIR wavelengths. PAI of the same phantom at
780 nm was acquired using a custom-built PAI system. Photoacoustic CNR
(arbitrary units, a.u.) was significantly increased for both MDA-MB-231 (2.7-fold;
p<0.05) and 4T1 (2.4-fold; p<0.05) tdTomato OATP1B3 cells incubated with 35
µg/ml-ICG, relative to CNR of ICG-incubated tdTomato Control cells and all
untreated controls (Figure 4.2B). PAI of tdTomato Control cells incubated with ICG
did not exhibit a significant difference in CNR relative to untreated Control cells.
Additionally, it is important to note that both MDA-MB-231 and 4T1 treated control
cells exhibited average fluorescence radiance that was greater than the
fluorescence radiance from untreated controls, indicating that there was marginal
uptake of ICG by control cells. However, on PAI, these same treated control cells
did not demonstrate contrast enhancement greater than untreated controls,
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suggesting that the threshold for detection for ICG using PAI is greater than that for
ICG using fluorescence imaging.
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Figure 4.2. In Vitro Fluorescence and Photoacoustic Imaging. A) Fluorescence
imaging, acquired with 780-nm excitation and 845-nm emission filters, of an asymmetrical
phantom with wells: (1) 35-µg/ml indocyanine green (ICG); (2) media; (3) MDA-MB-231
tdTomato Control cells; (4) MDA-MB-231 tdTomato Control cells incubated with 35 µg/ml
ICG; (5) MDA-MB-231 tdTomato OATP1B3 cells; (6) MDA-MB-231 tdTomato OATP1B3
cells incubated with 35-µg/ml ICG; (7) 4T1 tdTomato Control cells; (8) 4T1 tdTomato
Control cells incubated with 35-µg/ml ICG; (9) 4T1 tdTomato OATP1B3 cells; and (10) 4T1
tdTomato OATP1B3 cells incubated with 35-µg/ml ICG. Fluorescence radiance is
measured in p/s/cm2/sr. B) Photoacoustic imaging (PAI) of the same phantom acquired
with an optical excitation at 780 nm. Contrast-to-noise ratios (relative to the center of the
phantom) were quantified (arbitrary units, a.u.). Numbers, 1-10, on graphs correspond to
numbers on images. Scale bar, 1 cm. Error bars represent one standard deviation.
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4.3.3 ICG-enhanced FLI signal from Oatp1b3-expressing tumours
No significant difference in fluorescence radiance (p/s/cm2/sr) at tdTomato
wavelengths was found between tdTomato Control (n=4) and tdTomato OATP1B3
(n=4) tumours over time, suggesting comparable tumour growth rates (Figure
4.3A). Longitudinal FLI for ICG fluorescence after intraperitoneal administration of
8-mg/kg ICG determined that the largest significant difference in ICG signals
between tdTomato Control and tdTomato OATP1B3 tumours occurred at 24 hours
post-ICG (Figure 4.3B). Accordingly, a second cohort of animals was imaged prior
to ICG administration and 24 hours post-ICG. Neither tdTomato Control (n=6) nor
tdTomato OATP1B3 (n=5) tumours generated FLI radiance at ICG wavelengths
prior to ICG administration, confirming no possible contribution by zsGreen (Figure
4.3C, middle column). Prior to ICG administration, mean fluorescence radiance
measures (± standard deviation) for ICG were not significantly different between
tdTomato Control tumours (9.14 ± 3.49 x 106 p/s/cm2/sr) and tdTomato OATP1B3
tumours (7.41 ± 1.86 x 106 p/s/cm2/sr). In contrast, twenty-four hours after ICG
administration, tdTomato OATP1B3 tumours exhibited significantly increased (8.9fold) fluorescence (7.36 ± 1.77 x 108 p/s/cm2/sr) relative to tdTomato Control
tumours (8.22 ± 0.527 x 107 p/s/cm2/sr; p<0.05; Figure 4.3D). FLI signals at ICG
wavelengths were also detected from the abdomen of both tdTomato Control and
tdTomato OATP1B3 tumours 24 hours following ICG administration, likely from
physiological hepatobiliary clearance of ICG (20) (Figure 4.3C, last column).
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Figure 4.3. In Vivo Fluorescence Imaging of Engineered Tumours. A) tdTomato
fluorescence radiance (p/s/cm2/sr) of tdTomato Control (n=4) and tdTomato OATP1B3
(n=4) tumours over time. B) ICG fluorescence radiance (p/s/cm2/sr) of tdTomato Control
(n=4) and tdTomato OATP1B3 (n=4) tumours over time, up to 9 days, following
administration of 8 mg/kg ICG. C) Fluorescence imaging (FLI) for tdTomato (first column)
and indocyanine green (ICG) average radiance (p/s/cm2/sr) before (pre-ICG; second
column) and 24 hours following administration of 8-mg/kg ICG (24h post ICG; third column)
of a representative mouse burdened with a human breast cancer (MDA-MB-231) tdTomato
Control tumour (top panel) or with a MDA-MB-231 tdTomato OATP1B3 tumour (bottom
panel). Tumours are outlined with black dashed lines and/or pointed out via the “Tumour”
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label. tdTomato signal (first column) is directly proportional to tumour size. D) Fluorescence
radiance (p/s/cm2/sr) of tdTomato Control (n=6) and tdTomato OATP1B3 (n=5) tumours
before administration of indocyanine green (ICG; pre-ICG), immediately following
intraperitoneal injection of ICG (0h post ICG), and 24 hours following ICG administration
(24h post ICG). Error bars represent one standard deviation. Whiskers on the box graph
represent the range of observed values.
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4.3.4 ICG-enhanced PAI signal from Oatp1b3-expressing tumours
Prior to ICG administration, tdTomato Control and tdTomato OATP1B3
tumour morphology was discernible via US, enabling acquisition of PAI baseline
signals at field of views encompassing tumour boundaries (Figure 4.4A; i, iii). Since
there was variance in tumour size, background signals, and tumour morphology
within and across tdTomato Control and tdTomato OATP1B3 tumour groups, mean
hemoglobin (HbO2) PA signals, measured via acoustic average (a.u.) as l ∈ (855,
955); Dl=5nm, was calculated for each acquired spectrum and used to normalize
the signal acquired at 805 nm. This ICG-to-HbO2 signal ratio, referred to as
normalized PA signal (a.u.), was not statistically different between tdTomato Control
(0.72 ± 0.09 a.u.) and tdTomato OATP1B3 (0.85 ± 0.16 a.u.) tumours prior to ICG
injection. Normalized PA signal was also not significantly different between images
of tdTomato Control tumours collected before and after ICG administration (0.75 ±
0.13 a.u.; Figure 4.4C). In contrast, 24 hours post ICG, tdTomato OATP1B3
tumours demonstrated significantly increased normalized PA signals (1.92 ± 0.40
a.u.) relative to all other groups (p<0.05). Importantly, tdTomato OATP1B3 tumours
exhibited increased PAI signal within a narrow absorption band spanning from 695
to 855 nm, with a consensus maximum peak at 805 nm across all tdTomato
OATP1B3 tumours 24 hours post-ICG.
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Figure 4.4. In Vivo Near-Infrared Spectral Photoacoustic Imaging. A) Ultrasound image
(top row), PAI image at 805 nm (second row), and a spectrally unmixed image of
indocyanine green (ICG) distribution across all wavelengths (Unmixed; third row) of a
representative human breast cancer (MDA-MB-231) tdTomato Control Tumour (left panel)
and tdTomato OATP1B3 Tumour (right panel), both prior-to administration of ICG (i, iii; preICG) and 24 hours following administration of 8-mg/kg ICG (ii, iv; 24h post ICG). PAI
contrast enhancement on PAI is exhibited by tdTomato OATP1B3 tumours 24 hours
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following ICG administration, while tdTomato Control tumours do not exhibit increased
signals 24 hours following ICG administration. B) Near-infrared PAI spectra of a
representative tdTomato Control Tumour (top) and tdTomato OATP1B3 tumour (bottom),
before administration of ICG (dashed-line plot) and 24 hours following administration of 8mg/kg ICG (solid-line plot), each labelled with hemoglobin (HbO2; red) and
deoxyhemoblobin (Hb; blue) peaks. Increased photoacoustic signals are observed
exclusively within tdTomato OATP1B3 tumours 24h post ICG, with a maximum at 805 nm
(ICG peak). C) ICG-to-HbO2 ratio, referred to as the Normalized PA signal (arbitrary units,
a.u.), across tumour and treatment groups. Scale bar, 1 mm. Error bars represent one
standard deviation. Whiskers on the box graph represent the range of observed values.
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4.3.5 Ex vivo FLI confirms selective ICG retention in Oatp1b3-expressing tumours
zsGreen fluorescence (10-s exposure, 480-nm excitation filter, 520-nm
emission filter) was absent in tdTomato Control tumour sections but present in
tdTomato OATP1B3 tumour sections. Importantly, ICG FLI signal (10-s exposure,
780-nm excitation filter, 845-nm emission filter) was visible only in tdTomato
OATP1B3 tumour sections. Fluorescence microscopy was also conducted, and
further validated the presence and/or absence of tdTomato and zsGreen signals
from FLI of tumours (Figure 4.5).
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Figure 4.5. Ex Vivo Fluorescence Imaging. A) Fluorescence imaging (FLI) for tdTomato
fluorescence (first column), zsGreen fluorescence (second column), and indocyanine
green (ICG; third column) of tdTomato Control (top row) and tdTomato OATP1B3 (second
row) tumour slices. Scale bar, 1 cm. B) Fluorescence microscopy for tdTomato (first
column) and zsGreen (second column) of tdTomato Control (top row) and tdTomato
OATP1B3 (second row) tumour slices. Scale bar, 100 µm.
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4.4 Discussion
In this study we establish Oatp1b3 and ICG as a novel reporter gene-probe
system for in vivo PAI of engineered cell populations. We generated a novel lentiviral
vector encoding Oatp1b3, allowing for engineering of cell lines to stably express this
ICG transporter. Cells engineered to express Oatp1b3 demonstrated significantly
increased fluorescence signals at NIR wavelengths following incubation with ICG,
which was not observed in control cells. On PAI, Oatp1b3-expressing cells
incubated with ICG exhibited significantly increased signals in vitro, while ICGincubated control cells were virtually undetectable. We also demonstrated that
Oatp1b3-expressing breast cancer cells can be implanted to grow orthotopic
tumours in vivo, and significantly increased FLI and PAI signal was seen in small
tumours (<1mm3) 24 hours following administration of ICG. Importantly, we
demonstrate that the increase in PAI detection was specific to the 695 to 855-nm
wavelength range, with a consensus maximal peak at 805 nm, allowing for accurate
in vivo identification of reporter gene-enhanced PAI signal. We further validate
selective retention of ICG by Oatp1b3-expressing tumours.
Our study extends previous work on Oatp1b3, establishing it as a
multimodality reporter for numerous clinically-relevant modalities such as FLI, and
now PAI, and also introduces potential for Oatp1b3 reporter gene imaging on a
clinical 3-Tesla MR scanner. OATP1B3-enhanced PAI uniquely offers a non-ionizing
and cost-effective method to detect engineered cell populations with sensitivity and
relatively high resolution. Clinical PAI systems can image up to around 7 centimeters
(21), and thus future work should establish how many Oatp1b3-expressing cells can
be detected at specific depths in larger animal models. A caveat of this system is
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that the engineered cells to be imaged on PAI should not be located beyond an
optical-scattering material e.g., within the adult human skull, where the light needed
to excite ICG would be largely reflected by bone before getting to the engineered
cells. However, this issue may be solved through the use of more penetrative PAI
systems that are being developed (22, 23). The ability to evaluate the status of a
gene or cell population using whole-body (MRI) (24), localized (PAI) and
microscopic (fluorescence) imaging techniques with a single reporter gene system
could be broadly useful for many biomedical applications, such as tracking the
viability and migration of therapeutic cells in patients (25, 26). Rat-derived Oatp1a1
and the tracer 111Indium-EOB-DTPA have also been established as a reporter geneprobe pair for single photon emission computed tomography (SPECT) (27). Studies
evaluating human Oatp1b3 as a SPECT reporter gene are warranted to further
extend the potential utility of this human reporter beyond FLI, PAI, and MRI, and
improve cellular detectability via the higher probe sensitivity offered by SPECT.
The ideal PAI reporter gene would be specific to the biological process of
interest; exhibit an absorption maximum within the NIR window for deep tissue in
vivo imaging; and, be nontoxic to the cell. Though other reporter genes for PAI have
been described (e.g., NIR fluorescent proteins, photo-switchable fluorescent
proteins), the PAI reporter gene arguably considered to have the highest
translational potential is human tyrosinase, which initiates the conversion of
endogenous tyrosine into detectable melanin (19, 28-30). Though tyrosinase
presents desirable properties, including human origin, signal amplification due to
enzymatic action, and a detectible product with high photostability, it is not without
limitations (7). For instance, the melanin photoacoustic profile displays a broadband,
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featureless absorption spectrum, making it difficult to distinguish ectopic melanin
from other intrinsic signals with accuracy (12). Our Oatp1b3-ICG system, on the
other hand, features a distinct band within the NIR region that is easy to identify and
un-mix from hemoglobin and deoxyhemoglobin spectra, and from spectra of other
PAI reporters added to the biological system for more complex functional imaging.
It is also interesting to note that wells in the in vitro experiments containing a sample
of ICG-incubated Oatp1b3-engineered cells exhibited greater fluorescence radiance
(2.6-fold) and PAI signals (1.19-fold) relative to the positive-control well containing
a sample of ICG at the treatment concentration. This suggests that uptake of ICG
by OATP1B3 occurs in an active or active-coupled process, rather than simple
diffusion, which is in agreement with current theories describing uptake mechanisms
of the OATP1 family of transporters (31). While tyrosinase exhibits signal
amplification due to enzymatic action, Oatp1b3 may provide signal amplification
through active or active-coupled uptake of many ICG molecules. In addition, altered
cell phenotype and toxicity associated with ectopic tyrosinase activity has been
documented, (28, 32, 33) in so much that tyrosinase-encoding plasmid distributors
(e.g., Imanis Life Sciences), recommend inducible promoters to minimize undesired
biological effects during imaging studies. Though documented experiments are
limited in number, ectopic Oatp1b3 overexpression has not been reported to cause
cellular toxicity or confer observable phenotypic changes (14, 34), and we did not
observe any quantitative or qualitative differences in cell proliferation rates and/or
morphology in our own work, even when engineered cells were incubated in the
presence of ICG. As we performed here, it was important to assess the effectiveness
of this system at the preclinical stage using doses of ICG equivalent to current
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clinical guidelines. Though ICG is safe to inject at these doses, further safety
evaluation may be warranted on the intracellular toxicity of ICG once it is internalized
by the OATP1B3 transporter. It should also be noted that detection of engineered
cells near the hepatobiliary system would be difficult, as clearance of ICG within that
pathway obscure the ability to detect OATP1B3-engineered cells retaining ICG.
In the clinic, PET reporter genes have so far been used in patients for imaging
of adenoviral gene therapy (5) and cytotoxic T cell immunotherapies (6) in cancer
patients. These studies mark major milestones in reporter gene imaging, but limited
access and costs due to associated infrastructure and operation, in combination with
concerns over ionizing radiation may hinder broad applicability and longitudinal
imaging via PET reporter genes. These limitations highlight the need for alternative
reporter gene systems for safe, cost-effective, and accessible imaging modalities
within the clinic. Although nuclear imaging (PET/SPECT) is capable of whole-body
visualization, and photoacoustics is limited to localized imaging, reporter gene
imaging with PAI should be applicable for a variety of clinical problems that only
require imaging of specific tissues (35). For example, including the Oatp1b3 reporter
gene to the genetic engineering protocol of chimeric antigen receptor (CAR) T cell
therapies targeting prostate cancer stem cells (36) would allow for longitudinal
monitoring of these cells in the prostate via an intraperitoneal laser/transrectal
transducer system (37). We expect this technology to be particularly useful in clinical
trials that involve localized injection of a gene or cellular therapy into a specific
tissue, as it allows for real-time information on how a particular therapy is operating
in the patient. Questions of interest include: is the therapy getting to the target site?
Is it activating at the target site? For how long does it persist? Does reporter
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expression correlate with patient response? However, until more gene and cellbased therapeutics make their way into the clinic, we expect that this multimodality
reporter system will be more rapidly utilized for tracking of gene expression and cell
populations in preclinical animal models.
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CHAPTER 5 Summary and Future Work
This thesis presents work on Organic Anion-Transporting Polypeptide 1 (Oatp1) as a
reporter gene for multimodality cell tracking in preclinical animal models with high
sensitivity, high resolution, and surrounding anatomical context. At the start of this
research, a single publication existed describing rat Oatp1a1 as a magnetic resonance
reporter gene, using optimal parameters to prove its principle: high field strengths (7T,
9.4T), large doses of Gd-EOB-DTPA, and xenografts in animal models. At that point in
time, Oatp1 demonstrated great potential as a reporter gene, and provided a lot of
excitement for future utility. In our work, we were first interested in assessing the
feasibility of translating this system to the clinic. We showed that Oatp1a1 can be used
to track cells at 3 Tesla, with clinically-feasible doses of the paired imaging probe GdEOB-DTPA, and that these parameters allow for imaging high resolution distribution
patterns of viable cells in 3-dimensional space. Next, we transitioned to a closely-related
human transporter called Oatp1b3. We showed that Oatp1b3 can be used to track small
populations of spontaneously metastasizing cancer cells longitudinally via MRI, and
estimated its detection limit at about 104 cells. Finally, we demonstrated that Oatp1b3
can be used as a photoacoustic imaging reporter gene, based on its ability to take up
indocyanine green in vivo, allowing for rapid and cost-effective imaging of engineered
cells in tissues. This thesis represents an important step in the development of a
versatile imaging tool for tracking the location of viable engineered cells in preclinical
animal models and lays groundwork for translating this technology for tracking of genes
and/or cells in patients. The following sections outline a summary of the main findings in
each study, as well as challenges and limitations, and future research avenues.
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5.1

Discussion and Conclusions
5.1.1 Chapter 2 - High Resolution Oatp1 Imaging using Clinical MR Parameters
First, we tested the feasibility of using Oatp1a1 to track the growth of
primary tumours over time on MRI, at clinical field strengths of 3 Tesla and
clinically-feasible doses of 0.1-mmol/kg Gd-EOB-DTPA in mice. Using
bioluminescence imaging as a reference modality, we observed continued
growth in BLI signals from primary tumours over time at low resolutions. The
main findings of this chapter were: 1) Oatp1a1 enhances bioluminescence
imaging signals by mediating increased D-luciferin transport into engineered
cells; 2) there is significant in vivo contrast enhancement by Oatp1a1-engineered
cells on MRI at 3 Tesla, and 0.1-mmol/kg Gd-EOB-DTPA; and, 3) high resolution
contrast enhancement patterns of engineered cells on MRI strongly correlated to
distributions of viable cancer cells on matched histology.
Ultimately, this initial set of observations established the multi-dimensional
utility of using Oatp1a1 for tracking viable cells in vivo. Increased uptake of Dluciferin resulted in increased sensitivity on bioluminescence imaging, allowing
for detection of smaller and/or deeper populations of engineered cells, that would
have otherwise gone undetected. MRI demonstrated that engineered cells
appear enhanced at 3 Tesla, with relatively low doses of Gd-EOB-DTPA. Further,
with longitudinal monitoring, we were able to dynamically observe architectural
changes within primary tumours at high resolutions, including the emergence of
necrotic centres and non-cancer cells within primary tumour boundaries, and
were able to quantitatively validate these enhancement patterns at endpoint
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using matched histology. In summary, this chapter established Oatp1a1 reporter
gene imaging as a powerful tool to track viable engineered cells on MRI, with
concomitant BLI enhancement. The multi-ligand nature of Oatp1a1, in its ability
to take up D-luciferin and enhance BLI signals, as well as Gd-EOB-DTPA to
enhance MR signals, warranted investigation towards other hepato-specific
substrates, such as indocyanine green (ICG) for the enhancement of fluorescent
and photoacoustic signals (1). However, we observed only modest uptake of ICG
by Oatp1a1 in preliminary studies. At this point, we sought to investigate
additional Oatp1 transporters, namely human Oatp1b1 and Oatp1b3, to
characterize their uptake preferences for potential use in molecular imaging.
Oatp1b3 proved to be very useful, and the sequential chapters highlight our
major findings.

5.1.2 Chapter 3 - Whole-Body Tracking of Spontaneous Metastases on MRI
In the previous chapter, we initially planned to use Oatp1 as a tool to track
bulk groups of cells on MRI and held conservative views on the sensitivity of this
reporter gene technology. However, we were surprised to observe strong,
positive quantitative correlations between enhancement patterns on MRI and
matched histology at high resolutions in the previous chapter. As a result, we
became increasingly interested in the potential of this technology for dynamic
tracking of small populations of migrating cells. To this end, we used a
spontaneous metastasis model of breast cancer in preclinical mice. Additionally,
we were increasingly interested in studying the human Oatp1b3 transporter as a
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reporter gene, for future applications of cell tracking in humanized mice models
and clinical tracking of cell-based therapies in patients. The main findings of this
chapter were: 1) there is significant contrast enhancement by Oatp1b3engineered cells on MRI at 3 Tesla, and 1-mmol/kg Gd-EOB-DTPA in preclinical
animal models; 2) Oatp1b3 allows for longitudinal, whole-body tracking of
migrating cells with high sensitivity and resolution; and, 3) the in vivo detection
limit of Oatp1b3 is on the order of 104 cells, and sits on par with the detection
limit of bioluminescence imaging.
These findings were significant, as they offer a new approach for
assessing metastatic burden with high resolution, sensitivity, and across the
whole-body. With this technology, we were able to dynamically track the
metastatic process in deep tissues on MRI, from early-stage metastasis at the
single lymph-node level, to late-stage metastasis, when the cancer cells have
invaded distant organs, such as the lungs. While tracking metastases noninvasively with BLI allows for whole-body tracking of metastases, light scatter
from larger lesions may obscure smaller metastases. Additionally, light scatter
limits the resolution of imaging via bioluminescence, making it difficult to pinpoint
the exact locations of engineered cells in 3-dimensional space. Further, light
attenuation from surrounding signals make it difficult to distinguish between
signals stemming from smaller populations of superficial cells or larger
populations of deep-seated cells. In this way, light attenuation also contributes to
the difficulty of pinpointing exact locations of engineered cells on BLI, and the
capacity to quantify their signals on BLI. With Oatp1b3-MRI, we were able to
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reveal the true locations of engineered cells in 3-dimensional space, with
sensitivity comparable to that of bioluminescence. Notably, we were able to
reveal smaller micro-metastases via Oatp1b3-MRI, which were indiscernible on
BLI due to light scatter from larger lesions, allowing us to capture a “true picture”
of how the cancer cells grow and migrate throughout the body.

5.1.3 Chapter 4 - Photoacoustic Imaging with Oatp1 and Indocyanine Green
Finally, in the final research chapter, we wanted to explore the potential of
using Oatp1b3 as a multimodality reporter gene. Individual modalities present
with inherent limitations, whereas combining multiple modalities with
complementary advantages and limitations offers a more thorough understanding
of the biological phenomenon being studied. The initial Oatp1a1 reporter gene
paper introduced an indium-111 radionuclide analog of Gd-EOB-DTPA that was
used for SPECT detection of Oatp1a1-expressing cells. While SPECT offers a
clinical platform with increased sensitivity relative to MRI, it is far more limited in
resolution and accessibility. Taking on a different direction, we discovered
previous evidence suggesting that indocyanine green was a ligand for the
Oatp1b3 transporter (2). Following this data, we sought to establish Oatp1b3 as
a photoacoustic imaging reporter gene, as indocyanine green exhibits a high
extinction coefficient, low quantum yield, and has previously been demonstrated
as an effective photoacoustic contrast agent. The main findings of this chapter
were: 1) there was significant contrast enhancement on PAI by Oatp1b3engineered cells in preclinical animal models, following administration of 8
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mg/kg-ICG; 2) imaging was optimal at 24h post-intraperitoneal injection of ICG,
at which point any non-specific ICG across the body was largely cleared; and, 3)
specifically, broad increases in PAI signals within the NIR region (730-855 nm)
were detected, with a consensus maximal peak at 805 nm.
These findings provided support Oatp1b3 and ICG as a novel reporter
gene system for photoacoustic imaging. While photoacoustic imaging is limited in
its ability to capture whole-body images in non small animal models, largely due
to the cumulative attenuation of the exciting light and/or optical scattering of the
exciting light by materials like bone, there is still great utility for high-resolution
localized imaging at depths of several centimeters. The ability to assess genetic
and cellular information via the Oatp1b3-PAI reporter gene system paves the
path towards cost-effective, and therefore, potentially widespread in vivo
molecular imaging at the preclinical stage, and perhaps even for clinical
applications. Longstanding clinical approval and commercial availability of the
paired imaging probe, indocyanine green, may also facilitate the dissemination of
this technology for use in the laboratory and for clinical tracking of gene- and cellbased therapies in the clinic. Although more work is warranted, our initial studies
demonstrate promising feasibility of this photoacoustic imaging approach for
various applications requiring gene and/or cellular tracking.
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5.2

Challenges and Limitations
5.2.1 Sensitivity of Detection
The ultimate goal of molecular imaging is to detect molecular events as
they occur in a living organism. Several factors are important in assessing the
effectiveness of an imaging strategy for detecting a biochemical feature. One of
these is its sensitivity, defined as the detection threshold of the imaging
approach, which can be measured in a number of ways, such as probe
concentration, molecular events per second, or number of cells. Some imaging
modalities are inherently more sensitive than others. A PET scanner, for
instance, can detect probe concentrations between 10−11 mol/L to 10−12 mol/L,
whereas proton MRI has a probe sensitivity of around 10−3 mol/L to 10−5 mol/L,
which can be limiting (3). Due to the novelty of photoacoustic imaging, combined
with the assortment of systems built and used for studies in the literature, it is
somewhat challenging to estimate the sensitivity of photoacoustic imaging.
However, specific studies can provide insight on its sensitivity: the blue product,
5-bromo-4-chloro-indoxyl, generated by the β-galactosidase reporter gene has
been detected at depths of several millimeters at 10−6 mol/L to 10−9 mol/L
concentrations (4), which is more sensitive than MRI, but less sensitive than
PET. Still, with increasing tissue depth, photoacoustic imaging becomes less
sensitive and MRI more advantageous.
Perhaps a more pertinent measure of sensitivity, especially for cell
tracking purposes, is the minimal number of detectable cells. Some molecular
imaging strategies have already permitted detection of single cells in vivo, such
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as preloading of cells with iron oxide nanoparticles for detection on MRI (5). In
this case, the single cell detection limit of iron oxide nanoparticles has repeatedly
been validated at various field strengths, in a number of cell types including
cancer cells directed to the brain for metastasis modelling (6, 7), mouse
embryonic cells for tracking developmental cell migration (8), primary
hepatocytes for transplant quality assurance (9), antigen-specific cytotoxic
lymphocytes for targeting tumours (10), and mesenchymal stem cells for
regenerative medicine (11). Although cellular pre-loading methods with PET have
a limited timeframe due to radioactive decay, dynamic in vivo tracking of a single
cell on PET was very recently demonstrated using 68Ga-labeled mesoporous
silica nanoparticles: a single pre-labelled cancer cell was injected into the tail
vein of a mouse, where its velocity in the bloodstream was tracked until its arrest
in the lungs (12). The sensitivity of more traditional targeted probe methods for
PET is highly variable and depends greatly on probe design, but the most welldesigned PET probes in recent years have exhibited detection thresholds on the
order of 104 cells (13-15).
Reporter genes offer increased accuracy and sensitivity for monitoring of
cell trafficking, proliferation, and persistence over long periods of time, relative to
ex vivo cellular labelling methods (16). The sensitivity of a reporter gene in a
particular experiment depends on a number of variables which may vary from
study to study, including the efficiency of transfection or transduction, the
promoter regulating its expression, and, in relevant cases, the bioavailability of
the imaging probe to the reporter protein. Accordingly, studies employing
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constitutive promoters and stable transfection or transduction methods would be
able to provide information on sensitivity with optimized conditions. Recently,
single cell bioluminescence imaging in vivo was demonstrated with a red-shifted
luciferase-luciferin system (17). However, on more traditional luciferase systems,
as few as 101 cells can be detected at the skin surface, whereas 106 cells would
be required at depths of 2 cm due to light attenuation by surrounding tissues
(18).
With respect to clinically-relevant modalities, a comparative analysis of
several established PET reporter genes, including the human sodium iodide
symporter (hNIS), the human norepinephrine transporter (hNET), the human
deoxycytidine kinase double mutant (hdCKDM), and the herpes simplex virus
type 1 thymidine kinase (hsvTK), revealed detection limits between 105 to 106
cells (19). With MRI, experimental evidence suggest that the detection limit of the
ferritin reporter gene may fall above 105 cells in vitro at lower field strengths
(4.7T) (20), but can go as low as 104 cells at high field (11.7T), as demonstrated
in vivo by scientists from Carnegie Mellon University (21). In perspective, the
estimated in vivo detection limit of 104 cells at 3T presented by Oatp1b3 in deep
tissues is highly competitive, especially when combined with the positive
contrast, high resolution, high specificity, and detailed anatomical information that
are also provided by the system.
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5.2.2 Unintended Effects on Biology by Reporter Genes
The ideal reporter gene would provide detailed high resolution information,
with biologically and statistically significant signal-to-noise, high specificity to the
target of interest, and importantly, minimal effects on baseline physiological
processes, so as not to alter, confound, and/or cause toxicity to the biology being
studied (22). Two levels of reporter gene effects exist: 1) the method of reporter
gene delivery, a necessary step in cellular engineering, that is relatively
independent of the specific reporter gene used in a study; and, 2) any toxic or
undesired biological effects caused directly by the reporter protein encoded by
the gene introduced into the cell, which is highly dependent on the identity of the
specific reporter system used in a study. The means of reporter gene delivery
can be divided into methods that result in either transient expression of the
reporter gene, i.e. extrachromosomal, or integrating methods that result in a
stable cell line (23).
The studies presented in this thesis use lentiviral methods to integrate the
reporter gene into the host genome, which is a sub-class of retrovirus that can
infect both proliferating and non-proliferating cells, and generates a relatively low
immune response in target cells (24). This approach is efficient with respect to
transporting the reporter gene to its final destination in the genome. However, its
drawback is that integration occurs at preferentially-problematic positions in the
genome e.g. near transcriptional start sites, within transcriptional units, (25) and
has been previously been shown to result in disruption of important genes (26).
Lentiviral gene delivery could potentially confound results, as any engineered
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cells used in a study should ideally match the physiological behavior of the
original cell population.
Alternatively, the reporter gene product itself could potentially interfere
with vital biochemical pathways and also lead to the generation of engineered
cells with marked phenotypic differences relative to their ancestral cell
population. For example, one study that focused on the toxic effects of GFP and
LacZ revealed that engineered neuronal cells exhibited morphological differences
in vitro relative to control cells, including long processes which eventually
fragmented, smaller rounded cell bodies typical of dying cortical cells, as well as
rapid decreases in fractions of viable engineered cells over passaging intervals
(27). Although reporter gene-associated toxicity was observed in vitro, long term
expression of reporter genes in vivo was more readily sustained, likely due to the
presence of factors within the complex in vivo environment that provide support
and protection to the engineered cells (27).
In our own studies, in vitro proliferation rates of Oatp1a1- and Oatp1b3engineered cells were measured over time and found to not be significantly
different from those of their parental cell counterparts. Additionally, qualitative
observations of cell morphology did not indicate any biologically significant
changes in cellular structure and in vivo growth rates of Oatp1-engineered breast
cancer cells did not significantly differ from control tumours. Notably, the
metastatic potential of the Oatp1b3-engineered MDA-MB-231 breast cancer cell
line in mice was in close agreement with animals burdened with control MDAMB-231 luciferase control cells, as well as previously published timeframes of
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studies employing the same cell line and preclinical animal model (28). However,
more thorough experiments may be warranted to study specific effects of
Oatp1a1 and Oatp1b3 expression on baseline biochemical processes and
phenotypes such as resting membrane potential. It is assuring that some Oatp1
transporters with significant ligand overlap relative to Oatp1a1 and Oatp1b3, e.g.
human Oatp1a2, have widespread tissue expression (29).

5.2.3 Gadolinium Toxicity and Dose
Another aspect to consider when using reporter genes is the potential
toxicity of the reporter gene’s paired imaging probe. For our photoacoustic
reporter gene system described in Chapter 4, indocyanine green is already a
widely used contrast agent and has had longstanding approval for clinical use at
comparable concentrations to those used in our preclinical Oatp1b3 study (1),
and did not appear to have any effect on the proliferation rates of cells in vitro.
Although gadolinium-based contrast agents have also been granted clinical
approval for some time now, including the Gd-EOB-DTPA compound used as the
imaging probe for Oatp1a1 and Oatp1b3, recent concerns over the biological
effects of gadolinium have raised serious precautions over their utility in the clinic
(30). These include long-term retention of gadolinium in brains of patients after
single doses of gadolinium, the specific effects of which are not yet understood,
as well as the phenomenon of nephrogenic system fibrosis (NSF), which
manifests as scarring of the skin and internal organs as a direct result of
exposure to gadolinium (31, 32).
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These are not substantial concerns for preclinical studies, like those
investigated in this thesis: cells in vitro tolerated the gadolinium, as measured via
viability and growth assays, and cells in vivo developed tumours and metastatic
lesions at reasonable rates after repeated administration of gadolinium over
several weeks. The doses of gadolinium used in this thesis (0.1-mmol/kg in
Chapter 2, 1-mmol/kg in Chapter 4) also fell far below the median lethal dose for
rodents, that is 10-mmol/kg (33). The challenge, however, lies in the translation
of this system for clinical tracking of gene- and cell-based therapies in patients,
which would require a cap on the administered dose of gadolinium. The main
concern of chelated Gd constructs here comes from dissociation of free Gd3+
ions, which then go on to competitively inhibit Ca2+ in a number of physiologically
important processes, including adenosine triphosphatase (ATPase) (34, 35).
Under normal circumstances, the chelator allows sufficient clearance of
Gd-EOB-DTPA (!!⁄" = 1.8 ± 0.2 hours) before any biologically significant
dissociation occurs (36). Yet, with Oatp1, Gd-EOB-DTPA remains within
engineered cells, in the body, for several hours, and it is not yet known whether
dissociation of free Gd3+ is negligible under these parameters. In Chapter 2, we
successfully demonstrated that detailed intratumoral distributions of viable cells
could be mapped out on MRI at a clinically feasible dose of 0.1 mmol/kg.
However, the sensitivity of this system to track small populations of migrating
cells at clinically-relevant doses has not yet been assessed. It will be important to
maximize reporter expression and optimize imaging parameters for enhancing
the conspicuity of engineered cells in order to minimize gadolinium dose.
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5.3

Future Work
5.3.1 Genetic Engineering Methods
The studies presented in this thesis use lentiviral vectors to introduce the
gene into the genome and constitutive promoters to express the protein product
for basic cell tracking purposes. A translational bottleneck, however, is the
necessity to engineer cells with randomly-integrating vectors. CRISPR (Clustered
Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated
(Cas) targeted approaches for knock-in of reporter genes at a genomic safe
harbor locus may overcome these safety concerns. To date, our group has built
Homology Independent Targeted Integration (HITI) CRISPR/Cas9 plasmids for
precise AAVS1-targeted simultaneous knock-in of the Oatp1a1 reporter gene,
and observed increases in knock-in efficiency at the AAVS1 site using HITI
vectors compared to traditional homology-directed repair donor vectors (37).
Characterization of select HITI clones demonstrated significant Oatp1a1mediated uptake of Gd-EOB-DTPA, thereby supporting the feasibility of
introducing Oatp1a1 via safer genetic engineering approaches (37). Further into
the future, we are integrating the Oatp1b3 reporter gene into increasingly
complex genetic circuits, so that its expression is activated in response to a
specific stimulus, rather than having it simply expressed at all times (38, 39).

5.3.2 Manganese Probe for MR Imaging of Oatp1b3 Expression
With the goal of establishing human Oatp1b3 as a clinical-grade MR
reporter gene, the pairing of a gadolinium-based contrast agent as its imaging
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probe may considerably hinder its translation to the clinic, due to concerns over
toxicity. With this in mind, future work on the Oatp1b3 reporter gene system will
focus on developing a gadolinium-free manganese-based contrast agent as a
ligand specific to Oatp1b3. To accomplish this goal, manganese porphyrin
constructs offer a safe, sensitive, and versatile platform for molecular MRI, but
little work has been performed to target these agents towards specific molecular
biomarkers. We hypothesize that addition of an ethoxybenzyl (EOB) group to a
manganese(III) porphyrin construct would allow for its uptake by cells expressing
the Oatp1b3 transporter.
Decreased toxicity of free manganese(III) relative to free gadolinium(III) in
vivo (40), in combination with increased stability of the manganese(III) porphyrin
structure relative to gadolinium chelates (41, 42) offer increased safety.
Additionally, non-porphyrin manganese structures previously developed for MRI
sacrifice relaxivity for safety (40), but the planar geometry of the porphyrin
construct allows for water coordination both above and below the plane of the
agent, leading to increased relaxivity, since relaxivity is directly proportional to
the number of water molecules coordinated to the paramagnetic label and the
residency time of the water molecules. In conjunction with the ability to “tune” the
electron configuration at the paramagnetic center, these properties collectively
contribute to increased relaxivity of Mn(III)-EOB-TriCP relative to Gd(III)-EOBDTPA. Further, the porphyrin backbone offers four locations onto which different
functional groups may be added to alter important properties such as circulation
half-life and ligand activity. Promising preliminary data poses the possibility of
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replacing Gd-EOB-DTPA entirely with Mn-EOB-TriCP, pending future work
focused on comparing enhancement of Oatp1b3-expressing cells in vivo
between Mn-EOB-TriCP and Gd-EOB-DTPA in animals, as well as assessing in
vivo biodistribution, demetallation and toxicity of Mn-EOB-TriCP.

5.3.3 Syngeneic Reporter Gene Systems
A separate issue is that introduction of a foreign protein into the preclinical
animal model may elicit an immune reaction from the host, such that reporter
gene expression becomes inconsistent, suppresses tumour growth, limits
metastasis, and/or leads to therapeutic response misinterpretations (43). To
circumvent this issue at the proof-of-principle stage, immune-compromised
animal models were used to assess and characterize the Oatp1 reporter gene
system in this thesis. In the future, however, we hope to develop a syngeneic
reporter gene approach for cell tracking. In essence, we hope to develop mouse
Oatp1a1 for murine cell tracking in immune-competent mouse models, rat
Oatp1a1 for rat cell tracking in immune-competent rat models, and human
Oatp1b3 for cell tracking in humanized animal models (44). In theory, any T cells
that would have reacted to the reporter protein should have been negatively
selected and eliminated during immune system development. Future work will
focus on developing these systems and quantifying differences between reporterexpressing cells relative to non-reporter expressing cells. In combination, with
new genetic engineering methods (Section 5.3.1), a gadolinium-free manganese
probe for imaging (Section 5.3.2) and a syngeneic reporter gene scheme
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(Section 5.3.3), we hope to develop the Oatp1 reporter gene as a safe,
sensitive, non-confounding imaging system for cell tracking in preclinical animal
models, as well as cell tracking of gene- and cell-based therapies in human
patients down the line.
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of thesis submission on May 14, 2020.
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Permissions for figures acquired from third parties are included in this section.
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6.2.

Curriculum Vitae

Education
2016/9 - 2020/6 (expected)

Doctor of Philosophy, Medical Biophysics
Supervisors: Dr. Timothy Scholl and Dr. John Ronald
The University of Western Ontario, London, Canada

2012/9 - 2016/6

Bachelor of Science (Honours), Genetics
The University of Western Ontario, London, Canada

Awards and Recognitions
2020/3

Invited Student Keynote, Alan C. Burton Day
29th Annual Alan C. Burton Day, University of Western
Ontario [Cancelled, COVID]

2020/2

Graduate Educational Travel Award
International Society for Magnetic Resonance in
Medicine (ISMRM)

2019/9

Industry-Selected Award
World Molecular Imaging Society (WMIS)

2019/9

Finalist, Shark Tank Business Competition
World Molecular Imaging Society (WMIS)

2019/9

Invited Talk
Canadian Molecular Imaging pre-symposium, World
Molecular Imaging Society (WMIS)

2019/9

Drs. Madge and Charles Macklin Award
Schulich School of Medicine, University of Western
Ontario

2019/7

Young Investigator Award
Cellular and Molecular Imaging Study Group,
International Society for Magnetic Resonance in
Medicine (ISMRM)

2019/7

Molecular MRI Travel Award
Cellular and Molecular Imaging Study Group,
International Society for Magnetic Resonance in
Medicine (ISMRM)
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2019/4

Invited Talk with Dr. Silvio Aime
Cellular and Molecular Imaging Study Group,
International Society for Magnetic Resonance in
Medicine (ISMRM)

2019/4

Honourable Mention for Best Oral Presentation
London Health Research Day, Lawson Health
Research Institute and Schulich School of Medicine,
University of Western Ontario

2019/4

Lucille and Norton Wolf Award
Lawson Health Research Institute and Schulich
School of Medicine

2019/3

Alfred Jay Award in Cellular and Cardiovascular
Research
Department of Medical Biophysics, Schulich School of
Medicine

2018/9 - 2021/8

NSERC PGS Doctoral Scholarship
Natural Sciences and Engineering Council (NSERC)
of Canada

2018/6

2nd Place Oral Presentation
Cellular and Molecular Imaging Study Group,
International Society of Magnetic Resonance in
Medicine (ISMRM)

2018/6

1st Place Poster Prize
Oncology Research Day, Schulich School of Medicine

2018/6

1st Place Poster Prize
Robarts Research Retreat, Robarts Research
Institute

2018/5 - 2018/8

Translational Breast Cancer Research Scholarship
Breast Cancer Society of Canada

2018/4

Molecular Imaging Travel Award
Molecular Imaging Program, University of Western
Ontario

2018/3

Top Team, Proteus Innovation Competition
Richard Ivey School of Business and
WORLDiscoveries
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2017/9

Graduate Student Innovation Scholar
Richard Ivey School of Business

2017/7

Invited Student Keynote Speaker
Synthetic Biology Symposium, Ontario Genomics

2017/6

1st Place Oral Presentation Award
London Imaging Discovery Day, Schulich School of
Medicine

2017/5 – 2018/4

NSERC CGS Masters Scholarship
Natural Sciences and Engineering Council (NSERC)
of Canada

2017/5 – 2018/4

Ontario Graduate Scholarship [Declined]
The Government of Ontario

2016/9 – 2020/6

Western Graduate Research Award
University of Western Ontario

2015/4

Letter of Advanced Student Leadership
University of Western Ontario

2012/6

Merit in Science Award
Shad Valley

Journal Publications
NN Nyström, JJ Kelly, FM Martinez, TJ Scholl, JA Ronald. Whole-Body Profiling of
Spontaneously Metastasizing Cancer Cells. In Preparation.
JJ Kelly, M Saee-Marand, NN Nyström, Y Chen, MM Evans, AM Hamilton, JA Ronald.
A Safe Harbor-Targeted CRISPR/Cas9 Homology Independent Targeted Integration
System for Multi-Modality Reporter Gene-Based Cell Tracking. BioRxiv
doi.org/10.1101/2020.02.10.942672. In Revision.
NN Nyström, LCM Yip, JJL Carson, TJ Scholl, JA Ronald. Development of a Human
Photoacoustic Imaging Reporter Gene using the Clinical Dye Indocyanine Green.
Radiology: Imaging Cancer 2019 November; 1(2): e190035.
NN Nyström, AM Hamilton, W Xia, S Liu, TJ Scholl, JA Ronald. Longitudinal
Visualization of Viable Cancer Cell Intratumoral Distribution in Mouse Models using
Oatp1a1-enhanced Magnetic Resonance Imaging. Investigative Radiology 2019 May;
54(5): 302-311.
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Oral Presentations
NN Nyström, TJ Scholl, JA Ronald. Whole-body Detection of Metastasizing Cancer
Cells in Preclinical Animal Models. International Society for Magnetic Resonance in
Medicine, Virtual Conference, August 8-14, 2020.
M Mozaffari, NN Nystrom, A Li, M Bellyou, TJ Scholl, R Bartha. Chemical Exchange
Saturation Transfer MRI: Sensitive to Intracellular pH Change Over Time in a Rat Model
of Brain Cancer. American Association of Physicist in Medicine Congress, Virtual
Conference, July 12-16, 2020.
M Mozaffari, NN Nystrom, A Li, M Bellyou, TJ Scholl, R Bartha. Study of Tumour
Intracellular pH (pHi) in a Rat Model of Glioblastoma Using CEST-MRI. Canadian
Association of Physicists Congress, Virtual Conference, June 8-12, 2020.
NN Nyström, FM Martinez, JJ Kelly, TJ Scholl, JA Ronald. Tracking the Spontaneous
Metastasis of Triple Negative Breast Cancer Cells in Preclinical Animals via Reporter
Gene Imaging at 3 Tesla. Imaging Network of Ontario, Virtual Conference, March 26-27,
2020.
NN Nyström, TD Wang, JA Ronald. An Aerosolized Cancer-Activatable PET Reporter
Gene System for Early Detection of Lung Cancer. World Molecular Imaging Congress,
Montreal, Canada, September 4-7, 2019. Finalist, Business Shark Tank
Competition.
NN Nyström, HA Liu, XA Zhang, TJ Scholl, JA Ronald. Of mice and Mn: Preclinical
development of a gadolinium-free MRI probe targeting organic anion-transporting
polypeptides. World Molecular Imaging Congress, Montreal, Canada, September 4-7,
2019.
NN Nyström, LCM Yip, JJL Carson, TJ Scholl, JA Ronald. A human photoacoustic and
3T magnetic resonance reporter gene system that uses the clinical agents indocyanine
green and Gd-EOB-DTPA. World Molecular Imaging Congress, Montreal, Canada,
September 4-7, 2019. Industry-Choice Award.
NN Nyström. Development of Oatp1 as a Multimodality Reporter Gene. Canadian
Molecular Imaging Symposium, World Molecular Imaging Congress, Montreal, Canada,
September 3, 2019. Invited Talk.
NN Nyström, LCM Yip, JJL Carson, TJ Scholl, JA Ronald. In vivo cell tracking via a
clinically-relevant reporter gene for fluorescence, photoacoustic, and magnetic
resonance imaging at 3 Tesla. Cellular and Molecular Imaging Workshop, International
Society for Magnetic Resonance in Medicine, St. John’s, Canada, July 14-17, 2019.
Young Investigator Award.
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JJ Kelly, M Saee-Marand, NN Nyström, Y Chen, MM Evans, AM Hamilton, JA Ronald.
A Safe Harbor-Targeted CRISPR/Cas9 Homology Independent Targeted Integration
System for Multi-Modality Reporter Gene-Based Cell Tracking. Cellular and Molecular
Imaging Workshop, International Society for Magnetic Resonance in Medicine, St.
John’s, Canada, July 14-17, 2019.
MM Mozaffari, NN Nyström, A Li, M Bellyou, TJ Scholl, R Bartha. Tumor Intracellular
pH in a Rat C6 Model of Glioblastoma. Robarts Research Retreat, London, Canada,
June 7, 2019.
NN Nyström, S Aime. Developments of the Oatp1 Reporter Gene. International Society
for Magnetic Resonance in Medicine, Montreal, Canada, May 11-16, 2019. Invited
Talk.
NN Nyström, LCM Yip, JJL Carson, TJ Scholl, JA Ronald. Multimodality OATP1B3enhanced reporter gene imaging of engineered cells via fluorescence, photoacoustic,
and magnetic resonance imaging. International Society for Magnetic Resonance in
Medicine, Montreal, Canada, May 11-16, 2019.
NN Nyström, LCM Yip, JJL Carson, TJ Scholl, JA Ronald. In vivo cell tracking via
multimodality reporter-based fluorescence, photoacoustic, and magnetic resonance
imaging at 3 Tesla. London Health Research Day, London, Canada, April 30, 2019.
Honourable Mention for Best Oral Presentation.
NN Nyström, LCM Yip, JJL Carson, TJ Scholl, JA Ronald. In vivo cell tracking via a
clinically-relevant reporter gene for fluorescence, photoacoustic, and magnetic
resonance imaging at 3 Tesla. Imaging Network of Ontario, Toronto, Canada, March 2829, 2019.
NN Nyström, AM Hamilton, W Xia, S Liu, TJ Scholl, JA Ronald. Oatp1a1 reporter geneenhanced magnetic resonance imaging of triple negative breast cancer in animal
models at 3 Tesla. International Society for Magnetic Resonance in Medicine, Paris,
France, June 16-21, 2018. 2nd Place Oral Presentation Award in Cellular and
Molecular Imaging.
NN Nyström, AM Hamilton, TJ Scholl, JA Ronald. Novel MRI reporter genes for in vivo
imaging. Provincial Synthetic Biology Symposium, London, Canada, July 28, 2017.
Invited Student Keynote.
NN Nyström, TJ Scholl, JA Ronald. Overcoming the obscurity of triple-negative breast
cancer via Organic Anion-Transporting Polypeptide (OATP)-enhanced MRI. London
Imaging Discovery Day, London, Canada, June 27, 2017. 1st Place Oral Presentation
Award.
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Employment
2018/9 - present

BIOPHYS 9700 Graduate Teaching Assistant
Department of Medical Biophysics, University of Western
Ontario

2016/5 - 2018/8

Factory Worker
Williams Form and Rockbolt

Event Administration
2019/4 - present

Cellular and Molecular Imaging Study Group Trainee,
International Society for Magnetic Resonance In Medicine
(ISMRM) Congress
Preparing administrative group meeting materials; attending
virtual meetings with the study group council; and leading
the organization of the official study group-sponsored
member-initiated symposium (MIS) application for approval
by the Board of Governors of ISMRM. Elected as the official
trainee representative for the 2020-2021 conference year.

2019/9 - present

Ontario Rising Star Trainee Research Network Co-founder,
Ontario Institute for Cancer Research (OICR)
In conjunction with the Ontario Institute for Cancer
Research, the Ontario Trainee Network aims to facilitate the
professional development and collaborative coordination of
cancer research trainees, through mentorship activities,
travel awards, speaker series, newsletters, and more.

2017/5 - 2019/8

Executive Member, Robarts Association of Trainees (RATs)
Organized the Robarts Research Retreat and smaller
activities including professional development seminars and
socials; brainstorming novel events and scholarship prizes
unique to Robarts trainees; facilitating investigator/trainee
interactions between Imaging and Molecular Medicine
Divisions of Robarts Research Institute; and acting as a
council representative for the Imaging Division.

2017/8 - 2019/8

Canadian Cancer Society Research Information Outreach
Team (RIOT)
RIOT aims to communicate current cancer research
objectives to the general public in a number of different
ways, including through local newspaper publications, public
coffee workshops, and through its annual Let's Talk Cancer
event aimed towards high school students.
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2016/4 - present

Organizing Committee, Thames Valley Science and
Engineering Fair
Recruited secondary schools to participate; reviewed
individual abstract submissions for approval; and set up
students' posters in the Thompson Gym at the University of
Western Ontario on days leading up to the science fair.

2016/4 - present

Awards Committee, Thames Valley Science and
Engineering Fair
Listened to and discussed the research endeavours of
secondary school students as they presented their posters;
provided constructive feedback to the students regarding
their projects; coordinated with other judges in a closed room
on the distribution of awards and scholarships to the top
posters, advocating for certain posters over others.

2014/4 - 2015/4

Director of Programming, TEDxWesternU
Recruited various alumni and faculty from across the
University of Western Ontario to participate as speakers for
the conference; assisted speakers in preparation for their
lectures; provided transportation and living accommodations
for certain speakers; designed an itinerary handbook,
organized its printing and distribution to the attendees; and
participated in the conference as the master of ceremonies.

Mentoring Activities
2017/5 - present

4th Year Thesis Training, University of Western Ontario
Number of Mentorees: 4
Introducing the 4th year student to the project, its scope,
training protocols and publication materials; providing
training for relevant research techniques such as cell culture,
cloning, PCR analysis, sequencing, fluorescence
microscopy, fluorescence-activated cell sorting (FACS),
CRISPR design and engineering, luciferase assays and
bioluminescent imaging; and providing discussion to the
student regarding topics pertaining to the project; lecturing
and demonstrating data analysis.

2016/9 - present

Supervisor, Partners in Experiential Learning
Number of Mentorees: 3
Preparing training protocols and materials focused on
molecular techniques such as cell culture, cloning, PCR,
immunoblotting, sequencing, cell lysis, microscopy, BCA
normalization, luciferase assays and bioluminescent
imaging; supervising and providing feedback on
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methodology; lecturing and demonstrating data analysis; and
allowing the students to contribute to the research goals of
the Ronald Lab through data acquisition. Special note: One
of my students, Shirley Liu, went on to win gold at the
Thames Valley Science Fair, and received an additional
award at the Canada Wide Science Fair in 2017.
2013/9 - 2016/8

Guidance Tutor, Learning Disabilities Association of London
Region
Number of Mentorees: 12
Worked with elementary school students, individually and in
group settings, on building good work ethics and
organizational skills, as well as critical thinking; lectured on
the sciences and maths, going over homework, tackling
complex problems and delving into deeper thought
experiments; and a special focus was placed on overcoming
learning disabilities in science and math subjects, for
example by drawing out word problems instead of trying to
solve them straight from the reading.
End of Curriculum Vitae for Nivin Nyström
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